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The skin harbors numerous immune cells and a lymphatic vessel network coordinating initial 
steps of any immune response. Although the circadian clock has been identified as a key 
regulator of the immune system, influence of this clock on dermal lymphatic networks 
remains elusive. Here, I examined dermal dendritic cell (DC) trafficking using ex-vivo ear 
explant crawl-in assays allowing for the analysis of their migratory behavior. Assessment of 
cellular trafficking unveiled a time-of-day dependent migration of tissue-specific DCs towards 
and across lymphatic vessels, with the most prominent migration observed during the 
behavioral rest phase of mice. This circadian migration behavior was concerted by temporal 
up-regulation of trafficking molecules and enhanced chemokine micro patterning in lymphatic 
endothelial cells (LECs) as shown by quantitative immuno-fluorescence profiling. Moreover 
RNA sequencing of sorted dermal LECs uncovered an elevated adhesion gene expression 
during the rest phase. Chrono-pharmacological blockade and disturbance of chemotaxis, 
adhesion and transmigration of DCs within the lymphatic network abrogated circadian 
migration exclusively during the rest phase. Molecular oscillators of lymphatic vessels and DCs 
were then identified as key players since the genetic ablation of the core clock component 
Bmal1 in either cell type diminished the circadian phenotype in cell migration. Together, this 
study establishes a novel link between the circadian clock and lymphatic leukocyte trafficking 
in the skin and provides potential targets for the optimization of both timed treatment of 
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Our immune system is in daily contact with the environment. Every contact shapes and 
develops the immune system. As a result of this, microbes are continuously adapting as well, 
leading to new inflammatory challenges. Despite success and advances in modern research 
and therapies, it becomes more and more challenging to quickly tackle new diseases and 
develop therapeutic agents and strategies. One recent example to be mentioned here is the 
outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlighting 
how difficult and time consuming discovery of new therapies and treatment is. Thus, 
innovative strategies and improvements in therapy are required to successfully face currently 
existing and future diseases.  
One way to more efficiently respond to potential threats is to partition immune responses to 
specific time windows during the day when they are most likely to occur. Daily, recurring 
rhythms in the environment greatly affect rhythms in intrinsic biological processes. Intrinsic 
rhythms are found in every aspect of physiology and allow for the adaptation and evolution of 
biological processes. In the last decades, researchers have identified biological rhythms to also 
occur in the immune system. Although research has uncovered circadian clocks in virtually 
every mature immune cell type, our understanding of how clocks influence the cell and 
overall immunity still remains relatively obscure. Thus, a better understanding of the rhythmic 
immune system is essential for the time-tailored application of immunotherapies.  
The skin is the largest organ of the body and harbors a great diversity of immune cells as it 
presents one of the predominant entry points for pathogens. Thus, it is not surprising that the 
skin is a major site of infection and disease. The lymphatic system is crucial for fluid control, 
nutrient uptake, can be a site of bacterial dissemination and is exploited by cancer. For 
immune cells to initiate an immune response, the skin lymphatic vessel network is of high 
importance as it facilitates the correct and fast transport of antigens to the lymph node. 
Although basic concepts of the skin lymphatic biology are understood, it is not known how 
biological rhythms influence the skin lymphatic system. Thus, uncovering circadian 
mechanisms in the biology of skin lymphatics might be beneficial for basic immunology 





2.1 Basic concepts of immunity 
 
Although the immune system functions as one entity, it consists of various distinct cell types, 
each having unique and important roles. In general, it can be divided into the innate and 
adaptive immune system. The term ‘innate’ implies that receptors and mediators involved in 
an innate immune response are genetically encoded and do not undergo rearrangements or 
genetic variations. On the other hand, ‘adaptive’ immunity describes the genetic 
rearrangement of proteins involved in the adaptive response to ensure greater immune 
diversity. Together, the major roles of both are the adequate and correct elimination of 
microbial agents via the innate immune system, activation of the adaptive immune system via 
innate immune cells if it is appropriate to initiate an adaptive response, creating memory of 
adaptive responses and tolerance of self-antigens (sources used for chapters 2.1 and 2.1.1 
include [1-3]). 
The adaptive immune system consists of lymphocytes, which are together made up by B and T 
cells. Although they occupy a central stage in an immune response by determining the 
specificity of immunity, they rely on the innate immune system. The innate immune system 
presents antigens to the adaptive immune system and mediates immunologic functions. It 
entails dendritic cells (DCs), Langerhans cells (LCs), monocytes/macrophages, natural killer 
(NK) cells, neutrophils, mast cells, basophils and eosinophils. Together with the lymphocytes, 
they are grouped as leukocytes. Importantly, every leukocyte is presented with a great 
heterogeneity between organs and is highly specialized according to the organ it is residing in 
or migrating to.  
The primary lymphoid organs, including thymus and bone marrow (BM), are the site of 
maturation of naïve leukocytes. Mature leukocytes then migrate to secondary lymphoid 
organs, consisting of lymph nodes (LNs), spleen, Peyer’s patches and mucosal-associated 
lymphoid tissues (MALTs), and in the case of lymphocytes are scanning tissues for the 






2.1.1 Early steps of an immune response 
 
Early steps of an immune response include the capture of pathogens by antigen presenting 
cells (APCs) such as DCs, the processing of native antigens into peptides and their 
presentation by major histocompatibility complex (MHC) molecules, the migration of APCs 
through the extracellular matrix (ECM) and transmigration through blood and lymphatic 
vessels as well as the APC entry into LNs to activate and initiate the adaptive immune 
response. In this thesis the focus is on peripheral tissues and DCs. Therefore, the full adaptive 
immune response will not be discussed here. 
Before DCs encounter any pathogen, they are resting in a steady-state homeostasis. During 
this mode, they are capable of capturing and presenting antigens to T cells with an outcome 
of tolerance but not an immune response. The encounter with potentially harmful agents, 
however, allows the DC to become fully activated and initiate an immune response. This 
diverse response is possible due to the DC’s ability to sense changes in the environment by 
expression of different pattern recognition and activation receptors. These receptors, e.g. toll-
like receptors (TLRs), engage with viruses and microbes (pathogen-associated molecular 
patterns (PAMPs) or danger-associated molecular patterns (DAMPS)) as well as inflammatory 
cytokines and help internalizing the native antigen. 
Upon contact, DCs take up antigens by endocytosis, specifically macropinocytosis or receptor-
mediated phagocytosis. After internalization, antigens are processed into peptides, targeted 
to MHCII-positive endosomes, sequestered, and bound to MHCII dimers within the 
endosome. MHCII dimers carry the processed peptides and present them to by-passing cells 
on their cell surface. In the absence of harmful antigens or danger signals, however, the 
MHCII complex is loaded with self-peptides to limit the auto-immune reactivity and promote 
self-tolerance. MHCI is expressed on every nucleated cell, while MHCII is restricted to APCs 
and specific cells like epithelial cells, important for tolerance. MHCI on DCs initiates 
elimination of infected and malignant cells by CD8+ T cells, whereas MHCII initiate the CD4+ T 
cell immune response. Different DCs are better in sensing specific types of antigens (bacterial 
membrane proteins, nucleic acids, etc.) and are adapted to the microenvironment they reside 
in. 
To reach the LN and initiate an immune response or establish peripheral tolerance, the DC 
migrates through the ECM with the help of chemotactic gradients like chemokine C-C motif 
ligand 21 (CCL21). Due to receptors expressed on their surface, such as C-C chemokine 




lymphatic vessels (LV) as a route to reach the LN. The orchestrated mechanism of leukocyte 
trafficking into and through vessels depends on the type of vessel, but in general requires 
adhesion of the leukocyte to endothelial cells (ECs) lining the vessel wall and their subsequent 
transmigration through the endothelial layer. 
If DCs arrive at the LN via the lymphatic route, they enter the stromal layer through a sinus of 
lymphatic endothelial cells (LECs), from which they migrate into the T cell zone and initiate 
the immune response. After activation of T cells, DCs undergo apoptosis, as their presence is 
no longer required. 
 
2.2 Lymphatic vasculature 
 
Mice and humans harbor two distinct types of vessel systems. The closed blood circulatory 
system is the mediator of continuous movement of body fluids, transporting oxygen and 
nutrients to the tissues. Moreover, it regulates the migration of molecules and immune cells 
to and from tissues with the help of a muscular pump, the heart. 
On the other hand, the lymphatic system is a uni-directional and blind-ended system required 
for the high-pressure blood circulation. Small lymphatic capillaries line almost every major 
tissue, transport tissue draining fluid through larger collecting vessels into LN, from which it 
flows back to the blood stream. Movement of lymph through larger LVs is mediated by three 
major components: physical forces driving the initial formation of lymph in tissues, an intrinsic 
pump mechanism that pushes lymph forward, and extrinsic tissue pressures. Generally, LVs 
maintain fluid balances in every tissue by draining the blood capillary ultrafiltrate and 
extravasated plasma proteins back to the blood circulation. Furthermore, they are key players 
in transport of lipids and nutrients absorbed in the microvilli of the small intestine and are 
crucial for the transport of antigens and immune cells in case of an immune response and 
establishment of tolerance. Recently, it was also demonstrated that LVs play important roles 
in T cell development, are providing space for immune cell interactions and are targets of 
bacterial dissemination [4, 5].  
The lymphatic system was first described by Hippocrates and Aristotle around 400 BC and, 
later, the Greek physician Claudius Galen described the mesenteric lymph nodes to be filled 
with a milky lymph or chyle, consisting of fats originating from the small intestine [6]. From 
1622 onwards, first the small intestine villus LV (also called ‘lacteal’) was described [7], the 




the term vasae lymphaticae leading to the current term ‘lymphatic vessel’ was coined [6, 7]. 
With the help of electron microscopy [9], intra-vital microscopy [10], the development of LEC 
isolation techniques [11] and the generation of genetic reporter mice expressing fluorescent 
proteins under the promoters of biomarkers such as prospero homeobox protein 1(Prox-1)-
GFP [12], many aspects of the lymphatic role in the immune system have been revealed in 
modern research.  
 
2.2.1 Anatomy and organization of the lymphatic system 
 
LVs are described in almost every type of tissue. Although lymphatics in cartilage, cornea, or 
the central nervous system are yet to be fully understood, there are hints that also these 
organs harbor LVs either under steady-state or inflammatory conditions [13-16].  
The lymphatic system has a fractal and tree-like geometric organization, allowing for large 
surface area coverage with small initial lymphatics or capillaries. Lymphatic capillaries are 
located in close proximity to the microcirculation and – depending on the organ – form either 
a network/plexus or are completely blind-ended. They consist of a single layer of LECs and a 
discontinuous/porous basal membrane [17]. Capillary LECs have a distinct oak leaf shape 
allowing them to interdigitate and form loose discontinuous junctions and flaps (Figure 2-1). 
The formation of these ‘primary lymphatic valves’ is hypothesized to create a balance 
between high permeability for lymph uptake and adequate amounts of cellular trafficking [18-
20]. Necessary for functional valves are aggregates of junctional proteins forming tight 
junctions, which are anatomically and functionally different to blood EC (BEC) tight junctions, 
and called ‘buttons’. These contain junctional proteins like vascular endothelial (VE)-
CADHERIN, OCCLUDIN, CLAUDIN-5, endothelial selective adhesion molecule (ESAM) and 
junctional adhesion molecule A and C (JAM-A/C) holding LECs together [21]. The space 
between the buttons, also described as ‘flaps’, showcase another set of proteins like 
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and platelet and endothelial cell 
adhesion molecule 1 (PECAM-1/CD31; absent in buttons), and is the major site of leukocyte 
entry providing the lowest resistance [21, 22].  However, the exact shape of lymphatic 
capillaries depends largely on the tissue location (Figure 2-1 and Figure 2-2).  
Lymphatic capillaries drain into collecting lymphatics which are morphologically and 
functionally dissimilar. Collecting vessels have a single layer of LECs surrounded by a medial 




[23]. The larger the collecting vessels, the more layers of SMCs can be found. In contrast to 
capillary button structures, collecting vessel LECs form ‘zipper-like’ tight junctions, allowing 
for a more sealed vasculature prohibiting any fluid uptake or transmigration of cells under 
steady-state conditions [21, 24]. In addition to this, they embody periodic ‘secondary 
lymphatic valves’. These bicuspid valves prevent the backflow of lymph [25, 26] (Figure 2-1). 
Each space between two consecutive valves form a functional contractile unit or 
lymphangion, translated as ‘lymph heart’ [27]. The coordinated contraction of lymphangions 
together with functional secondary valves grants effective intrinsic pumping of the lymph and 
its content. Some tissues like the skin also have pre-collecting vessels that do not have SMCs 
but secondary valves, a mix of oak leaf- and rhombic-shaped LECs, together acting as conduits 
[21, 28] (Figure 2-2).  
Collecting vessels merge into large LVs (afferent lymphatics) that transport the lymph to the 
draining LN (dLN), from which the lymph is transported back to the blood circulation via 
efferent lymphatics (notably, in some parts of the system the lymph passes multiple LNs 
before coalescing into the blood circulation) [29]. Usually, 1 – 2 efferent lymphatics leave the 
LN and drain into the cisterna chyli, which leads into the left lymphatic duct, also known as 
the thoracic duct, depending on the site of origin [30, 31]. These large LVs flow back into the 
blood stream via the left and right subclavian vein [30]. In summary, most of the transported 
lymph reenters the blood circulation via the thoracic duct, the rest via the right lymphatic 
duct [32, 33]. 
Figure 2-1: Anatomy of lymphatic vessels 
(A) Lymphatic capillaries are blind-ended vessels surrounded by a discontinuous basal membrane 
(BM), embedded into an extracellular matrix (ECM) using anchoring filaments and fibrils. The oak 
leaf-shaped lymphatic endothelial cells (LECs) line the capillary and partly overlap each other at the 
junctions. LECs are connected via buttons, small aggregates of junctional proteins. Between buttons, 
flaps are formed helping cells such as dendritic cells (DCs) transmigrate. 
(B) Collecting vessels consist of rhombic-shaped LECs, covered with layers of smooth muscle cells 
(SMCs), inserted in a wide and continuous BM. They promote passive flow by generating pressure 




2.2.1.1 Lymphatic biomarkers 
 
In order to identify LECs and distinguish them from other types of ECs or stromal cells, 
research has uncovered several proteins currently used as common lymphatic biomarkers. 
Importantly, all these markers are expressed on other cells as well, but the combination of 
different markers allow for LEC discrimination. 
Probably the most important protein in lymphatic biology is PROX-1. Already at day 9.5 to 
14.5 of the embryological state the entire skin of the murine embryo is covered by lymphatic 
vasculature [34]. It is not surprising, that these initial LEC precursors are PROX-1+, as Prox1 
encodes a transcription factor directing lymphangiogenesis, LEC development and LEC 
movement during sprouting [35]. It is often described as the lymphatic master control gene, 
as it regulates the expression of other lymphatic markers such as the vascular endothelial 
growth factor receptor 3 (VEGFR3) and LYVE-1 [36]. 
VEGFR3 (also known as fms-related tyrosine kinase 4 (FLT4)) is a receptor tyrosine kinase 
binding VEGF-C and VEGF-D and mediating lymphangiogenesis [37-40]. Besides its expression 
on BECs during development, it is strongly expressed on LECs, with a high expression on 
lymphatic capillaries and lower expression on lymphatic collecting vessels [40].  
The integral membrane glycoprotein LYVE-1 is a homologue of CD44, involved in leukocyte 
migration [41] and, because of this, highly expressed in lymphatic capillaries (depending on 
the organ of interest) [42, 43]. Although LYVE-1 expression is also found on macrophages, 
liver and spleen sinusoidal endothelium, it is a commonly used marker for 
immunofluorescence staining of LECs in tissues [44]. Its specific role in lymphatic leukocyte 
trafficking is thoroughly discussed in 2.4.2.2. 
PODOPLANIN (PDPLN), initially described on rat kidney podocytes, is a mucin-type 
transmembrane glycoprotein suggested to be involved in intraluminal crawling of leukocytes 
within LVs [45, 46]. PDPLN together with CD31, a pan-endothelial marker, are widely used in 
fluorescence-activated cell sorting (FACS) of LECs as they are expressed in capillary and 
collecting LVs albeit differences in their degree of expression [20, 43]. PDPLN is also expressed 
on stromal cells, like fibroblastic reticular cells, in the LN [47]. The proposed role in lymphatic 
leukocyte trafficking is further discussed in 2.4.2.3. 
These proteins, together with Forkhead box protein C2 (FOXC2), important for lymphatic 
secondary valve maturation [48], REELIN, expressed especially in collecting LVs and important 
in T cell trafficking and leukocyte trafficking in the CNS [42, 49], and VE-CADHERIN have been 




2.2.2 Lymphatic heterogeneity 
 
In the past years, researchers recognized the influence of the microenvironment of different 
organs in shaping their vessels, whether it is blood vessels or LVs, and creating a tissue-
specific entity and molecular heterogeneity [54-58]. The great majority of experiments 
performed in this thesis are focusing on the skin lymphatic system (see 2.4). However, some 
experiments also focus on the lymphatic system of the lung, small intestine and LN. 
Consequently, these lymphatic systems will be briefly introduced and their importance in the 
immune system highlighted. 
 
2.2.2.1 The lung lymphatic system 
 
The lymphatic system of the lung is heavily involved in fluid balance of alveoli, allowing for 
optimal gas exchange. In mice, LYVE-1+ lung capillary LECs are observed in lung lymphatic 
networks in juxta-alveolar connective tissue lining with airway or blood vessels but not within 
thinner alveolar walls. They further converge into larger collecting vessels having valves and 
SMCs [59-62] (Figure 2-2).  
Apart from clearing excess fluids, the lung lymphatic system is involved in trafficking of 
immune cells. Lung lymphatics express chemokines like CCL21 and facilitate the transport of 
antigen loaded APCs to dLNs [63]. Lung lymphatics show strong chemokine immunoreactivity 
and increase expression after infection with Mycoplasma pulmonis [59]. Furthermore, lung 
LECs have unique expression patterns of surface molecules supporting the trafficking of 
immune cells like the activated leukocyte cell adhesion molecule (ALCAM) [64]. However, 
extensive research is required to further understand how immune cells use the lymphatic 
route in the lung to migrate to dLNs and initiate immune responses or tolerance.  
 
2.2.2.2 The small intestinal lymphatic system 
 
In comparison to the lung lymphatic system, the small intestinal lymphatic system is 
understood in more detail. Roles of LECs in the small intestine are very diverse, as they range 
between dietary absorption, tolerance of symbiotic microflora and food antigens to 




The small intestine contains millions of micro-villi, each comprising a central lacteal that is 
surrounded by a dense network of villus blood capillaries [65]. Lacteals branch into a 
submucosal network of lymphatics [66]. Additionally, the small intestine harbors another 
lymphatic network, located in parallel with circular or longitudinal muscle fibers in the 
muscularis mucosae [66]. These two networks then merge near the mesenteric border and 
flow into mesenteric dLNs via mesenteric LVs [66]. Notably, the small intestinal lymphatic 
system by definition does not have collecting vessels [67] (Figure 2-2). 
For its role in fat metabolism, lacteal LECs can take up chylomicrons containing fatty acids and 
nutrients released from enterocytes by transcellular crossing [68, 69]. Lacteals then transport 
the chylomicrons with the help of SMCs into the submucosal lymphatics [70, 71].  
Small intestinal LECs support tolerance induction and aid in immunity against pathogens from 
the lumen of the small intestine. It has been shown that lymphatics are established in close 
relation to parafollicular regions in the small intestine [62]. Loss of intestinal and mesenteric 
dLN LECs in mice expressing diphtheria toxin under the promoter of Lyve1 resulted in severe 
gut inflammation, sepsis and lethality [52].  
Generally, small intestinal lymphatics express common markers such as LYVE-1, PROX-1, 
NEUROPILIN-2 and VEGFR3 [72]. Nevertheless, global transcriptomic analyses of intestinal 
LECs have proven their uniqueness in comparison to for example skin LECs [73]. 
In the small intestine, DCs are one of the major cell types migrating through lymphatics to 
mesenteric dLNs. Vital for migration is a CCL21 gradient as CCR7-/- mice have reduced 
numbers of mesenteric dLN DCs [74, 75]. Likewise, innate lymphoid cells (ILCs) use the CCL21 
gradient and lymphatic route for trafficking to mesenteric dLNs [76]. Currently, it is not 
known, how neutrophils and T cells migrate through intestinal lymphatics and more research 






Figure 2-2: Lymphatic heterogeneity 
(A) Skin lymphatics comprise blind-ended capillaries (Cap.) flowing into pre-collecting vessels (Pre-CV) 
and drain into collecting vessels (CV) resembling the afferent lymphatic vessels (LV). While capillaries 
have a discontinuous basal membrane (BM), Pre-CVs and CVs are mounted with smooth muscle cells 
(SMCs) and a sealing BM. Afferent LVs transport lymph to draining lymph nodes (dLN). 
(B) Within the lung lobus, small lymphatic capillaries reside in the juxta-alveolar space and neighbor 
blood vessels (BVs) and bronchioles (Bro.). Capillaries then drain into CVs via pre-CVs in the 
interlobular septa, shown as a cross-section. Alv. = alveolus.  
(C) Small intestinal lymphatics start with singular capillaries / lacteal LVs in the villus, embedded in 
SMCs. They flow into submucosal LVs, which converge and form mesenteric LVs, flowing to 
mesenteric LNs. The submucosal LVs can be divided into two networks. All lymphatics in the small 
intestine are capillaries as they have a discontinuous BM, only mesenteric LVs outside the small 
intestine resemble a CV shape. 
(D) Afferent lymphatics feed into the LN and merge into a subcapsular sinus (SCS), that consist of two 
layers, ceiling and floor LECs. The floor LECs form cortical sinusoids, which coalesce into the interstitial 
space, from which the medullary sinus drains towards the hilum. Efferent LVs then leave the LN via 




2.2.2.3 The lymph node lymphatic system 
 
The lymphatic system of the LN is one of the best studied lymphatic systems. The LN creates a 
special environment for LEC and BEC interaction and is the major site for the initiation of an 
immune response.  
Modern approaches using single-cell RNA sequencing and immunofluorescence microscopy 
have shown molecularly and geographically distinct lymphatic beds within the LN [58]. 
Afferent lymphatics feed into a subcapsular sinus (SCS) that is lined by two different layers of 
LECs, ceiling and floor LECs. Ceiling LECs are adhering to the collagenous matrix of the capsule 
and floor LECs rest on a meshwork of stromal cells and conduit bundles [77]. The SCS contains 
migrating leukocytes from the afferent lymph, as well as resident SCS macrophages, that 
constantly survey the lumen and bypassing DCs [78] (Figure 2-2).  
Further downstream are several LEC sinusoids. Due to high complexity, exact lining and 
morphology of medullary and cortical sinusoids are not completely understood. However, 
recent advances in optical tissue clearing of LNs have opened new possibilities in the analysis 
of sinus architectures [79, 80]. In mice, at the hilum of the LN, LECs form a medullary sinus 
(MS) that traverses through the medulla into the cortical area of the LN and thus becomes a 
cortical sinus (CS). At the hilum, this medullary sinus converges into an efferent lymphatic 
vessel, leaving the LN. These sinusoids are filled with egressing lymphocytes and resident 
medullary sinus macrophages [81] (Figure 2-2). 
Every type of LEC in the LN expresses numerous biomarkers (PROX-1, LYVE-1, mucosal 
vascular addressin cell adhesion molecule 1 (MADCAM1), CCL20, programmed death-ligand 1 
(PD-L1), macrophage receptor MARCO and PENTRAXIN3) enabling molecular differentiation. 
Additionally, they express cytokines (IL-7, macrophage colony-stimulating factor 1 (CSF1) or 
VEGF), chemokines (CCL21, CCL20, CXC-chemokine ligand 1 (CXCL1), CCL5, CXCL19 and 
atypical chemokine receptor 4 (ACKR4)), trafficking molecules (intercellular adhesion 
molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1)), C-type lectins, 
scavenging receptors, Fc receptors as well as TLRs [82, 83]. A strong geographical and 
molecular heterogeneity promotes diverse immunological roles for LN LECs, including the 
adequate transport of leukocytes, antigen binding and uptake, interaction with resident 





2.3 The immune system of the skin 
 
The skin is the major focus point of this thesis. In the following parts, the functional anatomy, 
and immune cell landscape of the skin will be introduced in detail.  
 
2.3.1 The functional anatomy of the skin 
 
Histologically, murine skin does not differ much from that of other mammals. From outside to 
inside, the outer epithelial epidermis covers the connective tissue of the dermis, separated by 
a basement membrane, which in turn covers an underlying hypodermis composed of mostly 
fatty tissue. Between the hypodermis and a layer of loose connective tissue called adventitia 
are fine layers of skeletal muscle (panniculus carnosus) [84]. 
Although the epidermis is rather thin, it consists of four distinct layers (top to bottom), the 
keratinized stratum corneum, stratum granulosum (containing granules feeding the chemical 
barrier of the skin), stratum spinosum (supporting the integrity of the epidermal layer) and 
stratum basale (accommodating stem cells as well as melanin pigment). The dermis contains 
connective tissue together with blood and lymphatic vessels, hair follicles, associated adnexal 
glands and a strong innervation. The mouse ear skin specifically contains a thick layer of 
cartilage at the hypodermal / adventitial layer [84].  
Physiologically, the skin can be divided into four distinct layers or barriers (outside to inside): 
The microbiome barrier, chemical barrier, physical barrier, and immune barrier. Although 
their functions are distinct, they partly overlap.  
The outermost microbiome barrier hosts commensal bacteria, fungi, and viruses, covering all 
surface areas of the skin. The microbiome of the skin in mice and humans is unique and differs 
from the microbiome of the large intestine [85, 86]. The skin microbiome serves as a barrier 
as it actively stimulates immune cells to produce antimicrobial peptides and proteins, 
increases innate immune alertness and produces antibiotics to prevent survival of harmful, 
non-symbiotic bacteria, as shown in human studies [87-89].   
Although the second barrier, called the chemical barrier, is less defined, it is pivotal for the 
third, the physical barrier. The chemical barrier contains factors that create an acidic milieu 
and together with amino acids and their derivatives, electrolytes, urea, and lactates form the 




The physical barrier is built up by the stratum corneum and incorporates a vast system of tight 
junctions. Corneocytes (cells making up the stratum corneum) are continuously built up by 
terminal differentiation of maturing and moving keratinocytes [92, 93]. Additionally, the 
granulocytes of the stratum granulosum secrete granules containing keratin filaments and 
lipids [92].  
Lastly, the immune barrier contains an armada of resident and migratory immune cells. 
Together, they maintain barrier integrity, sense PAMPs and DAMPs, initiate adequate immune 
responses and local dermal inflammations, recruit cells from the circulation and further 
contribute to barrier repair and homeostasis [94]. 
 
2.3.2 The immunological landscape of the skin 
Under steady-state conditions, the cellular composition of epidermis and dermis spans a 
variety of resident immune sentinels like DCs (and other APCs), T cells, keratinocytes, innate-
like cells, as well as adaptive tissue-resident memory cells. Together they form one unit to 
build up a functional immune system. During an inflammation or pathological conditions, 
macrophages, monocytes, mast cells, B cells, neutrophils and eosinophils become key players 
as well. 
 
2.3.2.1 Dendritic cells 
 
DCs are the major APC type in the immune system and observed in every tissue. Since DCs are 
mainly responsible for the generation of the adaptive immune response, they are vital for the 
establishment of long-term and protective immunity. DCs make up a major leukocyte 
population in the skin and are highly motile considering  they can enter the skin from the 
circulation, migrate and patrol through the ECM, and traffic into dLN via lymphatics. 
Skin DCs are a highly heterogeneous population with functionally specialized subsets. 
Ontogenetically, LCs do not belong to DCs but arise from yolk-sac derived macrophages while 
dermal DCs are closely related to conventional DCs (cDCs, henceforth named as dermal cDCs), 
and derive from hematopoietic stem cells (HSC) and thus the BM. During steady-state 
conditions, LCs reside in the epidermis, whereas dermal cDCs localize in the dermis. Generally, 
DCs are phenotypically described as CD3-, CD66b-, CD19-, CD20- but MHCII+ cells, separating 




infiltrating immune cells during steady state and inflammation and transport cutaneous 
antigens to dLNs to initiate T cell responses. In order to fulfill their immune functions, DCs 
utilize and up-regulate a great variety of activation markers. An overview can be seen in Table 
2-1. 
 
2.3.2.1.1 Langerhans cells 
 
During skin homeostasis, LCs are the only resident APCs in the epidermis, making up for 3-5% 
of epidermal cells, and protrude their dendrites into the interstitial space of the epidermis to 
acquire antigens [95]. Murine LCs are CD11c+, LANGERIN/CD207+, epithelial cell adhesion 
molecule positive (EPCAM+), as well as CD11b+, CX3CR1+ and signal regulatory protein α 
(SIRPα)/CD172α+ [96, 97] (Table 2-1).  EPCAM is commonly used for FACS- and LANGERIN for 
immunofluorescence microscopy-based identification of LCs. LCs have a unique ontology as 
they do not need fms like tyrosine kinase 3 (FLT3) and its ligand FLT3L to develop (in contrast 
to cDCs). Instead, they require interactions with keratinocytes (see 2.3.2.3) and derive from 
macrophage progenitors via IL-34, CSF1 signaling and transforming growth factor β (TGF-β) 
[98, 99]. 
Once LCs are activated by external stimuli, e.g. UV light exposure or haptens, they reduce 
their adhesion to epithelial cells by down-regulating E-CADHERIN and start migrating towards 
LVs in the dermis [100]. Emigration from the epidermis is particularly facilitated by EPCAM 
(reduction of adhesion to keratinocytes) and CXCR4/CXCL12 interaction [96, 101]. 
Additionally, IL-1β, IL18 and tumor necrosis factor (TNF) secreted from keratinocytes are 
described to be important as Il1b−/− and Tnfr2−/− mice show decreased hapten-induced 
migration [102-105]. Within the dLN, LCs primarily initiate tolerogenic immune responses and 
promote the activation of T helper 17 (TH17) cells. The migration of LCs through the ECM and 
into LVs is explained in more detail in 2.4.2. In this thesis, LCs are defined as MHCIIhigh, 
CD11chigh, EPCAM/LANGERIN+ and CD103-. 
 
2.3.2.1.2 Skin conventional dendritic cell 1 and 2 
 
Skin cDCs can be divided into cDC1s, cDC2s and double-negative (DN) cDCs, exclusively found 
in the skin, whereas cDC1s and cDC2s are found across all lymphoid tissues. In skin, cDCs are 




In contrast to LCs, skin cDC1s, cDC2s and DN cDCs are derivatives of BM HSCs and make up 
the majority of DCs. In general, the development and differentiation of cDC1 and cDC2 is 
rather complex. Throughout development, cDCs share the same progenitors until they diverge 
into cDC1 and cDC2. Two of the major growth factors involved in their development are FLT3L 
and CSF2 [97]. One important protein to be mentioned here is C-type lectin domain family 9 
member a (CLEC9a) also known as dendritic cell natural killer lectin group receptor-1 (Dngr-1), 
which is a phenotypic marker of common cDC progenitor cells [106]. CLEC9a expression is 
preserved in cDC1s, whereas cDC2s lose CLEC9a expression during development [107]. This is 
particularly important for the mouse model of EYFP;Clec9acre-Bmal1flox/flox used here. Due to 
the nature of cDC development, it is possible to only target cDCs and not LCs or macrophages 
by using the promotor of Clec9a [107]. 
 
CDC1s are characterized as X-C motif chemokine receptor 1 (XCR1)+, CLEC9a+, cell adhesion 
molecule 1 (CADM1)+, TLR3+, CD141+, CD11c+ and interferon regulatory factor 8 (IRF8)+ [108] 
(Table 2-1). Moreover, they are positive for CD103, which is a marker frequently used for 
identification in flow-cytometric analyses. One of the major differences between dermal 
cDC1s and lymphoid tissue cDC1s is the expression of CD103 instead of CD8α [109]. cDC1s are 
highly mobile and have a high turnover rate, rapidly migrating into the T cell zone of the LN 
[110]. Although cDC1s are not as efficient as cDC2s in activating CD4+ T cells in the LN [111], 
they are adroit in the presentation of soluble exogenous and cell-associated antigens on MHCI 
proteins, a process called cross-presentation or cross priming [112]. This is particularly 
important in herpes simplex virus-1, influenza virus or vaccinia virus infections [113-116]. It 
has also been shown that cDC1s are more efficient in priming CD8+ T cells due to their 
expression of XCR1, the receptor of XCL-1 expressed by memory CD8+ T cells, and initiating 
TH1 immune responses [117]. Notably, a lot of knowledge is missing on dermal cDC1s, as the 
majority of knowledge derives from CD8α+ cDC1s. 
 
cDC2s are the most common population of dermal DCs. cDC2s are described as IRF+, CD11b+, 
CX3CR1+, SIRPα+, CCR2+ and CD11c+ [97] as well as negative for CD64, proto-oncogene 
tyrosine-protein kinase MER (MERTK) and Ly6C to allow absolute discrimination from 
macrophages and monocytes [118] (Table 2-1). In contrast to cDC1s, cDC2s co-express many 
genes associated with monocyte-derived DCs and their transcriptome is less unique [119]. 
However, this might be due to unresolved heterogeneity within cDC2s. Whereas cDC1s 
specifically migrate into the T cell zone, cDC2s are particularly described in the lymphatic 




within the cytoplasm, express a broad range of TLRs (except for TLR3 and TLR12) and are the 
only murine cDC subset expressing TLR7 [121, 122]. Furthermore, they seem to be involved in 
chemo-attraction, as they continuously express macrophage inflammatory protein 1 α/β 
(MIP1 α/β) and CCL5, especially after exposure to TLR7 and TLR9 agonists [123]. In addition, 
cDC2s are better in CD4+ T cell priming due to more efficient MHCII presentation and promote 
TH2 immune responses [124, 125]. Given these data, more knowledge is required on dermal 
cDC2s, as most of the studies have focused on non-dermal cDC2s. 
 
Finally, the mouse dermis contains a very minor population of DCs, which has been 
phenotyped as XCR1−, CD11blow (coining the name ‘double-negative’) LANGERIN−, CD11clow-int, 
CD103low, CD301b−, EPCAMlow, CD64−, SIRPα+, and CX3CR1+ [97]. This population is not 
described in any other mouse tissue than the skin and does not have a human homolog. 
Studies have shown that they are critical in a contact hypersensitivity response after 
administration of the agent dibutyl phthalate on the skin [110]. 
 
In this thesis, skin cDC1s and cDC2s are defined as MHCIIhigh, CD11chigh, EPCAM-/LANGERIN- 






Protein Function LC cDC1 cDC2 Ref 
CD103 
αEβ7 integrin, binding E-CADHERIN, 
adhesion 
- + - 
[108, 
126] 




Antigen cross-presentation, dead cell 
receptor, binds F-ACTIN 
- + - 
[108, 
127] 
CD11b CD18 binding integrin, adhesion, migration  + - + 
[108, 
128] 
LANGERIN Anti-viral immunity, pathogen binding + - - 
[108, 
129] 
CD301b Antigen presentation, CD4+ T cell activation -/+ - + 
[124, 
125] 
SIRPα Docking SHP-1 & SHP-2, migration + - + 
[97, 
130] 
CCR2 Chemotaxis to inflammatory sites - - + [97] 




CLAUDIN, CADHERIN and general junctional 
interaction 
+ - - 
[96, 
100] 
CX3CR1 CX3CL1 receptor, inflammation, chemotaxis + - + 
[97, 
132] 
CCR7 CCL21/19 receptor, chemotaxis + + + 
See 
2.4.2.1 




Cross-presentation, dead cell receptor 
antigen uptake 
+ + + 
[133, 
135] 
CD80 Costimulatory molecule T cell activation + + + [136] 
CD86 Costimulatory molecule T cell activation + + + [136] 
Table 2-1: Activation and migration markers of dermal dendritic cells 
Role and function of molecules in dendritic cell migration through skin lymphatics. LC= Langerhans cell, 
cDC1/2= conventional dendritic cell 1/2. All other abbreviations are explained in text. 
 
2.3.2.2 T cells 
 
The majority of T cells found in the skin are resident (epidermis and dermis), but to a lesser 
extend recirculating and adaptive T cells can also be found in the dermis: resident γδ T cells 
and CD8+ resident memory T (TRM) cells line the stratum spinosum of the epidermis (only in 
mice) and upper layers of the dermis. Less CD4+ TRM are found in the dermis together with 
circulating CD4+ and CD8+ T cells (TCM). In general, T cells are defined as CD3
+ cells. γδ T cells, 
also known as dendritic epidermal T cells (DETCs; only in mice) have a T cell receptor (TCR) 




representing a primitive and limited adaptive immune system that is replaced by TRM over 
time after accumulating antigenic pathogen contacts. Albeit their inability to recognize 
peptides bound to MHC molecules [138], they are activated by stress proteins and can secrete 
IL-17 to activate other immune cells further downstream [139, 140].    
In comparison to γδ T cells, CD8+ TRM are better understood. One unique feature of CD8
+ TRM 
throughout the body is that the core gene expression signature is conserved between organs 
[141]. CD8+ TRM can directly kill virally infected cells [142] and promote an antiviral state in the 
skin by releasing type I interferons (IFNs) and thus activating keratinocytes and other skin cells 
[143]. CD4+ TRM are rapidly activated by pathogen re-challenge and promote pathogen 
clearance from the skin [144].  
In case of an inflammation, the skin is also accommodating regulatory T cells (Treg) aiding in 
the local immune response [5]. 
 
2.3.2.3 Keratinocytes and innate lymphoid cells 
 
Keratinocytes constitute a major element in the immune system of the epidermis. They are 
acting as a first line of defense against potentially harmful microbes [145] and release 
cytokines like IL-1β, IL-18, IL-6, IL-10, TNFs and under specific circumstances chemokines like 
CXCL9, CXCL10, CXCL11, and CCL20 for immune cell activation and guidance [146]. 
Furthermore, keratinocytes express TLRs, thus contributing to their role in the forefront of an 
immune response [146].  An immune response is often induced by keratinocytes as the initial 
contact with PAMPs leads to a release of cytokines activating APCs, in turn upregulating MHCII 
molecules [146]. Keratinocytes are necessary for self-renewal and existence of LCs as they 
release IL-34 and express the keratinocyte-derived integrins αvβ6 and αvβ8 compulsory for LC 
residency [147]. 
Accumulating evidence has shown that also ILCs (ILC1-3) are found in skin [148]. Skin ILC 
subsets comprise migratory ILC1-3s. ILC1s are constantly trafficking between the circulation 
and LNs promoting TH1 cell generation via IFN-y production after immunization in a CD62L
- 
and CCR7--dependent manner. In contrast to this, ILC2s are resident in hypodermal areas 






2.3.2.4 Other immune cells 
 
The dermal layer of the skin comprises various other immune cells, such as monocytes and 
macrophages, mast cells, neutrophils, eosinophils, and B cells.  
Skin macrophages are MHCIIint, CD115+, F4/80+, CD11b+, CSF1R+, Ly6C± (monocytes are Ly6C+, 
macrophages Ly6C-) , CCR2−, CD64+, and MERTK+ and thus just by the phenotype are similar to 
cDCs [133]. However, tracing of genetic lineage and for example specific expression levels of 
CD64 and MHCII allow for a differentiation between DCs and macrophages. Monocytes and 
macrophages closely associate with hair follicles and are pivotal to local immunity [150].  
Monocyte derived macrophages and DCs are especially important in local inflammations (e.g. 
after hapten painting) and activation of T cells [151]. More importantly, macrophages actively 
contribute to a healthy skin homeostasis by being a positive regulator in hair regeneration, 
wound repair, cancer defense, and nutritional salt balance [152].  
Mast cells play a crucial role in allergic responses and the recruitment of immune cells. 
Further they are involved in wound healing by interaction with fibroblasts [153]. Skin 
neutrophils (CD66b+) come into play during inflammatory events by phagocytosing invading 
pathogens in case of a skin barrier malfunction, releasing of neutrophil extracellular traps 
(NETs) to immobilize pathogens and releasing chemokines to recruit more neutrophils to 
inflamed sites [153]. Neutrophils also secret LAMININ 5β-3 to induce adhesion of 
keratinocytes and are involved in angiogenesis to help out in wound repair [154, 155].  
Likewise, B cells (CD19+/B220+) are involved in delayed-type hypersensitivity reactions and 
involved in cutaneous autoimmune diseases by producing skin specific autoantibodies [153]. 
 
2.4 Dermal lymphatic leukocyte trafficking 
 
The major focus point in this thesis is the migration of skin DCs through LVs, as introduced in 
the following. 
2.4.1 The skin lymphatic system 
 
The skin lymphatic system is substantial for fluid homeostasis, transport of lymph containing 
various immune cells and antigens to the dLN as well as adequate immune responses, 




dependent on the thickness of the skin [159], but in general, capillaries and collecting vessels 
are lined in the upper and lower dermis and resemble a typical shape already described  (see 
2.2.1 and Figure 2-1). Just below the epidermis, lymphatic capillaries form a network of 
draining vessels with 10-30µm in diameter (but can reach up to 70µm depending on the type 
of skin and inflammatory state) [159, 160]. These capillaries then drain deeper into the lower 
cutaneous layer, forming a plexus of collecting vessels (via pre-collecting vessels) including 
intraluminal valves, a thick basement membrane and coverage of SMCs (see 2.2.1) [161]. 
These collecting LVs then merge and form large afferent LVs by decreasing their density but 
increasing their diameter in hypodermis and subcutaneous layers [159]. Finally, large 
collecting afferent LVs follow alongside arteries and eventually merge into the SCS of the dLN 
[162] (Figure 2-2). 
Dermal LECs from the lymphatic capillaries are defined as CD31+, LYVE-1+, PDPLNint,  VEGFR3+, 
CCL21high, VE-CADHERIN+ and PROX-1+; LECs from pre-collecting vessels are CD31+, LYVE-1low, 
PDPLN+,  VEGFR3inermediate, CCL21high, VE-CADHERIN+ and PROX-1+; collecting vessel LECs are 
CD31+, LYVE-1-, PDPLN+,  VEGFR3low, CCL21intermediate, VE-CADHERIN+ and PROX-1+ [35, 40, 41, 
45]. Another marker to identify the LVs of the skin is LAMININ, a structural protein in the 
basement membrane of vessels [163].  
Under homeostatic, non-inflammatory conditions and based on early cannulation studies 
conducted in sheep and healthy humans, the lymph of the skin contains numerous 
leukocytes, such as T cells (80-90%), DCs (5-15%) and in lower numbers neutrophils, 
eosinophils, basophils, monocytes, and B cells [164-166].  The T cell fraction can be divided 
into effector/memory CD4+ TEMs (majority), CD4
+ Tregs (approximately 20%, numbers increased 
during inflammation) and CD8+ T cells (minority), as demonstrated using adoptive transfers of 
naïve lymphocytes and transgenic mice expressing photo-convertible proteins like Kaede or 
Kikume [167-173]. Interestingly, and in contrast to the studies presented above, in laboratory 
mice equal percentages of DCs and T cells migrate to the dLN [167]. This is likely due to 
housing within an almost-pathogen free and sterile environment, leading to general antigen-
inexperience and thus, lower numbers of CD4+ TEMs [174].  
Herein, the focus of lymphatic trafficking is set onto DCs only. In general, trafficking of T cells 
and neutrophils through lymphatics is less well described, but has been concisely reviewed by  






2.4.2 Dendritic cell migration through skin lymphatic vessels 
 
In the past 20 years, the majority of the current understanding of DC trafficking has been 
established. Despite major efforts and great studies, the migration cascade is only now 
starting to be understood.  
In summary, the DC trafficking cascade can be divided into interstitial migration, LV entry via 
adhesion and transmigration, intralymphatic crawling, and the passive transport for entering 
the dLN.  
Except for passive transport in large collecting vessels, DCs rely on specific molecules involved 
in chemotactic guidance, and cell to cell contact. The current knowledge is largely based on 
either (time-lapse) imaging and flow-cytometric analyses of ear explants (crawl-in assay or 
crawl-out assay, see 3.2.4 or 3.2.5.1) or adoptive transfers of DCs into the skin and dLN [22, 
176]. Together they could show, that DCs first actively migrate through small pores within the 
ECM of the skin [177]. They are guided by chemotactic cues to be able to reach capillaries 
[178]. Surpassing the flap valves of LECs, they first adhere to LECs and then transmigrate into 
the lumen of the vessel. Once intraluminal, DCs crawl back and forth on the inner wall of LECs, 
until they eventually enter the collecting vessels [179]. With the help of pressure gradients, 
the secondary valves and contractions, the DCs are then passively transported to the dLN 
[180, 181] (Figure 2-3). The current state-of-the-art research investigating proteins involved in 
DC migration to dLN via LVs is summarized in Table 2-2. 
 
2.4.2.1 Interstitial migration  
 
In order to migrate through LVs, DCs first need to arrive at the lymphatic capillary and become 
activated. To overcome a dense environment of heparin sulfate proteoglycans, hyaluronan 
(HA), fibronectin and type I collagen fibrils, DCs perform an amoeboid migration pattern [182-
184]. Under steady-state conditions, DCs migrate through the ECM with a speed of 
approximately 4µm/min [185] and require about 1h for up to 100µm to navigate to a 
lymphatic capillary from the point of initial mobilization [186]. The number of DCs migrating 
towards lymphatics is considerably low at steady-state. However, under inflammatory 
conditions such as contact hypersensitivity the amount and speed of trafficking DCs is 
increased. This is due to keratinocyte-mediated activation of resident DCs via released 




increased interstitial fluid flow, accelerating the DC movement. Nevertheless, the interstitial 
migration appears to be random, unless a chemokine gradient has been reached [178]. 
Once the DC is activated, it relies on chemotactic guidance to reach the lymphatic capillary. To 
date, only a few chemokines and respective receptors have been functionally described to be 
involved in the DC guidance and migration within the skin: CCR7/CCL21/CCL19, ACKR4, 
CXCL12/CXCR4 as well as CX3CL1/CX3CL1R (Table 2-2). 
The chemokine CCL21 (and its receptor CCR7) is by far the best-studied molecule in skin 
lymphatic trafficking. CCR7 is upregulated on maturing DCs [188], whereas CCL21 is 
continuously expressed and released from LECs [189, 190], with higher expression in 
capillaries than in collecting vessels [179]. Genetic ablation of CCR7 and antibody-mediated 
blockade of CCL21 led to a stark reduction of lymphatic DC migration, proving its importance 
[191-193]. The positively charged C-terminus of CCL21 is bound to heparan sulfate-containing 
glycosaminoglycans present in the ECM and on the surface of LECs [194, 195]. Due to this and 
to continuous release, CCL21 forms a haptotactic, interstitial gradient, radiating around LVs 
with a maximum length of 80µm [178]. In contrast to other chemotactic gradients, CCL21 is 
built up exponentially, which is uniquely sensed by DCs [178]. Upon binding to CCR7, CCL21 
increases the activation state of DCs directing the amoeboid movement through a complex 
environment and intensifies both the actin polymerization through small GTPases Ras-related 
C3 botulinum toxin substrate 1 and 2 (RAC1/2) and the nuclear contraction via the RHO 
associated kinase ROCK [177, 185, 196].  
In mice, CCL21 exists in two forms, CCL21-Leucine and CCL21-Serine (due to its two genes 
Ccl21a and CCl21b/c). Experiments with paucity of LN T cells (Plt−/−) KO mice could show, that 
CCL21-Leucine is mainly expressed by peripheral LVs, whereas CCL21-Serine by e.g. LN LECs 
[197, 198]. CCL21 is stored in the Golgi network of the LEC before release [199]. Besides its 
continuous release, CCL21 is immediately secreted upon docking of DCs onto LECs due to 
enhanced Ca2+ signaling and in turn boosts the activation of transmigrating DCs [199]. DCs can 
proteolytically cleave off the positively charged C-terminal of CCL21, which increases the 
solubility of CCL21 and leads to a stronger recruitment of DCs, but this has only been shown 
in-vitro [200] (Figure 2-3).  
In contrast to CCL21, CCL19 is not expressed by LECs but by DCs playing only a minor role in 
trafficking as for example FITC-painting on CCL19−/− ears did not reveal any DC migration 
defects through dermal LVs [201]. Other chemotactic pathways like ACKR4, CX3CL1 or CXCL12 
are either involved in sequestering CCL19 to inhibit sensitization of CCR7 receptors or 
upregulated during inflammation to increase DC chemotaxis [202-206]. Dermal LECs also 




either utilized by other immune cells or functional studies about their impact on DC trafficking 
in the skin are lacking, which is why they are not further described here [206]. 
Before DCs can adhere to LECs, they need to migrate through a porous basement membrane. 
1µm pores within the basement membrane can be extended to 2µm making enough room for 
transmigrating DCs. Additionally, small deposits of CCL21 within these pores aid DCs to 
ascertain correct migration via haptotaxis [22, 187] (Figure 2-3). Once the DCs have 
successfully crossed the basement membrane, they are ready to adhere to LECs and 
transmigrate into the lumen. 
Figure 2-3: The lymphatic leukocyte trafficking cascade 
(A) During interstitial migration, dendritic cells (DCs) perform an amoeboid movement towards a 
chemotactic CCL21-Leucine (Leu) gradient built-up by lymphatic endothelial cells (LECs) lining 
lymphatic capillaries (Cap.). The exponential, extralymphatic gradient has a length of approx. 80µm, is 
attached to extracellular matrix (ECM) fibrils and interacts with CCR7 on the surface of DCs. Upon 
binding of DCs, actin starts polymerizing and contractions occur, creating propulsions. 
(B) Adhesion of DCs onto LECs is initiated by interactions of CCL21, residing in the pores of the basal 
membrane (BM). Upon contact, hyaluronan (HA) on the DC surface binds to LYVE-1 on the LEC surface. 
DCs dock onto LECs, which in turn release further CCL21 aiding in DC activation. Transmigration is 
facilitated by homophilic interactions between CD31 and CD99. 
(C) Within the lumen of capillaries, DCs follow an intraluminal gradient of CCL21-Leu and bind 
molecules like PODOPLANIN (PDPLN) on the surface of LECs with CLEC2. Crawling of DCs on the luminal 




2.4.2.2 Adhesion and transmigration  
 
In contrast to leukocyte transmigration through the blood vessel (BV) endothelium, for which 
interactions between β2 integrins and their Ig superfamily counter receptors are crucial [207], 
the crossing of the lymphatic endothelium relies on a bipartite system. Early studies 
investigating the function of ICAM1 revealed a role in cDC and LC trafficking from skin to dLN 
– but only under inflammatory conditions [208]. Moreover, antibody-based blockade of 
ICAM1, VCAM1 or lymphocyte function-associated antigen 1 (LFA-1) markedly reduced 
inflammation-induced DC trafficking from the skin to the dLN [205]. On the contrary, a study 
using adoptively transferred pan-integrin−/− DCs showed no defects in steady-state migration 
into lymphatic capillaries and dLNs, which was confirmed using CD11c YFP+/VE-CADHERIN 
Cre/Rosa26 Fl RFP+ chimeric mice [177, 187]. Thus, under steady-state conditions, dermal DCs 
traffic in an integrin-independent manner, whereas during inflammation, integrins are 
important and upregulated to maximize DC recruitment [206].  
As a consequence, recent studies started out identifying trafficking markers important under 
steady-state conditions. One marker strongly expressed by capillaries is LYVE-1. LYVE-1 and its 
interaction with HA on the DC surface is vital for skin DC transmigration as pharmacological 
blockage or genetic ablation of LYVE-1 reduced transmigration of dermal DCs [41]. Employing 
superselectivity, LYVE-1 is able to only interact with HA on the DC surface but not on the ECM 
[209]. This is possible due to a high density of HA on the DC surface glycocalyx, selectively 
required for homo-dimerization and finally binding to LYVE-1 [210-212]. Further LYVE-1 is 
involved in lymphatic endothelial junctional relaxation, promoting the diapedesis of DCs [213] 
(Figure 2-3). A full list of other proteins involved in transmigration or chemotaxis is 





Molecules State of knowledge ST? Ref 
ACKR2 
On LECs, regulating discrimination between mature 
and immature DCs. 
+ [214] 
ACKR4 On keratinocytes, scavenges CCL19 in epidermis. + [202] 
ALCAM On hLECs, block reduces DC emigration from LVs. - [215] 
CCR7/CCL21 
DC chemotaxis by extra- and intravascular gradients, 
CCR7-/- & CCL21 blockade reduce DC migration to 






CCR8/CCL1 Regulation of monocyte-derived DC migration to dLN. + [216] 
CD137 
On LECs, potentiates DC transmigration by 
upregulating ICAM1, VCAM1 and CCL21, shown in-
vitro. 
- [217] 
CD31 & CD99 
Support DC adhesion and transmigration by 
homophilic interaction, shown in-vitro. 
+ [218] 
CX3CL1/CX3CL1R CX3CL1 block and deletion reduces DC traffic to dLNs. - [204] 
CXCL12/CXCR4 
DC chemotaxis by extravascular gradient, 
CXCR4 block reduces DC traffic to dLNs. 
+ [205] 
ICAM1/VCAM1 
On LECs, upregulated during inflammation & 





JAM-A-/- mice & JAM-C block enhance DC migration to 
dLNs. 
+ [220, 221] 
L1CAM 
On LCs and LECs during inflammation, 
Tie2-Cre;L1camfl/fl mice reduce DC migration to dLNs. 
+/- [222] 
LTR-B4 & LTR C4 
Binding to DCs, upregulate CCR7 & CCL19, enhance 
migration to dLNs. 
+ [223, 224] 
LYVE-1 
On LECs, mediates DC adhesion to LECs, Lyve1-/- & 




In cDCs & LCs, block reduces LV emigration of DCs. +/- [225, 226] 
MMR-1 
On LECs, influencing migration of LCs to dLNs (not 
significant). 
+ [227, 228] 
PDPLN/CLEC2 
Less intraluminal CLEC2-/- DC crawling, reduced traffic 
to dLNs, CLEC2 initiates actin polymerization. 
+ [229] 
PGE2 
Binds to DCs, enhances migration to dLN modulating 
CCR7 signaling and MMP-9 expression. 
+ [226] 
ROCK 
In DCs, induces integrin de-adhesion, block reduces 
DC migration to dLNs 
+ [185] 
S1P1 Regulation of DC migration to dLNs. +/- [230] 
SEMA3A 
In LECs, activates nuclear contraction in DCs, DCs in 
Sema3a-/- mice reduce migration to dLNs & LV entry. 
+/- [231] 
Table 2-2: Molecules involved in dermal lymphatic dendritic cell trafficking 
ACKR= atypical chemokine receptor, ALCAM= activated leukocyte cell adhesion molecule, ICAM1= 
intercellular adhesion molecule 1, VCAM1= vascular cell adhesion molecule 1, JAM-A/C= junctional 
adhesion molecule A/C, L1CAM= L1 cell adhesion molecule, LTR= LEUKOTRIENE, LYVE-1= lymphatic 
vessel endothelial receptor 1, MMP-2 = matrix metalloproteinase-2, MMR-1= macrophage mannose 
receptor 1, PGE2= prostaglandin E2, ROCK= rho-associated protein kinase, Sema3A= SEMAPHORIN 3A, 






2.4.2.3 Intraluminal crawling  
 
After successful transmigration into the lumen of LVs, DCs start relocating to the dLN. In 
contrast to blood vessels, in LVs DCs crawl bi-directionally until they eventually enter 
collecting vessels, as shown by time-lapse imaging of YFP+ tagged DCs [179]. Recent studies 
have proposed, that the intra-capillary space is more than a highway to the dLN since DCs 
have been observed interacting with T cells within the space [179] (Figure 2-3).  
The term ‘intraluminal crawling’ is based on the fact, that the movement of DCs is not or only 
partly based on passive flow and pressure gradients, but rather on protein interactions and 
chemotactic gradients, that stimulate physical propulsion of DCs. Initial capillaries are not 
contractile due to missing SMCs, have an estimated lymph flow rate of only 200-300µm/min 
(2-3 orders of magnitude slower than blood capillaries and only a bit faster than the 
interstitial flow rate) and do not provide secondary valves [185, 232, 233]. Together, these 
features do not favor passive flow. Instead, DCs follow an intraluminal CCL21 gradient 
together with interactions of proteins like PDPLN or ICAM1 on the intraluminal LEC surface 
with a speed of around 5.7µm/min [185] (Figure 2-3).  
The intraluminal CCL21 gradient is sequestered on the surface of LECs and could be rebuilt in-
vitro. During in-vitro shear stress of 0.015dynes/cm2, close to physical lymph flow rates within 
the capillary, LECs secrete CCL21 from the luminal surface, which is rebound downstream to 
form a directionally oriented gradient [179]. The functionality of this gradient was further 
evidenced by employing CCL21 blocking antibodies or CCR7-/- DCs ablating DC emigration from 
lymphatic capillaries [179] (Figure 2-3). 
Despite required flow rates, CCL21 is likely sequestered with the help of other proteins like 
PDPLN. PDPLN is expressed on the intra- and extra luminal side of skin LECs, binds CCL21 with 
a high affinity and is involved in DC trafficking, as it binds CLEC2 on the surface of DCs [45, 
229, 234]. Furthermore, Clec2-deficient DCs display decreased crawling on PDPLN+ vessels and 
reduced overall migration to dLN [229] (Figure 2-3 and Table 2-2). 
Under inflammatory conditions, proteins like ICAM1 are upregulated on the intra-luminal 
surface, promoting an accelerated DC movement, which could be pharmacologically reduced 
in an in-vitro environment [206]. As with adhesion to the outer LEC surface, the adhesion and 
retraction at the inner surface also requires ROCK [185]. Nevertheless, the intraluminal 
crawling is by far the least investigated part of lymphatic migration. 
Once the DCs have reached the collecting vessels, passive transport takes over: internal 
(contractions through SMCs) and external pressure gradients together with controlled back-




Cornelia Halin (ETH Zurich, Switzerland) displayed direct trafficking of DCs into collecting 
vessels with the help of upregulated VCAM1 during inflammation (3rd Swiss vascular research 
symposium, Lucerne, November 14, 2019). This evokes the hypothesis that LVs under 
inflammation undergo a remodeling towards a venular phenotype, allowing for maximal and 
fast paced trafficking of DCs. This, however, remains to be elucidated. 
The entry of DCs into the dLN is gated by numerous proteins, chemotactic gradients and 
interactions with other immune cells but will not be discussed here. 
 
2.5 Circadian rhythms 
 
Not only are many proteins on immune cells under the control of a circadian clock, but also 
factors in different vasculatures show rhythmicity in expression. In this part, the molecular 
clock and entrainment of peripheral clocks and their influence on rhythmic leukocyte 
trafficking are discussed. 
 
2.5.1 The clock machinery 
 
The majority of organisms on this planet coordinates its behavior to daily environmental 
changes generated by the earth’s rotation. These changes include temperature, 
light/darkness and seasonal cycles. Additionally, behavior is adapted according to food uptake 
and availability. The continuous exposure to environmental cycles acts as a driving force for 
evolution and development of organisms. As a response organisms tune their metabolism and 
the immune system accordingly by establishing 24h rhythms in physiological processes [235]. 
These daily, circadian rhythms (circa diem, ‘for about a day’) impose oscillations in cells across 
many species, including fungi, cyanobacteria, plants, flies, birds and humans. Approximately 
10-20% of the mammalian genome is under direct, more than 20% under indirect, circadian 
control [236, 237]. This means, that at least 20% of genes experience a peak in expression 
once every 24h. 
This temporal programming is concerted by an intrinsic biological clock, preserved across 
different species [235]. In mice, virtually every cell contains the components of the clock 
machinery in its nucleus, including all leukocyte subsets [238]. Cells devoid of a nucleus, like 




rhythmic redox sensing system [239, 240]. The most obvious output of this clock machinery is 
the sleep-wake cycle, but also many other aspects of the mouse are influenced, such as 
locomotor activity, body temperature, cardiovascular and digestive system as well as 
endocrine and immune system [241-243]. It is possible that these biological clocks evolved a 
billion years ago as a response to potential damage through ionizing radiation and oxidative 
stress during exposition of single-stranded nucleic acids, e.g. during cell division [244]. This 
might be supported by the fact that DNA excision repair is tightly controlled by the molecular 
clock as well [245].  
The central circadian pacemaker, or central clock, is located in the suprachiasmatic nucleus 
(SCN) in the hypothalamus, consists of around 20,000 nerves [246] and entrains the 
peripheral clocks via endocrine and systemic cues [238, 247]. The SCN receives direct light 
input from the retina and resides above the optic chiasm, allowing it to translate the light 
information from the solar cycle into biological rhythms; it is furthermore resistant to phase 
perturbations from internal cues [238, 247]. Both the peripheral and central clocks work cell-
autonomously. Yet, the interaction between both is required for synchrony. This synchrony is 
vital as otherwise oscillations in peripheral clocks of multicellular organisms become 
desynchronized and flatten out over time [238].  
Essentially, both the master and peripheral clock share the same molecular architecture [248, 
249] as demonstrated in serum shock experiments on fibroblasts in an in-vitro culture setting 
[250]. The core clock components consist of intertwined oscillatory transcription-translation 
feedback loops concentrating around the transcription factor aryl hydrocarbon receptor 
nuclear translocator-like protein 1 (ARNTL) or brain and muscle ARNT-Like 1 (BMAL1, encoded 
by Arntl) and its heterodimerization partner circadian locomotor output cycles kaput (CLOCK) 
[251]. Molecularly, the clock machinery consists of at least three interlocking feedback loops 
(Figure 2-4). 
 
The BMAL1:CLOCK feedback loop. 
 
Within the nucleus, BMAL1 and CLOCK form the heterodimeric basic helix-loop-helix-PAS 
(PER-ARNT-SIM) transcription factor complex BMAL1:CLOCK, which activates the transcription 
of clock controlled genes (CCGs) by binding to respective E-boxes [251]. Two of these genes 
are the repressor genes Period 1/2/3 (Per) and Cryptochrome 1/2 (Cry). PER and CRY 
heterodimerize in the cytoplasm, form the repressor complex PER:CRY and relocate into the 
nucleus to inhibit BMAL1:CLOCK, reducing further transcription of CCGs. PER:CRY are 




BMAL1:CLOCK dimers being formed [252-254] (Figure 2-4). In addition to this, kinases (CKIα, 
CKIδ, and CKIε) and phosphatases (PP1, PP5) play an important role in PER:CRY degradation, 
nuclear movement as well as regulation of its activity, respectively [255, 256]. 
 
The REV-ERB – ROR feedback loop 
 
The second transcription-translation feedback loop is generated by the clock controlled 
transcription factors retinoid-related orphan receptors (ROR α, β, γ) and REV-ERBs (α, β; 
encoded as Nr1d1 and Nr1d2) [257, 258]. While RORs generally activate the transcription of 
BMAL1, REV-ERBs decrease the transcription rate of Bmal1 by binding to orphan receptor 
elements (ROREs) in its promoter region in a competitive fashion. This connects the first and 
second loop and fine tunes the Bmal1 transcription rate [259]. Furthermore, the REV-
ERB/ROR feedback loop delays Cry1 mRNA expression, which is critical for correct  circadian 





Figure 2-4: Components and interactions of the molecular clock 
Heterodimer BMAL1:CLOCK positively regulates the transcription of clock controlled genes like Per, 
Cry (forming the heterodimer PER:CRY), Dbp, Ror and Nr1d1/2 (REV-ERBs; REV). PER:CRY and REV-
ERBs negatively regulate Bmal1, whereas RORs positively influence Bmal1 transcription. DBP 
positively and NFIL3 negatively regulate PER transcription and are modulated by ROR/REV-ERB. These 




The DBP – NFIL3 feedback loop 
 
The third transcription-translation feedback loop comprises the albumin D-box binding 
protein (DBP), directly regulated by BMAL1 (loop 1), and repressor nuclear factor interleukin 3 
(NFIL3; also known as E4BP4), regulated via RORE elements (loop 2). Together, they act by 
binding to D-box elements and modulating the transcription of for example Per, where NFIL3 
acts inhibitory and DBP stimulating [242] (Figure 2-4).  
This tripartite system is pivotal for a functional clock with a 24h periodicity. Mutations in clock 
genes, such as PER2 (S662G), can lead to diseases and malfunctions in humans [261]. 
Moreover, disruption of the clock due to abnormal lighting or feeding behavior can induce 
pathological changes. As an example, shift work is associated with an increased risk of cancer, 
metabolic disorders and cardiovascular diseases [262-264]. 
 
2.5.2 Synergy of clocks and entrainment 
 
The major entrainment factor or Zeitgeber (from the German ‘time giver’) for the SCN is light. 
The eye is a light receptor in mammals. The SCN needs to transform this light information into 
neuronal signals and transmit it to peripheral clocks. This is possible owing to connections 
between the SCN and the hypothalamus-pituitary-adrenal (HPA) axis and autonomic nervous 
system (ANS). In turn, glucocorticoids as well as temperature act as internal Zeitgebers to 
orchestrate peripheral clocks in e.g. immune cells and vessels [238, 243, 265]. Albeit the 
humoral entrainment, feeding-related metabolic cues for clock synchronization are now 
recognized as being crucial to circadian rhythms as well. One example that is heavily 
influenced by food-uptake is the liver [266, 267]. Currently discussed other entrainment 
factors for leukocytes are reactive oxygen species (ROS) as well as the microbiota [268-270]. 
Studies have shown the influence of systemic cues on clocks within blood vessels and 
leukocytes [243, 271]; however the entrainment of the skin, whether by neuronal, thermal or 









2.5.2.1 Circadian terminologies 
 
In order to fully understand the research of circadian rhythms in immunity, one needs to be 
aware of different terminologies. For a biological process to be truly circadian with an 
approximately 24h period, meaning the time from peak to peak, it is required to be 
entrainable by external stimuli and endurable in constant conditions, such as permanent 
darkness. 
In chronobiology, researchers are interested in the amplitude of oscillations, difference 
between mean and peak values, as well as the acrophase, time of the peak value, and the 
trough/nadir, time of the lowest value. To transform the environmental timing, for example 
light and darkness, into internal timing, the term ‘Zeitgeber time’ (ZT) is used. ZT contains the 
timing of an entrainment stimulus, such as light. Therefore, ZT0 is regarded as the onset of 
light and ZT6 is 6h post light onset. Consequently, it easily allows for comparison of different 
chronobiological investigations and settings across studies. An oscillation in biological 
pathways between different ZTs is described as diurnal. However, if external stimuli do not 
change, e.g. constant darkness, the term ‘circadian time’ (CT) is used, as it reflects the 
subjective time of an organism without external cues.  
Thus, under light/darkness conditions, ZTs are used to represent timing of external cues (e.g. 
ZT12 = onset of light in a 12h:12h light/darkness schedule in an animal house), whereas under 
darkness/darkness conditions, CTs are used (e.g. CT12 = the start of the subjective night, 
when the lights would have switched off). 
 
2.5.3 Circadian rhythms in immunity 
 
Already around 60 years ago diurnal rhythmicity in host responses to lethal infections and 
endotoxins were demonstrated [272]. Likewise, susceptibility to pneumococcal infection 
shows periodicity that is dependent on light/darkness and rhythmic adrenocortical secretions 
[273]. Nevertheless, it is only recently, that research has identified molecular clocks in various 
leukocyte populations and described their role in trafficking of immune cells, host-pathogen 
interactions as well as activation of both innate and adaptive immunity [242, 274]. Every 
leukocyte population examined provides a functional molecular clock, including neutrophils 
[275], monocytes and macrophages [276-278], T cells [279, 280], B cells [278], and DCs [278]. 




development of ILC lineages and lymphocytes like IL-17-producing CD4+ T helper (TH17) cells 
and Bmal1-/- animals show defects in B cell development [279, 281-283]. However, general 
CD4+ and CD8+ T cells are not affected in their development by the clock. 
The molecular clock may help shaping the immune responses to maximize their efficiency but 
at the same time reduce metabolic costs. First, it temporarily limits innate immunity, to 
prevent synchronous and potentially over-reactive activation. This is translated into different 
peaks and troughs in expression and release of complement factors, antimicrobial peptides, 
cytokines and chemokines as well as activation of phagocytes such as DCs [276, 284-286]. For 
example, TLR9 expression is oscillating in mice and peaking at ZT10 in macrophages and ZT16 
in B cells whereas in DCs, no rhythmicity was found [284]. Rhythmic regulation of TLRs in turn 
is immune-protective against harmful events such as sepsis [287]. Secondly, due to temporal 
expression of inflammatory genes, the immune cell clock might control the length of 
inflammatory responses to find a compromise between fast activation and over-activation of 
immune compartments. For example, genetic deletion of Bmal1 or Nr1d1 does not alter the 
peak but alleviates the trough of LPS-induced inflammatory responses in macrophages [288]. 
As another example, it was shown that CRY proteins can directly modulate the inflammatory 
NF-κB pathway [289]. On the contrary, microbial products such as LPS also disrupt the phase, 
period and amplitude of immune cell clocks, shifting basal oscillations of genes towards 
pathogen-associated transcriptional programs [276, 290]. 
In conclusion, the circadian machinery influences every arm of immunity of various organisms. 
One important aspect is rhythmic immune cell trafficking, which will be explained in more 
detail. 
 
2.5.3.1 Circadian leukocyte trafficking 
 
Another way to control the efficiency of immune responses may be to direct the localization 
of immune cells. In the past years, multiple studies have established a strong impact of the 
molecular clock on immune cell distribution and locomotion. For instance, numbers of 
leukocytes in blood show oscillations throughout the day, with leukocytes leaving the blood 
and entering tissue at the behavioral rest phase of an organism (ZT13 in mice and inverted in 
humans) [56]. This time-of-day difference can be abolished by genetic ablation of Bmal1, thus 
linking phenotype and molecular clock [56, 243, 291]. To date, there is no study published 




many other tissues experience rhythms in homing and egress of leukocytes from the innate 
and adaptive immune system. 
In general, leukocytes cross the endothelial wall of veins at different times, e.g. the evening in 
mice. Indeed, genes involved in the trafficking cascade like Icam1, Vcam1, Sele, Selp, Cxcl1, 
Cxcl2 and Ccl2 as well as their proteins ICAM1, VCAM1, E-SELECTIN and P-SELECTIN show 
rhythmic variation across the day [271]. He and colleagues could show that circadian rhythms 
in leukocyte trafficking in the blood system are heterogeneous across organs, with a unique 
mosaic of trafficking molecules being expressed in organ-specific BECs and leukocytes. Albeit 
the organ-specific differences, homing to organs via the blood stream is generally elevated at 
ZT13 and depends both on the clock from the microenvironment as well as the intrinsic 
immune cell clock [56]. 
Specifically, chemokines seem to be strongly regulated by the clock machinery, as this has 
been shown for different organs and cell types. Neutrophil trafficking across the organism is 
highly influenced by circadian rhythms, as their recruitment to the lung and sites of parasite 
infections as well as their overall location is temporally gated by rhythmic expression of the 
chemokines CXCL5, CXCL12 and CXCL2 [275, 290, 292]. Likewise, CXCR4 or CCL2 regulate the 
migration of inflammatory monocytes from blood to BM and sites of infection in a time-of-day 
dependent fashion [276, 293]. Oscillations of T cells in human blood have been linked to 
oscillations in CXCR4 and CX3CR1, again indicating chemokine levels to be a key output of 
circadian immune control [294]. Druzd and colleagues could prove that the cellularity of LNs 
exhibits strong circadian oscillations, with highest lymphocyte numbers at the onset of the 
night in mice [291]. This was due to time-of-day dependent homing and egress of 
lymphocytes to and from the LN. Two of the key regulatory elements found were CCL21 
(tested on high-endothelial venules) and its receptor CCR7 (tested on T cells and B cells), both 
showing a peak in their expression at around ZT7 and suggesting molecular control by Bmal1 
since CCR7 rhythmicity was ablated in T cell specific Bmal1-/- mice. Both the 
microenvironment of the organ and the cell intrinsic clock promote rhythms in trafficking. 
Lymphocyte egress via efferent LVs from LNs is highly rhythmic, with highest counts in lymph 
observed at around ZT9 due to rhythmicity in the expression of S1pr1, a key gene involved in 
egress of lymphocytes [291, 295]. Thus, chemokines are a target of the molecular clock and 
seem to be strongly affected. Rhythms in trafficking molecules including chemokines are 
summarized in Table 2-3.  
Although it was demonstrated that DCs own a molecular clock, a lot of research is lacking 
about how the molecular clock regulates DC-specific immune aspects. DCs play a major role in 




Bmal1-/- mice lost the circadian rhythmicity of humoral immune response with a dampened 
immunoglobulin production at night [296]. Additionally, circadian variations in responses to 
antigens have been observed in mice and since DCs are the major APCs in the immune 
system, this might suggest circadian control mechanisms in DC biology [297]. DCs might also 





Origin AP Ref 
CCL2 Serum, art & ven BECs, brain CT12, ZT1, 7, 6 
[271, 288, 
298] 
CCL21 LN HEV 9 [291] 
CCL5 Serum CT12 [288] 
CCR1 B, eos, IM N/A [56] 
CCR10 CD4+ N/A [56] 
CCR2 CD8+, NIM N/A [56] 
CCR3 Eos N/A [56] 
CCR4 CD8+ N/A [56] 
CCR6 B N/A [56] 
CCR7 B, CD4+, CD8+ 13 [56, 291] 
CD11a N, B, CD4+, CD8+, eos, IM N/A [56] 
CD11b NIM N/A [56] 
CD18 CD4+, CD8+ N/A [56] 
CD29 N, IM N/A [56] 
CD44 Skin & SI BECs, B, CD4+, CD8+, eos, IM, NIM N/A [56] 
CD49d N, B, CD4+, CD8+, eos 7, 9, 9, 9, 13 [56] 
CD49e IM, NIM N/A [56] 
CD49f CD8+ N/A [56] 
CD62L N 1 [299] 
CX3CR1 IM, NIM N/A [56] 
CXCL1 Serum, art & ven BECs CT12, ZT1, 7 [271, 288] 
CXCL12 BM fluid, Plasma 21, 17 [299, 300] 
Cxcl2 Art & ven BECs 1,17 [271] 
CXCR2 N N/A, 13-21 [56, 299] 
CXCR3 CD4+, eos, NIM N/A [56] 
CXCR4 N, B, CD4+, CD8+, NK, eos, IM, NIM, HSC 
13/17, 13, 13, 




CXCR5 B, CD8+ N/A [56] 




Splenic, LN, liver, SI, PPs, muscle, art & ven 
BECs 
Ø 13, 1/7, 17 
[56, 243, 
271] 
ICAM2 Thymic, liver, gut, PPs BECs Ø 13 [56] 
L-SELECTIN N, B, CD4+, CD8+, eos 1, 13, 13, 17, 17 [56] 
MADCAM LN BECs N/A [56] 






Origin AP Ref 
P-selectin BM, thymic, splenic, ven BECs 13, N/A, 17 
[56, 243, 
271] 
PSGL-1 N, B, CD4+, CD8+, NK, eos, IM, NIM N/A [56] 
S1pr1 LN tissue 5 [291] 
S1pr3 LN tissue 5 [291] 
S1pr4 LN tissue 1 [291] 
S1pr5 LN tissue 1 [291] 
VCAM1 
Thymic, splenic, LN, lung, PPs, BM, art & 
ven BECs 
Ø 13, 1, 17 
[56, 243, 
271] 
Table 2-3: Rhythms in murine trafficking molecules & chemokines 
Comparative list of rhythmic trafficking molecules and chemokines in mice. Exact acrophases (Aps) of 
respective proteins are mentioned if stated in the publication. Italic indicates mRNA. AP shown in ZT as 




= T cells, NK= natural killer cells, eos= 
eosinophils, IM= inflammatory monocytes, NIM= non-inflammatory monocytes, HSC= hematopoietic 
stem cell, LN= lymph node, PPs= Peyer’s patches, SI= small intestine, BM= bone marrow, art= arterial, 
ven= venular, BEC= blood endothelial cell, HEV= high endothelial venule. PSGL-1= P-selectin 
glycoprotein ligand-1, other abbreviations explained in text. Ø = no organ-specific ZTs but only averages 
are given in the publication. 
 
2.5.3.2 Circadian rhythms in skin  
 
To date, there is no study examining the molecular clock of skin LECs or DCs under steady 
state. Although literature covering circadian rhythms in skin is scarce, there are studies 
showing that skin is heavily influenced by environmental factors. Mouse skin contains a 
functional molecular clock that is controlled by the SCN and feeding time [98, 302, 303]. One 
regulator of dermal clocks is melatonin [304]. It is secreted by the pineal gland in a rhythmic 
fashion, being high during the behavioral rest phase and low during the active phase [305]. 
Melatonin has been associated with suppression of skin UV damage, hair growth, wound 
healing and antitumor effects [304-306]. Collectively, this allows for the assumption that the 
immune landscape of the skin might be under circadian control.  
Although it was already shown about two decades ago that the skin expresses clock genes 
[307], time-of-day influence on the skin’s immune system is only now starting to be 
uncovered. Transcriptome analysis of total mouse skin harvested every 4h for 48h revealed a 
circadian regulation of more than 1400 genes including chemokines, pro- and anti-
inflammatory cytokines as well as anti-microbial peptides, with the majority peaking during 
the onset of the resting phase [302, 308]. Moreover, skin permeability in the stratum corneum 
is higher in the onset of the behavioral rest phase as AQUAPORIN 3 is regulated by the clock 




more proliferating keratinocytes during the resting phase [311]. Finally, clock genes heavily 
influence the nature of hair follicles, even during missing influence of the SCN [312].  
Various skin immune diseases like psoriasis disease show circadian variability [313, 314] and 
genetic clock ablation might even enhance pathological skin reactions [315]. This has also 
been observed in humans, for which night-shift work increases the incidence of psoriatic 
lesions due to misalignment of clocks in the skin [316]. Another study has shown that 
abolishment of circadian rhythms changes the trafficking of APCs in skin and impaired 
hypersensitivity reactions [317]. In addition to that, researchers applied imiquimod, a TLR7 
agonist, to murine skin to dampen the rhythmicity of skin inflammation and thereby could 
show circadian control of IFN-sensitive gene expression in skin [318]. 
Uncovering and examining the molecular clock of skin immune cells and vessels might aid in 
chronotherapy and timed vaccination strategies, as the skin is one of the major sites for 
vaccinations. 
 
2.5.4 Chronotherapy and the benefit of rhythms in immunity 
 
Scientists currently try to decipher how genetic or environmental disruption of the clock can 
translate into or exacerbate pathological conditions as outlined in many animal models and 
human studies [313, 316, 319-321].  It is well known in humans that diseases like asthma, 
rheumatoid arthritis, acute myocardial infarction and ventricular arrhythmias as well as acute 
coronary syndrome show time-of-day variation in occurrence, symptoms and disease markers 
[322-326]. Many studies investigating chrono-immunotherapy are arising from this, e.g. 
administration of drugs at specific times during the day. Notably, numerous drugs used in 
treatment of inflammatory, metabolic, neurologic and cancerous diseases influence clock 
controlled targets [327].  
More and more studies are initiated testing the timed delivery of vaccines. For vaccination, a 
functional lymphatic system and trafficking of dermal DCs are required. One study revealed 
that morning vaccination yields an enhanced antibody-response in comparison with afternoon 
vaccination in a cluster-randomized human trial [328]. Another recent study testing the anti-
tuberculosis vaccine Bacillus Calmette-Guérin pointed towards higher effectivity of 
vaccination in the morning. This circadian influence on vaccination efficacy could even be 
extended to very preterm infants and non-mammalian animals [329, 330]. Less knowledge 




be heavily involved as administration of vaccine during the day leads to a stronger and more 
efficient activation as well as proliferation during the day compared to the night [331]. 
Unfortunately, there are no circadian vaccination studies available surveying the skin DC 
trafficking. 
Taken together, a better understanding of the molecular clock of DCs and the lymphatic 
system would be of great benefit for the chronotherapeutic targeting of diseases as well as 
novel approaches such as timed vaccination and therapies. 
 
2.6 Objective & aims 
 
Within this thesis, I aim to decipher how the molecular clock of the lymphatic system and to 
lesser extent of the dermal DCs are influencing rhythmic dermal lymphatic leukocyte 
trafficking. This is accomplished by the following aims: 
 
1. Establishment of ex-vivo crawl-in trafficking assays as well as visualization of LECs and 
DCs. 
2. Demonstration of rhythmic DC trafficking into initial skin lymphatic capillaries. 
3. Assessment of the dermal LEC intrinsic clock by measuring rhythmic RNA and protein 
expression in LECs. 
4. Analysis of the dermal DC intrinsic clock functionality.  
5. Survey of functional rhythmic trafficking molecules and chemokine micro-patterning 
in skin. 
6. Establishment of genetic clock ablation and scrutinizing the molecular link between 










 Materials and Methods 3
3.1 Materials 
3.1.1 Buffers and media 
Buffer / medium Supplements Application 
R10 – RPMI 1640 
10% FCS (heat-inactivated) 





dendritic cell culture, staining 
buffer, crawl-in & crawl-out 
assay 
R10 + HEPES –  
Phenol-red free RPMI 1640 
10% FCS (heat-inactivated) 





Live-imaging of crawl-in 
assays 
FACS buffer (PEB) 
PBS 
0.02M EDTA 
20% FCS (heat-inactivated) 
FACS 








1M acetic acid  
Gel electrophoresis 





(pH = 8.5) 
gDNA isolation 
Table 3-1: Buffers and media 
 
3.1.2 Kits 





















All primers were designed using the PCR primer design tool and purchased at Eurofins 
(Munich, Germany). F= forward, R= reverse, MT= mutant, C= common, WT= wild type. 
Primer Sequence (5’ → 3’) 
Generic CRE F GCG GTC TGG CAG TAA AAA CTA TC 
Generic CRE R GTG AAA CAG CAT TGC TGT CAC TT 
Bmal1 flox F ACT GGA AGT AAC TTT ATC AAA CTG 
Bmal1 flox R CTG ACC AAC TTG CTA ACA ATT A 
Clec9acre C AAA AGT TCC ACT TTC TGG ATG ATG A 
Clec9acre WT TCA CTT ACT CCT CCA TGC TGA CG 
Clec9acre MT GGC TCT CTC CCC AGC ATC CAC A 
Prox1cre WT F GTG GAA AGG AGC GTA CAC TGA 
Prox1cre C CAC ACA CAC ACA CGC TTG C 
Prox1cre MT F GCC AGA GGC CAC TTG TGT AG 
Table 3-3: Genotyping primers 
 
3.1.4 Antibodies and staining reagents 
All antibodies used in this thesis target mouse proteins. 
3.1.4.1 Primary antibodies 
Antigen Conj. Dil. Clone Appl. Catalog # Supplier 




B220/CD45R PE-Cy7 1:100 RA3-6B2 FACS 103222 
Biolegend 
London, UK 


















CD11b AF700 1:200 M1/70 FACS 101222 
Biolegend 
London, UK 






CD11c APC/Cy7 1:400 N418 FACS 117323 
Biolegend 
London, UK 
CD11c BV510 1:300 N418 FACS 117337 
Biolegend 
London, UK 




Antigen Conj. Dil. Clone Appl. Catalog # Supplier 
Laagstraat, 
Belgium 
CD16/32 - 1:50 93 FACS 101302 
Biolegend 
London, UK 



























CD31/PECAM-1 AF488 1:100 390 IF 102413 
Biolegend 
London, UK 
CD4 BV605 1:100 RM4-5 FACS 100548 
Biolegend 
London, UK 







1:500 30-F11 FACS 103145 
Biolegend 
London, UK 
CD45 AF488 1:500 30-F11 FACS 103122 
Biolegend 
London, UK 




CD45 BUV395 1:300 30-F11 FACS 565967 
Biolegend 
London, UK 








CD8a APC-Cy7 1:100 53-6.7 FACS 100713 
Biolegend 
London, UK 




EPCAM/CD326 AF647 1:1000 G8.8 FACS 118212 London, UK 



























ICAM1 PE 1:100 YNI.7.4 IF 116108 
Biolegend 
London, UK 
























KI67 PE 1:100 16A8 IF 652403 
Biolegend 
London, UK 






















1:100 1A8 FACS 127615 
Biolegend 
London, UK 


































Antigen Conj. Dil. Clone Appl. Catalog # Supplier 
5.2 London, UK 

















NEUROPILIN PE 1:100 3E12 IF 145204 
Biolegend 
London, UK 























Table 3-4: Primary antibodies 
 
3.1.4.2 Secondary antibodies and streptavidin 
Target Host Conj. Dilution Clone Catalog # Supplier 


























3.1.4.3 Isotype antibodies 
Isotype Conj. Dil. Clone Appl. Catalog # Supplier 





































Rat IgG2a, κ PE 1:100 RTK2758 IF 400508 
Biolegend 
London, UK 












Rat IgG2a, λ 
PerCP-
Cy5.5 




Rat IgG2b, κ PE 1:100 RTK4530 IF 400608 
Biolegend 
London, UK 





3.1.4.4 Neutralization antibodies 
Target Host IG Conc. Clonality Catalog # Supplier 










































































Table 3-7: Neutralization antibodies 





3.1.5 Chemicals and reagents 
Chemical / reagent Supplier Location 
5x GoTaq Flexi Promega Madison WI, USA 
Agarose Biozym Scientific Oldendorf, Germany 
Buprenorphine / Temgesic Indivior UK Limited Hull, UK 
CellTrace Violet Thermofisher Darmstadt, Germany 
Collagenase IV Sigma-Aldrich Taufkirchen, Germany 
Corn oil Sigma-Aldrich Taufkirchen, Germany 
CountBrightTM absolute counting 
beads 
Life Technologies Darmstadt, Germany 
DAPI Biolegend London, UK 
dATP, dCTP, dGTP, dTTP 
nucleotides 
Promega Madison WI, USA 
Dispase II Sigma-Aldrich Taufkirchen, Germany 
DNAse I AmbionTM Life Technologies Darmstadt, Germany 
EDTA Life Technologies Darmstadt, Germany 
Absolute ethanol for molecular 
Biology 
AppliChem Darmstadt, Germany 
FastGene 11bp DNA Marker Nippon Genetics Düren, Germany 
FastGene Optima PCR HotStart Nippon Genetics Düren, Germany 
FCS  Life Technologies Darmstadt, Germany 
GoTaq Hot Start Promega Madison WI, USA 
Heparinase II & IV Sigma-Aldrich Taufkirchen, Germany 




South Logan, Utah, USA 
Isoflurane CP-Pharma Burgdorf, Germany 
Isopropanol (Propan-2-ol) Applichem Darmstadt, Germany 
Ketamine Medistar Munich, Germany 
L-glutamine Sigma-Aldrich Taufkirchen, Germany 
Lipopolysaccharide (LPS) from 
Escherichia coli 
Sigma-Aldrich Taufkirchen, Germany 
Magnesium Chloride (MgCl2) Promega Madison WI, USA 
mCCL21 Peprotech Hamburg, Germany 
Murine GM-CSF In house produced Martinsried, Germany 
Midori Green Advance Nippon Genetics Düren, Germany 
Normal Goat Serum Sigma-Aldrich Taufkirchen, Germany 
OCT compound Sakura Finetek 
Alphen aan den Rijn, 
Germany 
Paraformaldehyde solution 4% in 
PBS (PFA) 





Pen/Strep Sigma-Aldrich Taufkirchen, Germany 
Proteinase K Life Technologies Darmstadt, Germany 
RPMI Gibco Darmstadt, Germany 
SDS 10% Sigma-Aldrich Taufkirchen, Germany 
Sodium Chloride (NaCl2) Sigma-Aldrich Taufkirchen, Germany 




Chemical / reagent Supplier Location 
Tris AppliChem Darmstadt, Germany 
Triton-X100 Sigma-Aldrich Taufkirchen, Germany 
Trizol-LS Qiagen Hilden, Germany 
Xylazine / Rompun Bayer vital GmbH Leverkusen, Germany 
β-mercaptoethanol (β-me) Gibco Darmstadt, Germany 
Table 3-8: Chemicals and reagents 
 
3.1.6 Utilities 
Utility Supplier Location 
24-well plates Thermo Fisher Scientific Darmstadt, Germany 
Petri dish (4cm, 6cm and 10cm) Corning Kaiserslautern, Germany 
Surgery utilities Fine Science Tools Heidelberg, Germany 
Modelling Clay Städtler Nürnberg, Germany 
Cover glass Thermo Scientific Darmstadt, Germany 
Tissue Slide Thermo Scientific Darmstadt, Germany 
1.5ml & 2ml microfuge tubes Eppendorf Hamburg, Germany 
1ml, 2ml and 10ml syringes BBraun and Terumo 
Melsungen, Germany and 
Shibuya City, Japan 
15ml and 50ml Polypropylene 
conical centrifuge (falcon) tube 
Falcon / Fisherscientific Darmstadt, Germany 
Needles for injection BD Microlance Heidelberg, Germany 
40µm and 70µm strainer Fisherbrand Darmstadt, Germany 
1ml, 200µl, 20µl and 2.5µl pipette 
tips 
Starlab Hamburg, Germany 
Cryomold Tissue Tek Sakura Staufen, Germany 
S35 microtome blade Feather / Cellpath Ltd Newtown, UK 
Cell culture filter 50ml and 500ml Sigma-Aldrich Taufkirchen, Germany 
5ml FACS tubes w/o filter Falcon Darmstadt, Germany 
Cryotubes Thermo Fisher Scientific Darmstadt, Germany 
Table 3-9: Utilities and materials 
 
3.1.7 Machines 
Machine Supplier Location 
Gallios flow cytometer Beckmann Coulter Krefeld, Germany 
Light / Darkness cabinet (small) Parkbio Gaveland, MA, USA 
Light / Darkness cabinet (large) Tecniplast Buguggiate, Italy 
Mastercycler Epgradient S Eppendorf Munich, Germany 
NanoDropTM 2000 Life Technologies Darmstadt, Germany 
Coulter Z2 (cell counter) Beckmann Coulter Krefeld, Germany 
PowerPac Basic (for gel 
electrophoresis) 
BioRad Munich, Germany 
Electrophoresis chamber BioRad Munich, Germany 
ThermoMixer F1.5 Eppendorf Munich, Germany 
Vortex Genie 2 Scientific Industries Munich, Germany 




Machine Supplier Location 
Heraeus Multifuge X3R Thermo Fisher Scientific Munich, Germany 
Cryotom CM3050 S Leica Wetzlar, Germany 




Bright-field microscope (cell 
culture) 
Leica Wetzlar, Germany 
Gel imaging chamber INTAS Science Imaging Göttingen, Germany 
Mastercycler nexus Eppendorf Munich, Germany 
Minicentrifuge Eppendorf Munich, Germany 
Spinning disk confocal microscope Zeiss Jena, Germany 
LSRFortessa BD Heidelberg, Germany 
Gallios flow-cytometer  Beckmann Coulter Munich, Germany 





Table 3-10: Machines 
 
























































default filter & 



































































Default filter Filter range [nm] 




















































































405 387/11 382-391 
488 485/20 475-495 
561 560/25 552-572 
640 650/13 644-656 
10x ocular – (magnification = ocular x objective) 
Table 3-12: Microscope configurations 
 
3.1.8 Softwares 
The Matlab licence was kindly provided by the group of Dr. Tobias Bonhoeffer at the Max-
Planck Institute for Neurobiology Martinsried, Germany. 
Software Version Supplier Location 
ImageJ / Fiji 1.51n Open-Source USA 
Slidebook 6.0 




Matlab R2018b Mathworks USA 
Prism 7.0 GraphPad USA 
Excel  2010/2017 Microsoft USA 












All animals referred to as wild type animals (WT) in this doctoral thesis were male C57BL6/6N 
mice aged 6-8 weeks (or otherwise indicated) and purchased from either Charles River 
Laboratories (Sulzfeld, Germany) or Janvier labs (Le Genest-Saint-Isle, France). Genetically 
modified animals used in this work include: Cdh5-creERT2-Bmal1flox/flox (referred to as EC-
Bmal1-/-), Prox1-creERT2-Bmal1flox/flox (referred to as LEC-Bmal-/-), EYFP;Clec9acre-Bmal1flox/flox 
(referred to as DC-Bmal1-/-), Cd99-/- and Myd88-/- mice. Cdh5-creERT2 mice (B6) were 
previously obtained as a kind gift from Dr. Ralf Adams (Max-Planck-Institute for Molecular 
Biomedicine Münster, Germany) and crossbred with B6 Bmal1flox/flox mice obtained from 
Jackson Laboratories (Sulzfeld, Germany; as previously used in [56]) to be able to target blood 
and lymphatic ECs. B6 Prox1-creERT2 mice (purchased at Jackson Laboratories Sulzfeld, 
Germany) were crossbred with Bmal1flox/flox mice to obtain Prox1-creERT2-Bmal1flox/flox mice to 
specifically target LECs. B6 EYFP;Clec9acre mice were a kind gift from Dr. Barbara Schraml 
(LMU Munich, Germany) and were crossbred with Bmal1flox/flox at ENVIGO (Milano, Italy) to 
solely target cDC1 & cDC2. B6 Cd99-/- mice were a kind gift from Dr. Dietmar Vestweber (Max-
Planck-Institute for Molecular Biomedicine Münster, Germany, which was also the site of the 
experiments) and Myd88-/- mice were purchased from Jackson Laboratories. 
 
3.2.1.1 Housing & animal law regulations 
 
All animals except CD99-/- mice (14h:10h) were housed under a 12h:12h light:dark schedule 
with ad libitum access to water and food in the Core Facility Animal Models at the Biomedical 
Centre (CAM; LMU, Germany). Animals were supervised by multiple care takers and 
veterinarians. Upon each shipment, animals were given seven days to adjust to the new 
environment before experiments. All experiments were performed using age- and sex-
matched groups. All animal procedures and experiments were in accordance with the ministry 
of animal welfare of the region of Oberbayern and with the German law of animal welfare.  
Mice were always euthanized using an isoflurane chamber (>5% isoflurane) with subsequent 





3.2.1.2 Light / darkness (LD) experiments 
 
For each experiment, animals were either removed from the animal facility and directly used 
at time points indicated or placed into time shifted light cabinets to facilitate simultaneous 
experiments at different time points of the day. For each shift of 1h, animals were placed in a 
cabinet at least 1 day prior to the experiment (e.g., animals for experiments at ZT19, 2am, 
were harvested at 2pm and were thus placed into a +/- 12h shifted cycler 12 days prior to the 
experiment). 
For constant darkness experiments (to obtain information without rhythmic light influence), 
mice were kept under constant darkness conditions in red cages for at least 24h prior to 
experiments. As mice cannot perceive red light information [332], this simulated complete 
darkness. These animals were euthanized under red light. 
 
3.2.1.3 Tamoxifen treatment 
 
Cre/lox-directed gene knockout is based on the ‘floxing’ of an essential exon of the gene of 
interest with two loxP sites with ensuing expression of a recombinase Cre to excise the 
flanked exon, thus generating a null allele (or dysfunctional protein) in all cells where cre is 
active. The ligand-dependent chimeric CRE recombinases (CreER) consist of a CRE fused to 
mutated hormone-binding domains of the estrogen receptor which inhibits the release and 
function of CRE. CreER recombinases can be activated by the synthetic estrogen receptor 
ligand 4-hydroxitamoxifen (henceforth referred to as tamoxifen), allowing for temporal 
release and activation of CRE. The CreERT2 specifically contains a triple mutation 
(G400V/M543A/L544A) and is currently the best tool in the CreER utility box [333].  
To induce CRE expression, animals were given intraperitoneal (i.p.) tamoxifen injections for 5 
consecutive days at the age of 6 weeks. Prior to the injection, each mouse was weighed. For 
each 20g of mouse, 1mg of tamoxifen was injected (0.02 g/mL). Fresh tamoxifen was 
dissolved in corn oil under sterile conditions, sterile filtrated and directly used for injection 
using a 25G x 5/8 needle attached to a 1ml syringe.  Each day, the site of injection was altered 
to avoid further injuries and every injection was performed at the same time of day. Animals 





3.2.1.4 DNA isolation 
 
To obtain the genotype of Cdh5-creERT2-Bmal1flox/flox, Prox1-creERT2-Bmal1flox/flox and 
EYFP;Clec9acre-Bmal1flox/flox mice, ear clips were harvested by animal caretakers and used for 
genotyping. Biopsies were digested overnight in 200µl genotyping lysis buffer (Table 3-1) 
together with 1µl proteinase K (in total 1.5 U per sample) at 55°C while shaking at 700rpm. 
The next day, samples were thoroughly mixed, centrifuged at 4°C for 10min at 18,000 x g and 
its supernatant was transferred to a new tube containing 500µl isopropanol. Tubes were 
inverted multiple times to let the DNA precipitate and spun down at 4°C for 10min at 18,000 x 
g. The supernatant was removed and the DNA pellet was dissolved in 100µl TE-buffer (Table 
3-1) while being slowly shaken for 1h at 300rpm and 37°C. Either samples were directly used 
for polymerase chain reaction (PCR) or frozen and stored at -20°C.  
 
3.2.1.5 Genotyping PCR 
 
Cdh5cre & Bmal1, Prox1cre & Clec9acre genotyping had an individual PCR protocol. 
Consistently, 1µl of extracted DNA in TE-buffer was used. The primer concentration used was 
10µM (Table 3-3). DNA was added to the reaction mix (Table 3-14) and amplified according to 
PCR programs (Table 3-15) on a Mastercycler Epgradient S.  
 
 
Reagent 1x solution (19µl reaction vol.) [µl] 
Cdh5cre and Bmal1 reaction 
Nuclease-free H2O 8 
2x Fast gene buffer 10 
10µM F primer (1:10) 0.5 
10µM R primer (1:10) 0.5 
Prox1cre reaction 
Nuclease-free H2O 6,36 
5x Green buffer goTaqflix 4 
25 mM MgCl2 1.6 
1mM dNTP 4 
WT primer (1:10) 1 
Common primer (1:10) 1 






Nuclease-free H2O 7,875 
5x Green buffer goTaqflix 4 
25 mM MgCl2 1.5 
1mM dNTP  4 
WT primer (1:10) 0.5 
Common primer (1:10) 0.5 
Mutant primer (1:10) 0.5 
GoTaq 0.125 
Table 3-14: Genotyping PCR master mix 
 
Temperature [°C] Time Reaction 
Cdh5cre reaction 
95 3 mins Initial denaturation 
Start cycle 
95 20 sec Denaturation 
62 30 sec Primer annealing 
72 30 sec Polymerization 
End cycle – repeat 38x 
72 10 mins Final extension 
Bmal1 reaction 
94 3 mins Initial denaturation 
Start cycle 
94 30 sec Denaturation 
55 30 sec Primer annealing 
72 30 sec Polymerization 
End cycle – repeat 35x 
72 2 mins Final extension 
Prox1cre reaction 
94 3 mins Initial denaturation 
Start cycle 
94 15 sec Denaturation 
61.4 15 sec Primer annealing 
72 10 sec Polymerization 
End cycle – repeat 35x 
72 2 mins Final extension 
Clec9acre reaction 
94 3 mins Initial denaturation 
Start cycle 
94 30 sec Denaturation 
61.4 30 sec Primer annealing 
72 40 sec Polymerization 
End cycle – repeat 35x 
72 10 mins Final extension 





3.2.1.6 Genotyping gel electrophoresis 
 
For visualization, 1% agarose gels including Midori Green (1:25,000) were used. 10µl of the 
PCR product were added to the agarose gel. DNA samples ran for around 30-50min 
(depending on the product) at 200V together with a 100bp DNA ladder marker (Table 3-8). 
The gel was imaged using ultraviolet light on an UV transilluminator. The respective PCR 
products and examples of genotypes can be seen below (Table 3-16 and Figure 3-1). Only mice 
that express CRE in a hetero/hemizygotic fashion (abbreviated as CRE+) or WT were used, as 
hemizygotic CRE expression is sufficient for Bmal1 excision. For Bmal1, only mice homozygotic 
for flox (fl/fl) were used. Cre negative mice were used as control mice. 
 
 
Product  Size [bp] Reaction 
CRE band 324 Cdh5cre 
Flox band 431 Bmal1 fl/fl 
WT band 327 Bmal1 fl/fl 
CRE band 160 Prox1cre 
WT band 280 Prox1cre 
CRE band 597 Clec9acre 
WT band 407 Clec9acre 





3.2.2 Organ harvest & surgeries 
3.2.2.1 Ear harvest 
 
Once the mouse was euthanized (see 3.2.1), the ears were freed from loose hair using 70% 
ethanol and cut off at the transition from ear to head (seen by a color change of the skin, dark 
to bright). Ear sheets were then separated into dorsal and ventral sides using blunt forceps. 
The ear was placed ventral side up and held down with one pair of forceps. The other pair of 
Figure 3-1: Genotyping gel electrophoresis 
From top to bottom: Cdh5cre, Bmal1, Prox1cre and Clec9acre reactions. Bands were size matched and 
based on this, genotypes were created. Numbers on the left indicate the size of the DNA marker. 




forceps then carefully and slowly pulled off the almost transparent uppermost layer of the 
skin. Both layers contain epidermis and dermis, the ventral side contains less cartilage and 
was always used. 
 
3.2.2.2 Bone harvest for bone marrow-derived dendritic cell isolation 
 
To harvest femur and tibia for experiments, the mouse was euthanized as described 
beforehand (see 3.2.1). Legs were released from the pelvic bone by cutting the surrounding 
skin. A straight pair of scissors was used to cut major ligaments and muscle strands. Reverse 
rotations of the bone then separated the femur from the tibia. Intact bones were further 
cleaned with tissue paper and a scalpel and immersed in 70% EtOH.  
 
3.2.2.3 Superior cervical ganglionectomy 
 
The superior cervical ganglionectomy (SCGx) surgery was performed by Dr. Chien-Sin Chen 
(LMU Munich, Germany). Prior to the surgery, mice were anaesthetized by intraperitoneal 
(i.p.) injection of ketamine (100mg/kg) and xylazine (20mg/kg). Skin on the ventral neck area 
was depilated and the whole surgery was commenced as described in [243, 334]. Briefly, a 
ventral incision of the skin was performed from the anterior tip of the sternum to the chin to 
expose the mandibular glands. These were then separated by carefully tearing apart the 
connective tissues. After separation, the carotid bifurcation of the internal and external 
carotid arteries was exposed. This bifurcation was flipped outwards to the side using a fine 
suturing threat to expose the SCG, which was then gently removed by dissection with sharp 
forceps. The incision was then closed by using fine suture threats. Animals were given a 2 
weeks recovery period until the final experiment and received pain medication 









3.2.3 Cell culture 
 
Cells cultured and used for experiments in this thesis include WT and CCR7-/- bone marrow-
derived dendritic cells (BMDCs) as well as hybridoma cells for producing murine granulocyte-
macrophage colony-stimulating factor (GM-CSF).  
 
3.2.3.1 Bone marrow-derived dendritic cell culture 
 
To culture BMDCs, femur and tibia were harvested from euthanized mice as described above 
(see 3.2.2.2). Single cell suspensions were isolated from femur and tibia using a 21G needle 
attached to a small 1 mL syringe filled with PBS, quantified on a cell counter and used for 
plating 2.75x106 BM cells. BMDCs were cultured using full R10 medium (Table 3-1) 
supplemented with 20ng/ml GM-CSF.  
Depending on whether BMDCs were used for ex-vivo crawl-in live imaging or endpoint 
analysis, cells were cultured for 9 or 10 days, respectively, at 37°C and 5% CO2. On day 3, 10ml 
of R10 medium supplemented with 20ng/ml GM-CSF were added. On day 6 and 8, 10ml 
medium of the cell culture were exchanged with 10ml fresh R10 medium supplemented with 
20ng/ml GM-CSF. At day 9 or 10, all non- and semi-adherent cells were harvested and plated 
on a 6cm petri dish in R10 medium supplemented with 10ng/ml GM-CSF and stimulated with 
100ng/ml LPS for 24h.  
Viability and purity of BMDCs was tested before every experiment measuring the expression 
of MHCII and CD11c on DAPI- BMDCs. For this purpose, 1x106 BMDCs were first Fc receptor 
blocked with anti-mouse CD16/32 for 5min at RT and subsequently stained with fluorescence-
conjugated antibodies (Table 3-4 and Table 3-17) for 30min at 4°C. DAPI (0.3µM) was added to 
the cells, whose purity and viability were then analysed by flow-cytometry using a Gallios Flow 
Cytometer (Figure 3-2, Table 3-11 and Table 3-17). Viability and purity of cells were always 
greater than 94% and 80%, respectively, in every experiment. 
Antigen Fluorophore Machine 
MHCII PE/Cy5 
Gallios Flow Cytometer 
CD11c APC/Cy7 





3.2.3.2 CellTrace Violet bone marrow-derived dendritic cell stain 
 
After maturation and stimulation (see 3.2.3.1), the BMDCs were stained with CellTrace Violet 
(CTV). CTV dye was added to 1x106 cells (working concentration of 5µM, diluted in PBS) and 
incubated for 20min at 37°C in the dark, followed by 2x5min washes (300 x g and RT) using 
R10 medium. The cell concentration was then adjusted to 500,000 or 750,000 cells/ml and 
used for exogenous crawl-in assays. 
 
3.2.3.3 Granulocyte-macrophage colony-stimulating factor producing hybridoma cell culture 
 
GM-CSF producing hybridoma cells were a kind gift of Dr. Cornelia Halin. Frozen hybridoma 
cells were washed and then resuspended in 5ml R10 (day 0). Here, R10 was not 
supplemented with β-me. On day 3, 10ml of R10 were added to the cells. On day 6, cells were 
Figure 3-2: Bone marrow-derived dendritic cell culture viability and purity 
1x10
6
 bone marrow-derived dendritic cells (BMDCs) were cultured for 10 days and lipopolysaccharide 
(LPS) activated for 24h. Cells were then stained and analysed on a flow-cytometer. After single cell 




 BMDCs were checked. In each experiment, viability 




transferred to a larger cell culture flask and medium with 150ml R10 (3 days incubation time 
each). On the final day, hybridoma cells were harvested and spun down at 300 x g for 5min at 
RT and the supernatant was collected. GM-CSF in the supernatant was quantified using a GM-
CSF ELISA kit according to the manufacturer’s instructions (Table 3-2). GM-CSF was then 
sterile filtered, aliquoted and frozen until further usage.  
 
3.2.4 Crawl-in assays (cell trafficking assays) 
3.2.4.1 Exogenous crawl-in assay (end-point) 
 
To identify and examine the time-of-day dependent difference in lymphatic leukocyte 
trafficking, an exogenous crawl-in assay was utilized. 
For the ex-vivo mouse ear sheet crawl-in migration assay (here referred to as exogenous 
crawl-in assay), mice were euthanized as described above (see 3.2.1). The initial protocol was 
based on [178] and then adapted for rhythmic analyses. Ears were quickly harvested (see 
3.2.2.1) and rinsed in R10 medium (Table 3-1). The ear halves were then placed in custom 
built imaging chambers and immobilized (Figure 3-3A). Around 25,000-37,500 labelled BMDCs 
(exact numbers depending on the assay) were added on top of the open ears which were 
placed in 37°C, 5% CO2 for 10-30min (WT BMDCs were incubated for 15min, CCR7
-/- BMDCs 
and controls for 30min). During this incubation, BMDCs attach to the dermal tissue. After 
washing off any unbound BMDCs with PBS, the ears were completely covered with R10 
medium and incubated for 3h at 37°C, 5% CO2. Within this incubation time, BMDCs migrate 
towards LVs. 
Figure 3-3: Imaging chamber for ear whole mounts 
Imaging chambers were always assembled the day before the experiment.  
(A) The glass on top of the open ear ensures even flattening of the ear half and thus massively improves 
the imaging quality. Except for live imaging and initial incubation of added bone marrow-derived 
dendritic cells (BMDCs), the cover slip was always added for every skin whole mount. 
(B) For live imaging and initial incubation time of BMDCs, the ear was flattened using clay in an ellipsoid 





Ear sheets were then stained with different combinations of LYVE-1, CD31 or PDPLN (Table 
3-4) for 30min at RT and subsequently fixed for 1h in 4% PFA. For the end point analyses, 
staining was performed after the migration incubation, to reduce any effects of protein 
staining and possibly blocking of BMDC migration. After placing ear sheets in the custom build 
image chamber (Figure 3-3B), images were obtained using a Zeiss Axio Examiner.Z1 confocal 
spinning disk microscope (Figure 3-4 and Table 3-12). 
At least 8 images / ear sheet were taken from LVs (pre-collecting and capillaries) using a 20x 
magnification. For analysis, the number of cells outside or inside the vessels was counted 
using 3D visualization tools in Fiji and Slidebook 6.0 as well as orthogonal views and optical 
slicing (Figure 3-4). This number was then normalized to the calculated volume of the vessels. 
To calculate the volume of the vessels, an elipsoid structure of the vessels was assumed. 
  
Figure 3-4: Exogenous bone marrow-derived dendritic cell crawl-in assay 
(A) 25,000 CellTrace Violet
+
 bone marrow-derived dendritic cells (BMDCs) were added onto split ears 
& incubated for 180min at 37°C and 5% CO2. After 180min, BMDCs have localized inside the lumen of 
PODOPLANIN
+
 (PDPLN) vessels as exemplified with a 10x objective. 
(B) Higher magnification and 3D rendering visualizes BMDCs migrating into lymphatic capillaries.  
(C) Mean-fluorescence.-intensity (MFI) profiling of BMDCs enables a clear separation of BMDCs inside 




3.2.4.2 Endogenous crawl-in assay 
 
To analyse and better understand the time-of-day difference in endogenous dermal DC 
trafficking through LVs, an endogenous crawl-in assay was designed. For the endogenous skin 
DC mobilization and crawl-in migration assay (in this thesis referred to as endogenous crawl-in 
assay), mice were euthanized and ear halves harvested as described above (see 3.2.1 and 
3.2.2.1). After a 15min wash in R10 medium, ear sheets were stored on R10 medium dermis 
facing down at 37°C 5% CO2 for 6h or 24h in 24-well cell culture plates. During the incubation 
period, dermal DCs become mobilized and migrate towards lymphatic capillaries (see Figure 
3-5). Afterwards, ear sheets were fixed for 2h in 4% PFA and stained for CD11c and either 
LYVE-1 or CD31 for 30min at RT (Table 3-4). The number of cells in and outside the vessels as 
well as the vessel volume was then analysed as before (see 3.2.4.1, Figure 3-4B&C and Figure 
3-5). 
 
Figure 3-5: Endogenous crawl-in assay 
Ears were harvested, split and cultured dermis facing down for 0h, 12, 18h or 24h and stained for LYVE-
1 and CD11c. The longer ears were incubating on medium, the more CD11c
+
 dendritic cells migrated 
into LYVE-1
+




3.2.4.3 Live imaging of exogenous crawl-in assays 
 
For live-imaging of the exogenous crawl-in assay, mice were euthanized and ear halves were 
harvested as described above (see 3.2.1 and 3.2.2.1).  
Ear sheets were then stained for LAMININ with a primary antibody for 45min in R10 medium 
at RT, followed by a secondary FITC conjugated antibody for another 45min at RT in R10 
medium (Table 3-5) prior to the assay. Ear sheets were placed in custom built imaging 
chambers (Figure 3-3), immobilized and 50,000 BMDCs in R10 medium were added on top. 
After 10min incubation at 37°C 5%, CO2, unbound BMDCs were washed off with R10 medium 
and ear halves were immersed in phenol-red free R10 supplemented with 10 mM HEPES 
(Table 3-1). Imaging in a 5% CO2 chamber at 37°C was then commenced with one 30-40µm 
deep 3D image per 120 seconds for around 60min using either 10x or 20x objectives. 
 
3.2.4.4 Short crawl-in assays with zone segmentation 
 
To decipher the role of time-of-day dependent differences in the CCL21 chemokine gradient, 
short crawl-ins with zone segmentation of the dermal interstitium were employed. Mice were 
euthanized and ears harvested as described above (see 3.2.1 and 3.2.2.1). 
37,500 BMDCs in R10 medium were cultured for 10 days, LPS activated for 24h and then 
added to the opened & immobilized ear sheets for 15min at 37°C and 5% CO2. After a wash in 
R10, sheets were incubated in either 0min, 10min, 20min, 30min, 40min, 50min or 60min. 
Immediately after the assay, sheets were washed in PBS and stained for CD31-488 at RT for 
30min. After another wash, sheets were fixed in 4% PFA for 1h and mounted for imaging using 
custom-built imaging chambers (Figure 3-3). 5 3D (20x objective) with 30-40µm depth were 
acquired / sheet and transformed into maximum z-projections. In each projection, the LVs 
were manually outlined and a binary mask and distance dependent map was generated with 
distance zones as shown in Figure 3-6 using algorithms (see 7.2). CTV+ BMDCs were counted 









3.2.5 Flow cytometry 
3.2.5.1 Crawl-out assay and ear cellularity quantification 
 
To quantify and phenotype the ear cellularity and how well dermal DCs can emigrate the skin 
into medium, ears were harvested from euthanized mice as described beforehand (see 3.2.2.1 
and 3.2.1.1), weighed and placed  onto R10 medium (Table 3-1) dermis facing down for 1h to 
wash. 
After incubation, ear halves were stored on fresh R10 medium for 24h which was either plain 
or supplemented with 1µg/ml mCCL21 (henceforth described as crawl-out assay). 24h later, 
ear halves were harvested, pooled and gently digested for 20min at 37°C with collagenase IV 
(1mg/ml), DNase (0.2mg/ml) and dispase II (0.2mg/ml). If no crawl-out but direct 
quantification or phenotyping of the ear cellularity was desired, ear halves were quickly 
washed in PBS after harvest and directly digested. After digestion, cells were filtered through 
a 70µm cell strainer, washed in PBS (5min, 300 x g at RT) and resuspended in FACS buffer 
(Table 3-1). Simultaneously, the medium containing emigrated DCs was harvested, pooled, 
washed with PBS (5min, 300 x g at RT) and both the ear cell suspension and medium cell 
suspension were first Fc receptor blocked with anti-mouse CD16/32 for 5min at RT and 
subsequently stained with fluorescence-conjugated antibodies for 30min at 4°C (Table 3-4 and 
Table 3-18). DAPI (0.3µM) and full-bright counting beads were added to the cells, which were 
then analysed by flow-cytometry using either a Gallios Flow Cytometer or LSRFortessa flow-
cytometer at the LMU Munich or University of Geneva (Table 3-11 and Figure 3-7 for the 
gating strategy). 
 
Figure 3-6: Zone segmentation of the lymphatic interstitium 
Segmentation of the interstitium of lympativ vessels (LV) was performed using Matlab. A region of 
interest was drawn based on CD31 signal resembling LVs. An algorithm then segmented the space 
into 20µm contours that were used for analysis. Cells in the LV were excluded from the analysis. The 




Antigen Fluorophore Experiment Machine 
CD103 FITC 























































Figure 3-7: Skin dendritic cell & crawl-out assay gating strategy 
(A) For flow-cytometric analysis of ear cellularity & phenotyping, ears of mice were harvested and 
directly digested and stained.  
(B) To quantify the amount of emigrated skin dendritic cells (DCs; crawl-out assay), ears were cultured 
on R10 medium for 24h. Medium was then harvested, pooled and cells were stained.  
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3.2.5.2 Sorting of skin LECs  
 
To sort murine skin LECs for RNA sequencing, 4 ears from two mice were harvest, digested as 
described above (see 3.2.4.1 and 3.2.5.1) and pooled per biological replicate and time point. 
Harvesting of ears was always done at 8am using light/darkness cabinets to minimize side 
effects. After isolation, the cell suspensions were prepared solely on ice for sorting on a BD 
FACSAriaIIIu (Table 3-11). The cell fraction was stained with fluorescence-conjugated 
antibodies for 30min at 4°C (Table 3-4 and Table 3-19). Immediately before the sort, DAPI 
(0.3µM) was added to the cells. Live PDPLN+CD31+ LECs were sorted directly into 350µl Trizol-
LS at 4°C using a 100µm nozzle and with a purity > 90% as determined after every sort (Figure 
3-8). The cell numbers sorted ranged between 3000 and 5000 cells / two pooled ear pairs (see 
3.2.8 for exact numbers). Directly after sorting, the samples were shock-frozen on dry-ice.  
 
Antigen Fluorophore Experiment Machine 
PODOPLANIN PE 
LEC sort FACSAriaIIIu CD45 PE/dzl594 
CD31 APC 
Table 3-19: Staining panel for lymphatic endothelial cell sort 
Figure 3-8: Gating strategy of sorted lymphatic endothelial cells  














3.2.6 Functional neutralization of proteins and chemokine gradient disturbance 
 
To investigate the functional relevance of proteins involved in rhythmic dermal DC trafficking, 
neutralization antibodies or chemokine disturbances were utilized. Split ears used for 
exogenous crawl-in assays were incubated with R10 medium containing diluted neutralization 
antibodies prior to the cell migration assay for 1h at RT (Table 3-7). In case of the endogenous 
crawl-in assay, neutralization antibodies or reagents were directly added to the R10 medium 
for 24h. In general, isotype antibodies of neutralization antibodies were used as controls 
(Table 3-7). Endogenous and exogenous crawl-in assays were further performed as described 
above (see 3.2.4). 
For disturbing the extracellular CCL21 gradient in the skin, ear halves were incubated with 
either heparinase II and IV (100 mIU) at 37°C for 1h or placed in PBS containing 0.1% BSA and 
0.6µg/ml CCL21 at 4°C for 90min prior to the endogenous crawl-in (Table 3-8). After 
heparinase incubation, ear halves were thoroughly washed to remove any remaining CCL21. 
Ear halves were then stored on R10 for 24h and the endogenous crawl-in assay was 
performed as described above (see 3.2.4.2). 
 
3.2.7 Immunofluorescence staining 
 
All immunofluorescence stainings were imaged using a Zeiss Axio Examiner.Z1 confocal 
spinning disk microscope. In general, ear whole mounts were imaged using a custom-built 
imaging chamber (Figure 3-3).  
 
3.2.7.1 Quantitative immunofluorescence staining 
 
To measure the expression levels of trafficking molecules in LECs, mice were euthanized as 
previously described (see 3.2.1) and organs (ear, inguinal LN, lung and small intestine 
(cleaned)) were harvested, placed in OCT, shock frozen on dry ice and stored at -80°C. The 
next day, organs were shifted to -20°C and sectioned at a thickness of 10µm on a cryostat to 
ensure only having one layer of cells on a glass slide (organs were given 1h to warm up to -20 




resistant pen. Sections were then fixed with cold methanol (100%) for 10 min at RT followed 
by a 5min wash in PBS at RT and blocked and permeabilized in PBS containing Triton-X100 
(0.5%) and normal goat serum (20%). Sections were always stained for LYVE-1-AF488 in 
combination with the proteins of interest labelled with either PE or APC o/n at 4°C (Table 3-4). 
For quantification and as negative controls, isotype stains (Table 3-6) were employed. On the 
next day, samples were washed with PBS for 2x5min in PBS at RT and imaged. 
For staining intracellular CCL21 in sections using a biotinylated anti-CCL21 antibody, the tissue 
slides were fixed for 10min using cold methanol (100%) and blocked and permeabilized in PBS 
containing triton-X100 (0.5%), normal goat serum (20%) and avidin (20%; Table 3-2). After a 
wash for 10min in PBS at RT and incubation in PBS containing 20% biotin, the sections were 
stained for LYVE-1 and CCL21 o/n at 4°C (Table 3-4). On the next day, samples were 3x5min 
washed with PBS, incubated in streptavidin-PE (2.5µg/slice) at RT for 15min (Table 3-5) and 
washed again for 3x5min using PBS for. 
2D images were obtained using a 20x objective with at least 5 pictures of the region of 
interest. For quantification, 5 images of one slice were averaged and counted as one 
biological replicate. Automated thresholding was applied to identify LYVE-1+ capillaries and 
create a mask, which was then applied to the fluorescent signal of the protein of interest 
(Figure 3-9). 
The average mean-fluorescence intensity of 5 isotype stains was then deducted from the 
mean fluorescence intensity of the protein of interest. It was always made sure, that the LYVE-
1+ area size did not differ significantly between samples within one type of organ.  
 
Figure 3-9: Quantitative immunofluorescence analysis 
(A) 10µm skin sections were stained for LYVE-1 and JAM-A o/n. LYVE-1
+
 lymphatic vessels were selected 
with a region of interest (ROI; shown in yellow). 
(B) Images were cleared for any fluorescent signal outside the ROI. 
(C) Using automated thresholding, only the LYVE-1
+
 capillary was selected (shown in red). 
(D) The ROI (shown in yellow) of the automated thresholding was applied to the JAM-A fluorescent signal 




3.2.7.2 Whole mount immuno-fluorescence staining 
 
To better understand the 3D architecture of proteins expressed on LVs or cellular structures 
in the skin, ears were collected as described beforehand (see 3.2.1 and 3.2.2.1). In general for 
whole-mount staining of skin, split ears were either 4% PFA fixed for 1h before or after 
staining of proteins with fluorescence-conjugated and primary/ secondary antibodies or biotin 
and streptavidin (see 3.1.4). In case of staining for CD31 or PROX-1, fixation was done after 
staining. If staining for LYVE-1, PODOPLANIN, LAMININ, CCL21, JAM-A, JAM-C, CD99, VE-
CADHERIN, CD11c, CD103, LAMININ, KI67 and GOLPH4, split ears were fixed before staining. 
For proteins expressed on the surface of cells, split ears were blocked in R10 medium for 2h at 
RT. Split ears were then placed in the staining solution for either 30min at RT or o/n at 4°C. 
After 3x15min wash in PBS at RT, the whole mounts were ready to image. 
 
3.2.7.3 Intracellular whole mount staining of CCL21, GOLPH4, PROX-1 and KI67 
 
To image intracellular proteins in skin whole mounts, harvested ears were first fixed in 4% PFA 
at RT for 1h and then blocked and permeabilized in R10 medium containing 0.3% triton-X100 
for 1h. Ear halves were further (without washing) incubated in R10 medium supplemented 
with primary or in the case of PROX-1 and KI67 staining fluorescence-conjugated antibodies 
o/n at 4°C (Table 3-4). Ears were washed for 2x15min in PBS at RT and either directly imaged 
(PROX-1 + DAPI (0.3µM)) or incubated in R10 containing secondary antibodies and 
streptavidin (Table 3-5). After 3x15min wash in PBS at RT, DAPI (if needed; 0.3µM) was added 
to the cells and whole mounts were imaged.  
To analyse the intracellular amounts of golgi- and vesicular CCL21 in LYVE-1+ LECs in skin, 5 
different regions of lymphatic capillaries were imaged. Maximum z-projections of 30-40µm 
deep z-stacks were then taken for analysis in FIJI. A makro (see 7.2) was used to minimize any 
human bias. The makro first created a ROI based on LYVE-1 expression and automatically 
excluded non-lymphatics and lymphatic-membrane regions, so that only the nucleus and 
cytoplasm of LECs were left. CCL21 was then first quantified in GOLPHhigh regions, resembling 
the golgi apparatus (regarded as golgi CCL21). The golgi area was then deducted from the 
cellular compartment, and CCL21 in the remaining GOLPH4low staining was quantified 




the isotype MFI signal from GOLPH4high and GOLPH4low regions was deducted (analysis is 
based on the example shown in Figure 3-9) 
 
3.2.7.4 CCL21 whole mount staining and gradient analysis 
 
To visualize and analyse the extracellular CCL21 gradient, ears from euthanized mice were 
harvested as described above (see 3.2.1 and 3.2.2.1) and directly fixed for 1h in 4% PFA. After 
blocking in R10 medium containing avidin (20%) for 1h at RT, leaving split ears in PBS and 
Biotin (20%) for 30min, split ears were stained for LYVE-1 and CCL21 (Biotin) o/n at 4°C (Table 
3-4). Next day, ears were incubated in streptavidin-PE for 3h at 4°C in the dark (Table 3-5). 
After washing for 3x15min in PBS at RT, split ears were mounted and imaged. 
Images used to quantify the average intensities of interstitial CCL21 chemokine signal were 
maximum intensity projections ranging between 30-40µm Z-stacks with a z-step size of 1µm. 
Within an area of 512x512 pixels (341.33µm x 341.33µm), LV capillaries were manually 
outlined based on LYVE-1 staining, converted into binary masks and transformed into distance 
maps (via Matlab, see 7.2). The average intensity images of CCL21 staining were then 
integrated into distance-dependent fluorescence intensities (Figure 3-10). 5 average distance-
dependent fluorescence intensities from different locations within one mouse ear were 
averaged and counted as one biological replicate.  All samples from ZT7 and ZT19 were 
normalized to the highest average fluorescence intensity of ZT7. Isotype stains were taken as 
negative controls. 
  
Figure 3-10: Extracellular CCL21 gradient analysis 
(A) Ear sheets were stained for LYVE-1 and CCL21 o/n and subjected to analysis. 
(B) LYVE-1
+
 capillaries were outlined to create a region of interest. Based on this, the image was 
transformed into a binary mask. 
(C) The image was converted into a distance map which was applied to (D) to measure the averaged 
intensity at every distance from the binary mask. The algorithm can be seen in the appendix (see 7.2). 





3.2.8 RNA sequencing of lymphatic endothelial cells 
 
Shock frozen, sorted LECs (see 3.2.5.2) were stored at -80°C and then given to Dr Julia 
Phillipou-Massier in the Laboratory for Functional Genome Analysis (LAFUGA; Gene Center 
LMU, Germany), which performed the RNA isolation, cDNA reverse transcription, gene bank 
generation as well as the RNA sequencing. The analyses were partly done by Julia Philippou-
Massier and Stephan Holtkamp. The methods description was provided by Julia Philippou-
Massier. 
Zeitgeber Time # Cells Purity [%] RNA conc. [ng/µl) RIN value 
1.1 3544 91 
Not provided by 
Core Facility 
Not provided by Core 
Facility 
1.2 3627 94 
1.3 3448 96 
1.4 3791 93 
1.5 3217 95 
7.1 4355 96 
7.2 4894 97 
7.3 5595 91 
7.4 5599 91 
7.5 3847 92 
13.1 3449 94 
13.2 3807 95 
13.3 3424 93 
13.4 3906 95 
13.5 3398 97 
19.1 6819 96 
19.2 3538 95 
19.3 5684 92 
19.4 5465 91 
19.5 5659 92 
Table 3-20: Cell counts of sorted lymphatic endothelial cells 
 
Briefly, RNA of cells harvested in TriZol LS was purified using Direct-zol RNA mini Prep Kit 
(ZymoResearch) following manufacturer’s instructions. Isolated RNA was quantified using the 
Nanodrop (Thermofisher) and analyzed on a Bioanalyzer (Agilent) using the RNA 6000 Nano or 
Pico Kit (Agilent). Next, 75 ng of eluted total RNA was digested with DNase (Thermofisher) to 
remove DNA contaminations. An additional purification step with RNAClean XP Beads 
(Agencourt) was performed. The purified, bead bounded RNA was directly used as input in the 
SMART-Seq v4 Ultra Low Input RNA Kit (TaKaRA Bio). Full-length cDNA was generated 




HS Assay Kit (Invitrogen) with the Qubit fluorometer. Finally, sequencing libraries were 
generated using 500 pg full-length cDNA following the NexteraXT protocol (Illumina). Briefly, 
in a single tube enzymatic reaction cDNA is simultaneously tagmentated and tagged with 
Illumina sequencing adapters before the obtained sequencing libraries are amplified. Finally, 
sequencing libraries were quantified on a Bioanalyzer (Agilent) using the DNA 1000 Kit 
(Agilent) and sequenced on a HiSeq1500 system (Illumina) with a readlength of 100 nt, single-
end mode.   
For data processing, obtained transcriptome profiles were processed on a Galaxy web 
interface [335] hosted by LAFUGA, Gene Center, Munich. After demultiplexing and 
recommended trimming data was mapped against the mouse genome (mm10) using RNA-
STAR mapper (Galaxy Version 2.5.2b-0). Abundant reads were counted using HTSeq-count 
(Galaxy Version 1.0.0). Afterwards gene expression analysis to detect differentially expressed 
genes was performed using DESeq2 (Galaxy Version 2.11.40.6) setting the FDR <0.05. 
Shown RNA counts in the results section were normalized to gene length and presented as 
either log2 or raw values. Heat maps of genes were generated using GraphPad Prism 7.0. 
 
3.2.9 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 7.0. All data are represented as 
mean ± SEM. For comparison of two groups, either an unpaired student’s t-test or a Mann-
Whitney test was performed. One-way ANOVA followed by Tukey’s post hoc test, two-way 
ANOVA followed by a Šidák correction or a Kruskal-Wallis test were executed if three or more 
groups were analysed.  
In order to examine the oscillations and rhythmicity of data, a cosinor-based 
rhythmometry/statistical technique was employed [336]. The more a fitting curve lining 
through the data of different time points mirrors the shape of a cosinor’s curve, the lower the 
p-value and more significant the oscillation of the data is. Statistical significance was assessed 







4.1 Visualization of lymphatic vessels 
 
The study was commenced by establishing the visualization of LECs in skin, LN, small intestine 
and lung using quantitative immunofluorescence imaging and a spinning disk confocal 
microscope.  
First, 10µm sections of these four organs were stained for LYVE-1, PDPLN and CD31. Imaged 
sections of the skin revealed large triple positive LVs (Figure 4-1A). Notably, the depicted 
central large vessel is marked with an arrow, and surrounded by small, blind-ended LYVE-1+ 
capillaries (Figure 4-1A). LN LECs were triple positive for LYVE-1, PDPLN and CD31 as well, with 
LYVE-1 showing the strongest signal intensity. This triple positivity extended to all lymphatic 
sub-regions, the SCS, CS and MS (Figure 4-1B). 
Captured small intestine sections presented LYVE-1+ lacteals and outer small intestinal 
submucosal LVs (SMLVs). This LYVE-1+ signal overlapped with PDPLN+ and CD31+ signals, 
forming a triple positivity for these biomarkers as well (Figure 4-1C).  
Finally, stained lung sections displayed a dense vascular network, in which evenly distributed 
small LYVE-1+ vessels could be observed. These LVs were double positive for CD31 and PDPLN. 





I then moved from 2D visualization to 3D visualization allowing for a better understanding of 
the 3D lymphatic architecture. For this purpose, a whole mount staining technique for the 
skin and small intestine was set up (see 3.2.7.2). 
Similar to 2D images, 3D images of stained whole-mounted ears showed LYVE-1high capillaries 
merging into LYVE-1low pre-collecting vessels. These vessels were also positive for PDPLN, 
CD31 and LAMININ. Since CD31 and LAMININ stain other cellular structures as well, LVs in the 
respective images are highlighted with an arrow (Figure 4-2A). Higher magnification visualized 
an accumulation of LYVE-1 and CD31 in cell to cell contact regions (junctions), whereas PDPLN 
was evenly dispersed on the LEC surface and LAMININ on the basal membrane (Figure 4-2A).  
Figure 4-1: 2D Fluorescence microscopy of lymphatic biomarkers 
Fixed and permeabilized 10µm slices of sectioned ears (A), inguinal lymph node (B), small intestine (C) 
and lung (D) were stained for LYVE-1, PODOPLANIN (PDPLN), and CD31. Each image contains 4 
patched images to facilitate a greater view. 
(A) Arrow directs at a large lymphatic vessel. Scale bar = 70µm 
(B) Scale bar = 100µm. SCS = subcapsular sinus, CS = cortical sinus, MS = medullary sinus. 
(C) Scale bar = 100µm. Lac = lacteal, SMLV = submucosal lymphatic vessel. 




This was visualized with a Slidebook 3D software tool at higher magnification, confirming 
LYVE-1 to be expressed on LEC junctions and that PDPLN was evenly distributed on the LEC 
membrane (Figure 4-2B). 3D visualization of lacteals in the small intestine exposed a singular 
LYVE-1+ LV, which is engrafted into an intertwined CD31+ small capillary network (Figure 4-2C). 
Lacteals flow into outer SMLVs, that were LYVE-1+ and CD31+ (Figure 4-2C).  
Based on these results, I decided to make use of LYVE-1, CD31 and PDPLN for visualizing LVs in 
all following experiments.  
  
Figure 4-2: 3D Lymphatic whole mounts of biomarkers in skin and small intestine 
(A) Split ears were stained for LYVE-1, PODOPLANIN (PDPLN), CD31 or LAMININ. Upper pictures 
consist of 4 patched images of skin whole mounts; lower pictures show a higher magnification. Arrows 
indicate lymphatic vessels. Scale bar = 70 / 50µm. 
(B) Split ears were stained for LYVE-1 and PDPLN and visualized with the Slidebook 3D visualization 
tool. Scale bar = 10µm. 
(C) Small intestines were cut, cleaned, and stained for LYVE-1 and CD31. Both the lacteal and 
submucosal lymphatic vessel (SMLV) regions were visualized with the Slidebook 3D visualization tool. 




4.2 Demonstration of rhythmic dendritic cell migration into dermal 
lymphatic capillaries 
 
I then moved on to design two complementing trafficking assays, exogenous and endogenous 
crawl-in assays (see 3.2.4). Using these approaches, it was tried to assess the migratory 
properties of either dermal DCs or exogenous BMDCs in the skin with respect to the time of 
day.  
First, an ex-vivo mouse ear crawl-in migration assay using cultured BMDCs was adapted for 
circadian experiments as this allowed a survey of the initial steps in an immune response and 
conclusions with respect to the micro-environment. Fresh BM cells were isolated and 
differentiated into BMDCs. BMDCs were then stained with CTV and subsequently added onto 
split ears harvested from mice at four different times of the day. In the first experiment, ears 
from different time points received their own batch of cells (Figure 4-3A). Surprisingly, BMDC 
migration into lymphatic capillaries and pre-collecting vessels was highly dependent on the 
time the ear was harvested. BMDCs migrated into lymphatic capillaries with a rhythm, peaking 
at ZT7 and troughing at ZT19, with a significantly higher ratio of cells being located within the 
lymphatics compared to cells located on the outside (Figure 4-3B). Neither were differences 
seen between overall transferred BMDC cell counts present in the ear after the assay, nor 
were differences observed in the analyzed vascular volume (Figure 4-3C). Since using different 
batches of cells might compromise the comparability between different ZTs, I further 
harvested ears at the same time from phase-shifted mice allowing us to simultaneously 
transfer the same batch of BMDCs onto different ears (Figure 4-3D). The data generated in 
this manner were almost identical to the previous experiment with BMDCs predominantly 
migrating into afferent lymphatics at ZT7 compared to other time points (Figure 4-3E). As 
before, LV volume and the amount of overall transferred CTV+ BMDCs did not differ between 
time points (Figure 4-3F). This rhythmic behavior is shown as an example in skin whole 
mounts, indicating a higher percentage of BMDCs within PDPLN+ vessels at ZT7 compared to 
ZT19 (Figure 4-3G). Viability and purity of transferred BMDCs in both experiments were not 
lower than 92% and 70%, respectively, and did not vary between cells (see 3.2.3.1 for gating 
strategy and exemplary flow-cytometry plots; data shown in Figure 4-3H). These data thus 






I subsequently assessed whether endogenous dermal DCs located within ears exhibit this 
rhythmic trafficking pattern as well, by measuring their ability to migrate into lymphatic 
capillaries of the skin. Split ears were cultured with the dermis facing down for 6h and stained 
for endogenous DCs (CD11c+) and lymphatic capillaries and  finally the number of DCs within 
or outside LVs was tracked (Figure 4-4A). Due to the small trauma induced by the ear sheet 
separation, dermal DCs slowly become activated and migrate towards lymphatic capillaries 
allowing for scrutiny of the initial step of an immune response. 
In close analogy to the migration assays using ex-vivo generated BMDCs, site-specific dermal 
DCs showed elevated numbers inside the lymphatic capillaries at ZT7 compared to ZT19 after 
6h incubation (Figure 4-4B). The volume of analyzed LVs as well as total imaged CD11c+ cell 
numbers did not differ between time points (Figure 4-4C). I additionally performed 
Figure 4-3: Higher trafficking capacity during the day in dermal lymphatic vessels 
(A/D) Schematic overviews of exogenous crawl-in setups. Numbers represent Zeitgeber time (ZT) of ear 
harvest. 
(B) Individual bone marrow-derived dendritic cell (BMDC) batches were used for different crawl-ins. 
Left: numbers of Celltrace Violet (CTV
+
) BMDCs intralymphatic or extralymphatic normalized to 
lymphatic vessel (LV) volume (# = two-way ANOVA, *= Šidák’s multiple comparisons test); right: ratio of 
intravascular versus extravascular BMDCs (#= one-way ANOVA, * = Tukey’s multiple comparisons test). 
N = 3 mice across 4 time points measured each.  
(C/F) Left: LV volume; right: absolute number of imaged CTV
+
 BMDCs normalized to LV volume (C refers 
to B and F refers to E). 
(E) One BMDC batch was used for different ZTs. Statistical testing and arrangement equal to B. N = 3 
mice across 4 time points measured each.  
(G) Exemplary whole mount staining of split ears for PODOPLANIN (PDPLN) containing migrated CTV
+
 
BMDCs after exogenous crawl-in assays. Arrows point at orthogonal views. Scale bar = 50 / 10µm. 
(H) Flow-cytometric analyses of BMDC viability and purity used for crawl-in assays in E (left) and B 




endogenous crawl-in assays with 24h incubation of ears harvested at the peak and trough 
times observed thus far (ZT7 and ZT19, respectively), as 6h incubation time might be too short 
for the majority of DCs to become activated and migrate into LVs (Figure 4-4D). After 24h 
incubation, an even more pronounced migration difference was observed between ZT7 and 
ZT19, with ZT7 presenting a ratio of 1.8 and ZT19 a ratio of 0.5 (Figure 4-4E). Again, no 
differences in either imaged DC counts or LV volume were found (Figure 4-4F). These data 
indicated, that even after a longer incubation period, the time point at ZT19 was insufficient in 
catching up with the ZT7 time point. Indeed, examination of both ratios of intravascular 
versus extravascular DCs after 6h and 24h incubation revealed only a mere increase in ears 
harvest at ZT19, whereas at ZT7, the ratio had more than doubled (Figure 4-4B/E). This 
difference is exemplified in Figure 4-4H, in which the majority of DCs is associated with LVs at 
ZT7. 
Diurnal DC trafficking through lymphatic capillaries can only be termed circadian, if the 
oscillation persists under constant conditions. I thus performed LD/DD/DL experiments to 
allow the conclusion of circadian rhythmicity and regulation via intrinsic clocks. While DC 
trafficking in mice housed under LD and DD condition peaked at ZT7 and had its nadir at ZT19, 
DC trafficking in mice housed under DL (jetlag) condition exhibited an inversed rhythm (Figure 
4-4G). Consequently, mice exhibit a circadian rhythmicity in dermal DC trafficking, peaking 









4.3 Rhythmic protein and RNA levels in lymphatic endothelial cells 
 
In my initial experiments different timing of the dermal environment impacted changes in 
BMDC and dermal DC migration. Thus, I investigated whether molecules, essential for DC 
adhesion and transmigration, on tissue-specific LECs oscillate over the course of 24h during 
steady-state conditions. I performed quantitative immunofluorescence profiling on non-
inflamed, sectioned ears, lungs, small intestines and inguinal LNs harvested over four time 
points of the day (see 3.2.7.1). In detail, I examined dermal lymphatic capillaries, overall lung 
LVs, lacteals and SMLV of small intestines and SCS, CS and MS of inguinal LNs using LYVE-1 as 
biomarker (Figure 4-5A). Surprisingly, this method yielded a mosaic of temporally expressed 
Figure 4-4: Circadian rhythm in dermal dendritic cell migration into lymphatic vessels 
(A/D) Schematic overviews of endogenous crawl-in setups. Numbers represent Zeitgeber time (ZT) of 
ear harvest.  
(B/E) 6h (B) or 24h (E) endogenous crawl-in assays. Left: number of dermal CD11c
+
 dendritic cells (DCs) 
normalized to lymphatic vessel (LV) volume (# = two-way ANOVA, * = Šidák’s multiple comparisons 
test); right: ratio of intravascular versus extravascular DCs (# = one-way ANOVA, * = Tukey’s multiple 
comparisons test for B and * = unpaired student’s t-test for E). N = 3 mice across 4 (B) or two (E) time 
points measured each.  
(C/F) Left: LV volume; right: absolute number of imaged CD11c
+
 DCs normalized to LV volume (C refers 
to B and F refers to E). 
(G) 24h endogenous crawl-in assay performed with animals kept in Light (L): Dark (D), DD or DL 
conditions. # = one-way ANOVA. N = 3 mice across all time points measured each. 
(H) Exemplary whole mount staining of split ears harvested at ZT7 or ZT19 for CD11c and LYVE-1 after a 





proteins with a marked tissue-specificity (Figure 4-5AB). The skin shows strong rhythmicity for 
LYVE-1, JAM-A, CD99 and JAM-C on capillaries, while other markers were either present but 
not oscillatory or not expressed. Every marker except JAM-A peaked at ZT1, whereas JAM-A 
peaked at ZT7 (Figure 4-5E). In lung, LYVE-1 (peaking ZT1), ICAM1 (peaking ZT7), ALCAM 
(peaking ZT1) and CD99 (peaking ZT7) showed rhythmicity in expression (Figure 4-5F). The 
other two investigated lymphatic structures and respective sub-regions presented a high 
heterogenic temporal expression of trafficking markers. For instance, on small intestinal 
lacteals LYVE-1 (peaking ZT1), MMR1 (peaking ZT1), L1CAM (peaking ZT7), ICAM1 (peaking at 
ZT7), JAM-A (peaking ZT7), JAM-C (peaking ZT7), CD99 (peaking ZT7) and E-SELECTIN (peaking 
ZT1) displayed an oscillatory expression. However, on SMLVs, only LYVE-1 (peaking ZT1), 
L1CAM (peaking ZT7), ICAM1 (peaking ZT1) and E-SELECTIN (peaking ZT1) exhibited rhythmic 
expression. Remarkably, ICAM1 peaks at different time points although examined LVs are 
situated in the same organ (Figure 4-5G). Similar phenotypes were observed in different 
regions of the LN (Figure 4-5H). In all tissues analyzed, the averaged, integrated expression of 
rhythmic proteins revealed a peak in expression between ZT1 and ZT7 and nadir at ZT19 
(Figure 4-5C). This was also true for integration of dermal-only protein expression data (Figure 
4-5D). To better understand the expression of JAM-A, JAM-C and CD99 on LVs in the skin, 
whole mount staining of each molecule using LYVE-1 as biomarker was performed. JAM-A and 
JAM-C were expressed evenly on the LEC surface comparable with PDPLN, and CD99 is 
expressed on LECs in the fashion of CD31 or LYVE-1 (Figure 4-5I/J/K). 
These data might be responsible for the strong circadian influence of the micro environment 
on rhythmic DC trafficking as shown in the crawl-in assays. Moreover, they point towards site-
specific regulation of proteins by LEC intrinsic clocks, highlighting the importance of 





Figure 4-5: Tissue-specific oscillations in lymphatic adhesion and transmigration molecules 
(A) LYVE-1 expression on 10µm slices from sectioned ears (skin), lung, small intestine (SI) lacteals, SI submucosal 
lymphatic vessels (SMLV) and inguinal lymph node (iLN) subcapsular sinus (SCS), medullary sinus (MS) and cortical 
sinus (CS). Scale bar = 50µm. 
(B) Quantitative immuno-fluorescence microscopy protein screen of LYVE-1
+
 lymphatic vessels (LVs) using 10µm 
organ sections. Dark green = >2 fold significant difference in expression between Zeitgeber times (ZTs), light green = 
<2 fold difference in expression, grey = no rhythmic expression (Not rh.) and white = no expression (No exp.) as 
mean fluorescence intensity (MFI) <1.5% of max MFI. For calculations, isotype MFIs were substracted beforehand. 
N = 5 mice with 4 ZTs measured each.  
(C-D) Integration of all rhythmically expressed molecules over all organs (C) or skin (D) across 4 time points and 
normalized to ZT1 or ZT7 values. * = one-way ANOVA, # = cosinor analysis. N = 5 mice with 4 ZTs measured each. 
Dotted line represents SD, dashed line represents fit curve. 
(E-H) MFI profiles of screened molecules on LVs in skin (E), lung (F), SI (G) and LN (H) from B. Isotype MFIs were 
deducted from shown MFIs. * = one-way ANOVA, # = cosinor analysis. Dotted line represents SD, dashed line 
represents fit curve. 
(I-K) Whole mount staining of split ears for LYVE-1 with JAM-A (I), JAM-C (J) or CD99 (K). Scale bars = 50µm; *p<0.05, 




Besides adhesion and transmigration, chemotactic cues and their guidance through the 
interstitial space are integral parts of dermal lymphatic DC trafficking. Different chemokines 
were screened and the focus was set on CCL21, as it is not only the best described but also 
most important chemokine in dermal lymphatic trafficking (see 2.4.2).  
As an initial experiment, I stained and quantified the expression of CCL21 within LYVE-1+ areas 
in sectioned skin (Figure 4-6A). Quantification of the signal intensity uncovered a peak of 
CCL21 expression on LECs at ZT7 (Figure 4-6B). To generate further insight into the 
intracellular CCL21 architecture in LECs, whole mount staining of permeabilized LVs in the skin 
was performed and stained for LYVE-1 and CCL21 (see 3.2.7.2). The majority of intracellular 
CCL21 was confined to a small region, less CCL21 was evenly dispersed in the cell (Figure 
4-6C). Skin whole mount staining of the Golgi apparatus using the biomarker GOLPH4 unveiled 
CCL21 and GOLPH4 double-positive regions in LYVE-1+ capillary LECs (Figure 4-6D). To further 
dissect the temporal regulation of the intracellular CCL21 quantity, I evaluated the CCL21+ 
signal in either GOLPH4high (resembling the Golgi apparatus) or GOLPH4low regions (resembling 
small vesicles within the cell) employing LYVE-1 mask algorithms (see 3.2.7.4 for methods and 
Figure 4-6E for data) [199]. In both examined regions, the CCL21 fluorescence intensity was 
maximal at ZT7 and lowest at ZT19. Although the highest CCL21+ signal intensity was found in 
the Golgi apparatus (GOLPH4high), the difference between ZT7 and ZT19 was most striking in 
GOLPH4low regions, pointing towards higher vesicular trafficking and possibly release of CCL21 
at ZT7 (Figure 4-6F). 
Taken together, temporal expression of various molecules involved in lymphatic leukocyte 
adhesion and transmigration as well as chemotactic guidance was found. Not only does this 
hint at a functional intrinsic clock of LECs, but could also explain the elevated migration 




Given the strong oscillatory protein expression in LECs, I next sought to elucidate how LECs 
adapt to environmental changes on a broader molecular level in a time-of-day-dependent 
manner. Dermal CD31+PDPLN+ LECs were sorted at four different time points to perform RNA-
sequencing analyses. Every sort (with purities > 90%) was performed at the same time of day 
using phase-shifted mice to minimize side-effects. Isolated RNA of LECs had sufficient quality 
Figure 4-6: Elevated expression, storage and traffic of intracellular CCL21 in dermal lymphatic 
endothelial cells 
(A) Representative 2D immuno-fluorescence microscopy staining of CCL21 and LYVE-1 in 10µm skin 
slices. Scale bar = 50µm. 
(B) Quantitative immune-fluorescence microscopy profiling of the CCL21 mean fluorescence intensity 
(MFI) on LYVE-1
+
 lymphatic vessels (LVs) in 10µm skin sections. * = one-way ANOVA, # = cosinor 
analysis. N = 5 mice with 4 Zeitgeber times (ZTs) measured each. Dotted line represents SD, dashed 
line represents fit curve. 
(C) Whole mount staining of split and permeabilized ears for LYVE-1, CCL21 and DAPI. Left: picture 
contains 4 patched images. Scale bar = 70 / 10µm. 
(D) Representative whole mount staining of split and permeabilized ears for CCL21, GOLPH4, LYVE-1, 
and DAPI. Left: CCL21 staining, 20x objective; center: CCL21, GOLPH4 and LYVE-1 staining, 20x 
objective; right: CCL21, GOLPH4, LYVE-1 and DAPI staining, scale bars = 50 / 10µm. 
(E) Representative whole mount staining of split and permeabilized ears for GOLPH4. Arrows indicate 
GOLPH
low 
regions, resembling small intracellular vesicles. Scale bar = 10µm. 
(F) Quantitative immuno-fluorescence microscopy profiling of the CCL21 MFI in LYVE-1
+
 lymphatic 
endothelial cells (LECs) in whole-mounted, permeabilized and split ears. Left: CCL21 MFI in the 
GOLPH4
high
 area (intra-golgi); right: CCL21 MFI in GOLPH4
low
 area (intra-vesicle). N = 3 mice ZT7 and 
ZT19 measured each, * = unpaired student’s t-test; *p<0.05, **p<0.01. All other data are represented 




and amounts for performing RNA sequencing (see Figure 3-8 for LEC gating strategy and 
3.2.5.2 and 3.2.8 for experimental procedures). 
Robust expression of dermal LEC-specific marker genes Lyve-1, Flt4, Prox-1, Pdpln, Pecam1 
and Reelin (Reln) ensured high purity of samples used for sequencing. On the contrary, the 
dermal BEC-, leukocyte- or stromal cell-specific markers Integrin subunit alpha 2b (Itga2b), 
Flt1, Notch receptor 4 (Notch4), Neuropilin 1 (Nrp1), Von willebrand factor (Vwf), E-selectin 
(Sele; encoding for E-SELECTIN), Protein tyrosine phosphatase receptor type C (Cd45/Ptprc), 
Fibulin 1 (Fbln1) and Procollagen C-endopeptidase enhancer (Pcolce) were not expressed 
(Figure 4-7A). Notably, Esele is only upregulated in dermal LVs under inflammatory conditions, 
demonstrating the non-activated state of examined LECs. Interestingly, the two markers Prox-
1 and Reln displayed a peak in expression at ZT1 (Figure 4-7G). 
Principal-component analysis (PCA) could not entirely cluster sequenced samples according to 
time of harvest. However, samples harvested at ZT1 and ZT19 give an indication of grouping in 
opposite directions (Figure 4-7B). Importantly, PCA analyses are relying on strong differences 
between sample groups and rhythmic gene expression often fails to provide high amplitudes. 
Indeed, gene overlap analysis revealed 265 differentially expressed genes between ZT1 and 
ZT19, as represented by the outer arc of the circos plot. Likewise, ZT13:ZT19 comprise 163 
and ZT1:ZT7 155 differentially expressed genes, respectively (Figure 4-7C). Moreover, 
overlapping genes which appear in multiple sample comparisons (for example gene A is 
significantly different between time points ZT1:19 and ZT7:19) and genes that were unique to 
one gene comparison and do not appear in other comparisons (gene A is only significantly 
different in ZT1:19 and not in ZT7:19) were illustrated in the inner arc of the plot. Strikingly, 
the majority of genes was not connected with other comparisons (inner arc) and thus found 
to be unique to the ZT1 and ZT19 comparison (Figure 4-7C). In general, gene expression 
analyzed at ZT19 was most distinct compared to other time points (Figure 4-7C).  I then 
continued with further analyses considering that samples harvested at ZT1 and ZT19 provided 
uniquely altered transcriptional regulation. 
Since ZT1:ZT19 had by far the most significant targets based on the DeSeq2 analysis, I decided 
to further dissect transcriptional alterations (Figure 4-7D). All significant genetic comparisons 
were clustered into functionally related groups based on gene ontology. Enriched gene 
ontology clustering, however, did not reveal differences between ZT1/ZT7 and ZT19 with 
respect to adhesion. ZT1:ZT13 provided differences for adhesion, extracellular matrix 
organization, ZT7:ZT13 variation in water homeostasis and ZT13:19 change in cell motility 
regulation. Many other gene ontologies were enriched that were not the main topic of this 




Given LECs present oscillatory, transcriptional alterations in several pathways, initial targets 
for further analysis were molecular clock genes. Indeed, Bmal1 (peak at ZT1/19), Clock (peak 
at ZT1), Per2 (peak at ZT13), Per3 (peak at ZT13), Dbp (peak at ZT7), Nr1d1 (peak at ZT7) and 
Nr1d2 (peak at ZT7/13) show significant differences in their expression across 24h. This 
demonstrated that components of the circadian clock were expressed in a rhythmic manner 
and proved a good quality control for the experiment, given that these were peaking at the 
expected times. Per1 and Cry2 expression levels did not exhibit statistically significant 
oscillation (Figure 4-7F). In summary, RNA sequencing of sorted LECs exposed major 
transcriptional differences between ZT1 and ZT19. Moreover, RNA sequencing uncovered 
robust rhythms in molecular clock gene expression, potentially regulating genes involved in 






Figure 4-7: Lymphatic endothelial cells express a molecular clock and are transcriptionally 
most distinct between ZT1 and ZT19 
(A) Expression of lymphatic endothelial cell (LEC-), blood endothelial cell (BEC-, leukocyte (LEU-) and stromal cell 
(SRC-) -specific genes as measure for the high purity of sorted and sequenced skin LECs. N = 20 mice, # = one-way 
ANOVA.  
(B) Principal component analysis (PCA) of sequenced cDNA from sorted LECs based on all genes. N = 5 across 4 
different Zeitgeber times (ZT) each.  
(C) Gene overlap analysis depicted as a circos plot (left) and corresponding table of overlapping genes (right). 
Each ZT contains the average of 5 biological replicates. The inner arc highlights the overlapping genes which 
appear in multiple sample comparisons in dark orange and genes in light orange are unique to one gene 
comparison and do not appear in other comparisons. 
(D) MA plot visualizing the transformed values of ‘M’ (log ratio) and ‘A’ (mean average) ZT1 and ZT19.  
(E/H) Enriched ontology cluster cumulating hierarchically enriched terms/pathways based on sequencing data 
between different ZTs (E). –log10 of p values shown to express significance. List of terms/ GO pathways shown in 
H. 
(F) Molecular clock gene expression profile of sorted LECs. * = one-way ANOVA, # = cosinor analysis. N = 5 mice 
across 4 ZTs measured each. Dotted line represents SD, dashed line represents fit curve. 
(G) Visualization of LEC specific genes from A across 4 ZTs. # = one-way ANOVA, * = Tukey’s multiple comparisons 
test. N= 5 mice with 4 time points measured each; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. All other data 




Considering the clear expression profile of the molecular clock components and required high 
amplitudes for successful principal-component and DeSeq2 analysis, an overlooked temporal 
regulation of adhesion genes was estimated. Analyses of adhesion genes listed in the ontology 
cluster ‘cell adhesion’ (GO:0007155) were performed and each gene was tested for its 
rhythmic expression using one-way ANOVA statistics. A list of rhythmic adhesion genes (121 
expressed adhesion genes experienced a peak in expression once during 24h) was compiled in 
a structured heat map, showing the gene with the highest counts at ZT1 first and the gene 
with the lowest counts at ZT1 last. Interestingly, a great majority of genes peaking at ZT1 was 
downregulated at ZT19 and vice versa (Figure 4-8A). Of note, a large fraction of these genes 
was not significant in the DeSeq2 analysis as their amplitudes between time points tested 
were too little. Nevertheless, this supports the initially reported difference in temporal 
transcriptional regulation between ZT1 and ZT19 (Figure 4-7B-D). 
I thereafter grouped genes of interest based on their role in migration and activation, the 
cytoskeleton, neuronal influence and voltage gated channels, permeability and extracellular 
matrix in a second heat map (Figure 4-8B). Integration of all rhythmic adhesion genes (except 
Ackr4, see 5.2) uncovered a peak in expression at ZT1 and a trough at ZT19 (Figure 4-8C). 
Integration of classified adhesion genes illustrated the transcriptional upregulation of 
migration and activation, as well as cytoskeletal genes at ZT1 (Figure 4-8D). In comparison 
with the protein screen in Figure 4-5, Lyve1, Ccl21, Cd99, F11r/Jam1 and Jam2 could either 
not be sequenced or were not found to be rhythmically transcribed.  
However, other enriched targets from the sequencing include interleukins and receptor 
components such as Il20r, Il2r and Il6, chemotaxis genes Cxcl12 and Ackr4, neuronal receptor 
Adrb2, and several genes involved in permeability and the cytoskeleton regulation, such as 
Myoc, Cdh5 and Fbn1 (values are shown in the appendix).  
Together these data provide novel temporal adaptation of adhesion gene expression 
according to the time of day in dermal LECs. Adhesion genes were upregulated at ZT1, 
coinciding with a higher trafficking capacity as previously shown (Figure 4-3 and Figure 4-4). 







4.4 Evaluation of migratory behavior and chemotaxis ability amongst 
dendritic cell subtypes 
 
Transcriptome and protein signatures of dermal LECs seemed to be strongly influenced by the 
time of day. I next searched for possible consequences of rhythmic regulation in skin under 
steady-state conditions. Specifically, I further dissected the influence of biological rhythms on 
dermal DC subtypes. 
Figure 4-8: Rhythmic adhesion gene signature in lymphatic endothelial cells 
(A) Heat map of rhythmic adhesion genes (Gene ontology (GO):0007155) based on one-way ANOVA 
testing in sorted and sequenced lymphatic endothelial cells (LECs). Normalized gene counts shown as 
binary logarithm. N = 5 mice across 4 different time points measured each. ZT = Zeitgeber time. 
(B) Grouping of selected adhesion genes from A into migration and activation, cytoskeleton, neuronal 
influence (Neu.-inf.) and voltage-gated channels (V-g. ch.), permeability (Perm.) and extracellular matrix 
(ECM). Normalized counts shown as binary logarithm.   
(C-D) Integration of all rhythmic adhesion genes from A (C) or selected genes from B (D). Normalized 
counts shown as binary logarithm. # = one-way ANOVA, * = Tukey’s multiple comparisons test; *p<0.05, 




Ears from phase-shifted mice were harvested at four different time points and the amount of 
dermal DCs and respective subtypes was quantified using flow-cytometry (see Figure 3-7 for 
gating strategy and 3.2.5.1 for methods). Importantly, the weight of collected ears did not 
vary across time points tested (Figure 4-9A). Surprisingly, the number of assayed CD45+ 
leukocytes oscillated, peaking at ZT7 and troughing at ZT19. Likewise, CD11c+MHCII+ DC cell 
numbers increased at ZT7 and were lowest at night and onset of day. This extended to 
EPCAM+ LCs and EPCAM-CD103- cDC2s but not CD103+ cDC1s with highest numbers at ZT7 
(Figure 4-9B). Apart from rhythmic egress being a likely contributor for the oscillatory count, I 
speculated whether a higher turnover of cells may also be caused by varying proliferation 
states of DCs within the skin. For this purpose the marker KI67 was utilized, which is 
associated with cellular proliferation [337], and whole mount staining of KI67 in skin to 
visualize proliferating cells was established (Figure 4-9C). Interestingly, the amount of KI67 in 
CD11c+ cells as well as relative numbers of KI67+ CD11c+ cells varied throughout the day, 
peaking at ZT7 (Figure 4-9D). This might represent a possible mechanism in the temporal 
regulation of cellularity in skin and could be important in the regulation of immune responses. 
Figure 4-9: Diurnal rhythmicity in skin cellularity 
(A) Weight of harvested ears in milligrams (mg). N = 9 mice at 4 different Zeitgeber times (ZT) each. 
(B) Flow-cytometric analyses of cellularity normalized to tissue weight from harvested ears. LC = 
Langerhans cell, cDC1/2 = conventional dendritic cell 1/2. # = one-way ANOVA, * = Tukey’s multiple 
comparisons test. N = 9 mice across 4 time points measured each. 
(C) Representative whole mount staining of CD11c, KI67 and DAPI in permeabilized, split ears. Scale 
bar = 50µm. 
(D) Left: mean fluorescence intensity (MFI) profile of KI67 signal in CD11c
+
 DCs from skin whole 




 cells in skin whole mounts. # = one-way 
ANOVA and cosinor analysis, * = Tukey’s multiple comparisons test. Dotted line represents SD, dashed 
line represents fit curve. N = 3 mice across 4 time points measured each; *p<0.05, **p<0.01. All other 




Quantity and migration capacity of dermal DCs vary throughout the day as shown by several 
crawl-in assays and flow-cytometric profiling of the skin. I was wondering if by splitting ears 
and performing crawl-in assays, dermal DCs also emigrate into the incubation medium in a 
time-of-day dependent manner. Thus, I designed a crawl-out assay, in which split ears were 
cultured on plain or supplemented medium for 24h. During these 24h the majority of DCs 
remain in the ear within the LVs. However, a small fraction emigrates into the medium, which 
was quantified by FACS (see 3.2.5.1 for methods and Figure 3-7 for gating strategies). By 
reason of altering total numbers of DCs in the ear, I decided to analyze the number of 
emigrated DCs in relation to remaining DCs. After 24h incubation, 22% of total DCs (the sum 
of ear and medium cellularity) emigrated the ear at ZT7 compared to 15% at ZT19. This 
difference could be extended to LCs (only a tendency) and cDC2s, but not cDC1s (Figure 
4-10A-C). On the one hand this secured that the majority of DCs remains in the ear, justifying 
the used crawl-in cell migration assays. On the other hand, this implied differences in 
transitory migration behavior between DC subtypes. 
I expanded my endogenous crawl-in assay to explore, which DC subtype is migrating into the 
lymphatic capillaries. First, I established the whole-mount staining of LANGERIN and CD103 in 
the epidermis and dermis. Under steady-state conditions, the great majority of LANGERIN+ 
DCs (LCs) resides in the epidermis, whereas cDC1s and cDC2s populate the dermis (Figure 
4-10D). In light of low cDC1 numbers and lack of rhythmicity in the crawl-out assay, I excluded 
them from the experiment. Split ears from phase-shifted mice were cultured for 24h and 
subsequently examined. The total and relative numbers of imaged DCs did not differ between 
the time points (Figure 4-10E). Analysis of intravascular versus extravascular LCs and cDC2s 
revealed a marked increase in migration of both subtypes at ZT7 compared to ZT19. 
Interestingly, this difference was slightly more pronounced in LCs (Figure 4-10F/G). Together, 
these differences pinpoint heterogeneity between different dermal DCs in terms of migration 
and activation throughout the course of a day, potentially exerted by DC-specific molecular 
clocks. This might be especially of relevance for pathogen-specific immune responses and the 





Figure 4-10: Dermal dendritic cell subtype-specific rhythms in migration 




dendritic cells (DCs) from cultured, split ears 
(crawl-out assay) into medium. Values shown as fraction of total DCs, the sum of ear and medium DCs. 
LC = Langerhans cell, cDC1/2 = conventional DC 1/2. N = 3 mice across Zeitgeber Time (ZT) 7 and ZT19 
measured each. * = unpaired student’s t-test. 
(B) Representative flow-cytometry plots of DCs (top) and DC subtypes (bottom) using EPCAM and CD103 
for differentiation at ZT7 and ZT19. 
(C) Ratio of DCs that either emigrated or remained inside the ear tissue. N = 3 mice across ZT7 and ZT19 
measured each. # = two-way ANOVA. 
(D) Representative whole mount staining of epidermis (left) and dermis (right) of permeabilized, split 
ears for LANGERIN, CD103 and CD11c during steady state. Arrows point at LCs, star shows cDC1. Scale 
bar = 50 / 10µm.  
(E) 24h endogenous crawl-in assays of CD11c
+
 DCs divided into LANGERIN
+
 LCs and LANGERIN
-
 cDC2s. 
Top: relative amount of CD11c
+
 DCs that are LCs or cDC2s. Bottom: absolute number of CD11c
+
 cells 
imaged normalized to the lymphatic vessel volume. # = two-way ANOVA. N = 3 mice across ZT7 and ZT19 
measured each.  
(F) Ratio of intravascular versus extravascular cDC2s (top) or LCs (bottom) after 24h endogenous crawl-in 
assays. N = 3 mice across ZT7 and ZT19 measured each. * = unpaired student’s t-test.  
(G) Representative images stained for LANGERIN, CD11c and LYVE-1. Scale bar = 50µm; *p<0.05, 




This potential heterogeneity within dermal DCs was subjected to further analysis. First, I 
assayed the individual chemotaxis abilities of DCs regarding CCL21 by combining a crawl-out 
with a chemotaxis assay. Ears from phase-shifted mice were simultaneously harvested, split 
and cultured dermis facing down onto medium supplemented with CCL21 at ZT7 and ZT19. 
During the 24h crawl-out assay, dermal DCs were activated by exogenous CCL21 and migrated 
towards the extracellular chemokine source to localize inside the medium. Interestingly, at 
ZT7 around 65% of total (sum of ear and medium cellularity) dermal DCs emigrated whereas 
at ZT19 only 37% left the ear. Specifically, LCs and cDC2s, but not cDC1s, presented significant 
differences in migratory behavior between time points (Figure 4-11A-C). Collectively, this 
suggests a transitory upregulation of trafficking molecules such as CCR7 on the DC surface 
concomitant with an elevated global alertness and better migration of DCs at ZT7.  
Because of this, Coline Barnoud (University of Geneva, Switzerland) phenotyped non-
activated, homeostatic LCs, cDC1s and cDC2s isolated from harvested ears at four time points 
across the day using flow-cytometric quantitative immunofluorescence profiling. She 
quantified activation markers (CD80, CD86, CD40, CD201, CD301b) as well as molecules 
involved in the trafficking cascade (CCR7, JAM-A) on respective DC subsets. This approach 
yielded a temporal expression map for dendritic cell molecules that seemed to be DC subtype-
specific (Figure 4-11D). LCs probed during the onset of the day show higher expression levels 
of CCR7, CD86 as well as JAM-A and cDC2s higher expression levels of CD86 and CD40 (Figure 
4-11E-F). These findings support the idea of an elevated global alertness and chemotaxis 
ability of steady state DCs during the day and corroborate the trafficking data obtained earlier 







Figure 4-11: Elevated activation and chemotaxis of dendritic cells during the day 




 dendritic cells (DCs) from cultured, split ears 
(crawl-out assay) into medium. Values shown as fraction of total DCs, the sum of ear and medium DCs. 
Ears were cultured on culture medium supplemented with 100ng/µl CCL21. LC = Langerhans cell, 
cDC1/2 = conventional DC 1/2. N = 3 mice across Zeitgeber time (ZT) 7 and ZT19 measured each. * = 
unpaired student’s t-test. 
(B) Representative flow-cytometry plots of Dcs (top) and DC subtypes (bottom) using EPCAM and CD103 
for discrimination at ZT7 and ZT19. 
(C) Ratio of DCs that either emigrated or remained in the skin tissue. N = 3 mice across ZT7 and ZT19 
measured each. # = two-way ANOVA. 
(D) Flow-cytometric quantitative analyses of activation markers and trafficking molecules across 4 
different time points on the surface of LCs, cDC1s and cDC2s. Blue = rhythmic expression validated by 
one-way ANOVA testing. Grey = non-rhythmic expression. White = not expressed as mean-fluorescence 
intensity (MFI) < 1.5% of max MFI. N = 5 mice across 4 different time points measured each.  
(E-F) MFI profile of screened LCs (E) or cDC2s (F) from D. * = one-way ANOVA and # = Tukey’s multiple 





4.5 Assessment of diurnal CCL21 gradient micro-patterning, adhesion and 
transmigration 
 
Both, LECs and DCs together govern rhythms in dermal DC trafficking. Further, LCs and cDC2s 
were shown to better migrate towards an external CCL21 source and upregulate pro-
migratory factors during the day. Based on this, I sought to delineate the functional relevance 
of molecules partaking in the multi-faceted cascade of lymphatic trafficking with respect to 
the time of day.  
Since adhesion and transmigration of dermal DCs heavily rely on functional chemotaxis, I 
studied the spatio-temporal gating of dermal chemotactic gradients first. I determined CCL21 
to be the perfect candidate for investigation due to its rhythmicity in the intracellular 
compartment and importance for trafficking (Figure 4-6). For this purpose, I employed 
quantitative immunofluorescence imaging to quantify the naturally built-up gradient. Staining 
for CCL21 and LYVE-1 in non-permeabilized, whole-mounted ear sheets revealed a chemokine 
gradient that is concentrating in close proximity to lymphatic capillaries (Figure 4-12A). By 
adopting distance-dependent fluorescence maps of CCL21+ signal in LYVE-1+ capillary 
environments, I was able to quantify the exponential CCL21 gradient. Interestingly, gradients 
varied according to the time of the day with ZT7 presenting a higher concentration at close 
proximity to LVs which is why statistical analysis was only significant for a total distance of 
around 50µm (Figure 4-12B/C). These findings highly support the rhythmicity observed in 
crawl-in assays as a more pronounced chemotaxis at ZT7 might enhance interstitial DC 
migration.  
The intralymphatic space harbors low numbers of DCs for induction of self-tolerance and T 
cell communication. In order to quantify the intralymphatic amount of DCs under steady-state 
conditions, ears were harvested from phase-shifted mice at four different time points of the 
day, split, stained and directly imaged. Quantification of the intravascular versus extravascular 
ratio of DCs uncovered an increased cellularity within the lymphatic space during the day 
compared to night time points (Figure 4-12D). Thus, rhythmic CCL21 gradients functionally 




Additionally, I designed short exogenous BMDC crawl-in assays ranging from 0-60min, 
allowing me to delineate the physiological relevance of rhythmic gradients for DC migration. 
For the analysis, interstitial space between LVs was segregated into five different zones (see 
3.2.4.4 and Figure 3-6). Next, the number of cells was counted in the respective zones at ZT7 
and ZT19 from exogenous crawl-in assays. Throughout the course of 60min, more DCs 
accumulated within 20µm distance to the LV at ZT7, whereas in ZT19, the increase was much 
lower (Figure 4-12E). 
Figure 4-12: Rhythmic CCL21 micro-patterning influences dermal dendritic cell distribution 
(A) Representative whole mount staining of split, non-permeabilized ears for CCL21 and LYVE-1. 
Scale bar = 50µm. 
(B) Normalized (to highest value at ZT7) and averaged mean fluorescence intensity (MFI) profile of 
CCL21 in specific distances to lymphatic vessels (LVs). Top displays a maximum distance of 50µm, 
bottom a maximum distance of 100µm.  N = 5 mice at Zeitgeber time (ZT) 7 and ZT19 measured 
each. * = Mann-Whitney U test. 
(C) Exemplary whole mount staining of CCL21 in split and non-permeabilized ears at ZT7 or ZT19. 
LVs are indicated with a dotted line (based on LYVE-1 staining). Scale bar = 50µm. 
(D) Cumulative distance distribution of CD11c
+
 cells in relation to LYVE-1
+
 LVs in split ears under 
steady state conditions. N = 3 mice at ZT7 and ZT19 measured each.  
(E) Relative number of bone-marrow derived dendritic cells (BMDCs) after 0-60min (indicated by 
colored lines) crawl-in assays in specific distances to CD31
+ 
LVs. Left: all time points; right: 60min 
crawl-in assay for ZT7 and ZT19. * = Tukey’s multiple comparisons test, # = unpaired student’s t-test. 
N= 1 mouse across all incubation and Zeitgeber times measured each; *p<0.05, **p<0.01, 





Following this, I explored the consequences of disturbing CCL21 gradients in the skin at ZT7 
and ZT19. I either masked, by adding exogenous CCL21, or completely ablated, using 
heparinase digestion or antibody blockade, the extracellular gradient of CCL21 while 
performing endogenous and/or exogenous crawl-in assays (see 3.2.6).  
For antibody-mediated blockade of CCL21, ears from different ZTs were simultaneously 
harvested, incubated in blocking or isotype antibodies and subjected to trafficking assays 
using time-shifted mice. In the exogenous assay, chrono-pharmacological inhibition of CCL21 
led to a 2.5-fold decrease of DC trafficking at ZT7, while no change was seen at ZT19 (Figure 
4-13A). Similarly, targeting CCL21 in endogenous crawl-in assays, I noticed a 4.5-fold decrease 
in DC migration only at ZT7 (Figure 4-13B). Importantly, isotype antibody administration did 
not interfere with the diurnal trafficking phenotype in both experiments. Antibody-mediated 
neutralization of CCL21 led to a loss of DC orientation, as they appeared to be randomly 
distributed in the interstitial space and less directed towards LVs compared to isotype 
controls (Figure 4-13C).  
Heparinase cleaves the heparin sulfate at the linkage between hexosamines and CCL21, thus 
releasing the bound CCL21 from the ECM and disturbing the naturally built-up gradient 
(Figure 4-13D).  Digestion of the CCL21 gradient using heparinase caused a 1.5-fold decrease 
in DC trafficking at ZT7 compared to ZT19 and controls (Figure 4-13E).  
Applied exogenous CCL21 binds to hexosamine structures on the ECM of the skin, leading to 
accumulation of CCL21 and thereby masking the natural gradient (Figure 4-13F). 
Correspondingly, adding exogenous CCL21 led to a 2.2-fold reduced DC trafficking solely at 
ZT7 (Figure 4-13G). 
To confirm the neutralization of CCL21, I employed genetically modified BMDCs lacking CCR7 
expression. CCR7-KO BMDCs are not able to sense CCL21 or CCL19 gradients and are thus 
blind to the stimulus. After culture and activation, CCR7 KO or WT BMDCs were added to split 
ears from time-shifted mice for exogenous crawl-in assays. The migratory behavior of CCR7 
KO BMDCs was almost completely ablated as they failed to migrate towards LVs. ZT7 ears 
containing CCR7-KO BMDCs present a 16-fold, whereas ZT19 ears containing CCR7-KO BMDCs 
a 5-fold decrease in migration compared to WT levels (Figure 4-13H).  
These results suggest a fundamental role for diurnal dermal CCL21 gradients to promote 




After interstitial migration DCs adhere and transmigrate into the lumen of LVs. Previously, I 
described factors involved in these two steps to be rhythmically expressed. Consequently, I 
performed endogenous and exogenous crawl-in assays and neutralized molecules involved in 
adhesion and transmigration via antibody-mediated blockade together with employing 
isotype-matched controls. Specifically, I decided to target LYVE-1, CD99, JAM-A and JAM-C as 
Figure 4-13: Manipulation of the CCL21 gradient leads to dysfunctional dendritic cell migration 
during the day 
(A-B) Exogenous (A) or endogenous (B) crawl-in assays using αCCL21 or isotype antibody-treated ears. 
Left shows the ratio of intravascular versus extravascular bone marrow-derived dendritic cells (BMDCs) 
or dermal CD11c
+
 DCs, respectively, in LYVE-1
+
 lymphatic vessels (LVs; #= two-way ANOVA, *= Šidák’s 
multiple comparisons test); right displays the fold change of antibody blockade in comparison with 
isotype controls (* = unpaired student‘s t-test). N = 4-5 (A) or 3 (B) mice across Zeitgeber Time (ZT) 7 
and ZT19 measured each. 
(C) Exemplary whole mount staining of split ears for CD11c and LYVE-1 after 24h incubation of an 
endogenous crawl-in using αCCL21 or isotype antibodies at ZT7. Arrows direct at higher magnifications. 
Scale bar = 50 / 10µm. 
(D) Exemplary whole mount staining of CCL21 and LYVE-1 in non-permeabilized, split ears after 
heparinase or PBS treatment. Scale bar = 50µm. 
(E) Endogenous crawl-in using heparinase or PBS treated ears. Arrangement and statistical tests equal 
to B. N = 3 mice across ZT7 and ZT19 measured each.  
(F) Exemplary whole mount staining of CCL21 and LYVE-1 of non-permeabilized, split ears after addition 
of PBS or exogenous CCL21. Dotted lines resemble LVs (aligned with LYVE-1 staining). Scale bar = 50µm. 
(G) Endogenous crawl-in using ears treated with exogenous CCL21 or PBS. Arrangement and statistical 
tests equal to B. N = 3 mice across ZT7 and ZT19 measured each. MFI = mean fluorescence intensity. 
(H) Exogenous crawl-in using WT or CCR7 KO BMDCs. Arrangement and statistical tests equal to B. N = 3 
mice across ZT7 and ZT19 measured each; *p<0.05, **p<0.01, ***p<0.001. All data are represented as 




they showed strong oscillations in expression across the day during homeostasis and have 
been implicated in DC adhesion and transmigration before (Table 2-2). 
In exogenous crawl-in assays, targeting LYVE-1 (3-fold reduction), JAM-A (2.2-fold reduction) 
and CD99 (1.5-fold reduction) reduced DC trafficking at ZT7, whereas at ZT19 these effects 
were not detected (Figure 4-14A/D/G). I then tried to reproduce the effects of LYVE-1, JAM-A, 
and CD99 neutralization in endogenous crawl-in assays. Similarly, targeting LYVE-1 led to a 3-
fold reduction, JAM-A led to a 1.7-fold and CD99 led to a 2.0-fold reduction in DC migration at 
ZT7 (Figure 4-14B/E/H). Close observations of whole-mount staining of LVs and CD11c+ DCs 
after blockade unveiled that DCs manage to arrive at LVs in each of these scenarios, however 
they seemed to be immobilized on the LV wall and transmigrate at lower rate compared to 
isotype controls (Figure 4-14C/F/I). Due to strong oscillations of CD99 expression in LECs 
(Figure 4-5), I used genetically modified mice lacking CD99 expression. In an endogenous 
crawl-in setting using CD99-/- ears, DC trafficking was markedly reduced at ZT7 compared to 
expected WT values, whereas at ZT19 only a slight reduction was noted (Figure 4-14J).  
Neutralizing JAM-C in an endogenous crawl-in setting did not reduce DC migration in a 
statistically significant manner (Figure 4-14K). Since the effect of blockage was low, I did not 
follow up on the functional role of JAM-C with an exogenous crawl-in assay.  
Moreover, CD31 was not found to be rhythmic in skin and thus, neutralization should 
decrease trafficking both at ZT7 and ZT19 serving as a control experiment. Endogenous crawl-
in assays of CD31-blocked or isotype-stained ears led to a strong reduction in DC trafficking at 
both time points (Figure 4-14L).  
In summary, these data highlight the relevance of rhythms in adhesion and transmigration 
molecules on LECs. Malfunction of targeted molecules led to dysfunctional migration of DCs 
into the lumen of LVs. This functionality, together with diurnal micro-patterning of CCL21 






Figure 4-14: Chrono-pharmacological block of adhesion and transmigration reduces dendritic 
cell migration during the day 
(A-B) Exogenous (A) or endogenous (B) crawl-in using αLYVE-1 or isotype antibody-treated ears. Left 
shows the ratio of intravascular versus extravascular bone marrow-derived dendritic cells (BMDCs) or 
dermal CD11c
+




 lymphatic vessels (LVs; #= two-way ANOVA, *= 
Šidák’s multiple comparisons test); right displays the fold change of antibody blockade in comparison 
with isotype controls (* = unpaired student‘s t-test). N = 5 (A) or 3 (B) mice across Zeitgeber time (ZT) 7 
and ZT19 measured each. 
(C/F/I) Exemplary whole mount stainings of split ears for CD11c and CD31/LYVE-1 from 24h endogenous 
crawl-in assays using αLYVE-1 (C), αJAM-A (F) or αCD99 (I), or respective isotype antibodies at ZT7. 
Dotted lines (cross) and arrows facilitate magnifications and orthogonal views. Scale bars = 50 / 30µm. 
(D-E) Exogenous (D) or endogenous (E) crawl-in assays using either αJAM-A or isotype antibody-treated 
ears. Arrangement and statistical tests equal to A-B. N = 5 (D) or 3 (E) mice across ZT7 and ZT19 
measured each. All data are represented as mean ± SEM. 
 (G-H) Exogenous (G) or endogenous (H) crawl-in assays using either αCD99 or isotype antibody-treated 
ears. Arrangement and statistical tests equal to A-B. N = 5 (G) or 3 (H) mice across ZT7 and ZT19 
measured each. 
 (J) Endogenous crawl-in assay using WT or CD99-KO ears. Dotted lines resemble expected WT levels at 
different ZTs. N = 5 mice at ZT7 and ZT19 measured each. 
(K-L) Endogenous crawl-in assay using αJAM-C (K) or αCD31 (L) and respective isotype antibody-treated 
ears. Arrangement and statistical tests equal to B. N = 3 (K) and 4-5 (L) mice across ZT7 and ZT19 





4.6 Effects of lineage-specific clock deficiency on lymphatic dendritic cell 
migration 
 
In previous experiments, I could link oscillations in pro-migratory molecules with rhythmic 
trafficking behavior and tried to uncover their functionality in the context of time-of-day 
dependent trafficking. However, for drawing conclusions to intrinsic clocks as initiator of 
rhythmic trafficking, a definite molecular link was yet to be uncovered.  
For this purpose, I generated genetically modified mice lacking a functional molecular clock in 
key cell subsets to explore the link between rhythmic trafficking and the intrinsic clock 
machinery. In detail, together with my research group I generated mice deficient in the 
circadian clock gene Bmal1 specifically in ECs using two different models, inducible 
Cdh5creERT2 mice, targeting both BECs and LECs and inducible Prox1creERT2 only targeting LECs. 
As tested in whole-mount staining of the skin, biomarkers PROX-1 and VE-CADHERIN are 
strongly expressed in dermal LECs and thus are eligible promoters for Cre expression in LECs 
(Figure 4-15A/B). I then performed exogenous (3h) and endogenous (6h and 24h) crawl-in 
assays to appraise the migration capacity of LVs using WT or KO ears. Interestingly, compared 
to control animals, Cdh5cre-Bmal1-/- and Prox1cre-Bmal1-/- mice failed to exhibit a rhythm in 
the immigration capacity of DCs into lymphatic capillaries at ZT7 in all migration assays tested 
with no significant differences between the two genetic models (Figure 4-15C/D/F/G). DCs 
required more time to arrive at the LVs concomitant with slower transmigration ability as 
shown in exemplary whole mount images (Figure 4-15E/H). These experiments implied LEC-
specific Bmal1 as a key player for rhythmic lymphatic DC trafficking and a molecular link 
between the previously observed phenotypes and the clock machinery.  
In line with my previous experiment, I additionally investigated the DC molecular clock. For 
this, my research group generated mice deficient in the clock gene Bmal1 using Cre 
expression within the promoter of Clec9a (Clec9acre-Bmal1-/- mice). cDC1s and cDC2s in the 
skin both express Clec9a during their development whereas LCs have a different, macrophage 
origin and do not express Clec9a. As a consequence, Bmal1 is not expressed in the cDCs of 
these mice. I decided to use a cDC Bmal1 KO model, since cDC2s were the most abundant DC 
cell type measured in skin and showed strong rhythmicity in trafficking behavior and they 
were readily available in the lab (Figure 4-9 and Figure 4-10). I performed 24h endogenous 
crawl-in assays to examine to what extend the DC intrinsic clock contributes to rhythms in 
lymphatic DC trafficking. Surprisingly, the migration of DCs was only reduced in Clec9acre-
Bmal1-/- mice tested at ZT7 in comparison with control animals (Figure 4-15I). Likewise, the 




capacity (Figure 4-15J). In comparison with data from Cdh5cre-Bmal1-/- and Prox1cre-Bmal1-/- 
mice, Clec9acre-Bmal1-/- mice yielded a slightly lower reduction at ZT7.  
Together these data for the first time link both lymphatic vasculature and cDC clocks with 
rhythmic cDC migration within the skin. Interstitial migration as well as transmigration of the 
lymphatic endothelium was markedly reduced in Bmal1 KO animals. Both the LEC and DC 
clock partially influenced the rhythmic behavior and both cellular clocks were required to 
facilitate a functional rhythm. These findings should be helpful in exploring the consequences 






Figure 4-15: Lineage-specific clock deficiency leads to dysfunctional dermal dendritic 
cell trafficking 
(A-B) Whole mount staining of split, permeabilized ears for PODOPLANIN (PDPLN), PROX-1 
and DAPI (A) or for LYVE-1 and VE-CADHERIN (VE-CADH; B). Arrows point towards and dashed 
line outlines lymphatic vessels (LV). Scale bars = 50 / 10µm. 
(C-D) Ratio of intravascular versus extravascular dermal CD11c
+
 dendritic cells (DCs) or bone 
marrow-derived DCs (BMDCs) in endogenous (C; left 6h, right 24h) or exogenous crawl-in (D) 
assays, respectively, using Cdh5cre-Bmal1
-/-
 (EC-KO) or WT ears. #= two-way ANOVA, *= 
Šidák’s multiple comparisons test. N = 5-7 (C) or 5-6 (D) mice across 4 or two time points 
measured each. Zeitgeber time = ZT. 
(E/H/J) Exemplary wholemount staining of split ears for CD11c and LYVE-1 after 24h 







 (DC- KO; J) and WT animals at ZT7. Scale bars = 50µm. 
(F-G) Ratio of intravascular versus extravascular dermal CD11c
+
 DCs or BMDCS in endogenous 
(F; left 6h, right 24h) or exogenous (G) crawl-in assays, respectively, using Prox1cre-Bmal1
-/-
 
(LEC- KO) or WT ears. Statistical tests equal to C-D. N = 4-6 (F) or 4-5 (G) mice across 4 or two 
time points measured each.  
(I) Ratio of intravascular versus extravascular dermal CD11c
+
 DCs in exogenous crawl-in assays 
using Clec9acre-Bmal1
-/-
 (DC-KO) or WT ears. Statistical testing equal to C-D. N = 4-5 across 
ZT7 and ZT19 measured each; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. All data are 




Since mice lacking Bmal1 in LECs exhibit defects in DC migration, I further wanted to 
investigate the connection between the molecular clock and rhythmic migration. For this 
purpose, I repeated the quantitative immune-fluorescence profiling of chemokines, adhesion 
and transmigration proteins in sectioned skin samples from both Cdh5cre-Bmal1-/- and 
Prox1cre-Bmal1-/- as well as control animals. Loss of Bmal1 reduced levels of previously 
described rhythmic proteins LYVE-1, JAM-A, JAM-C, CD99 and intracellular CCL21 at ZT7 but 
not ZT19 in comparison to WT controls (Figure 4-16A/B). As expected, non-rhythmic CD31 
levels were not affected in both genetic models (Figure 4-16A/B).  
To further shed light on the link between the molecular clock and chemokine micro-
patterning I analyzed the extracellular CCL21 in Prox1cre-Bmal1-/- and control animals. By 
employing the same algorithm used in Figure 4-12, I visualized the CCL21 gradient in the 
dermal capillary environment. Surprisingly, the CCL21 gradient analyzed in Prox1cre-Bmal1-/- 
mice at ZT7 presented dramatically lower concentration and loss of diurnal upregulation 
compared to gradients in WT ZT7 as well as WT ZT19 and KO ZT19 ears (Figure 4-16C). Genetic 
ablation of Bmal1 also reduced the shape of the CCL21 gradient (Figure 4-16C/D) possibly 
owing to reduced production or release in KO mice. 
These data create a strong link between regulation of DC trafficking and intrinsic molecular 
clocks. In particular, the LEC clock influences chemotaxis, adhesion and transmigration of 





Figure 4-16: Loss of Bmal1 in lymphatic endothelial cells leads to downregulation of 
trafficking factors and chemokine micro-patterning 
(A-B) Mean fluorescence intensity (MFI) profile of trafficking molecules measured by quantitative 
immuno-fluorescence microscopy in 10µm ear sections from WT and Cdh5cre-Bmal1
-/- 
(EC-KO; A) or 
Prox1cre-Bmal1
-/- 
(LEC-KO; B) mice at Zeitgeber time (ZT) 7 or ZT19. 
(C) Normalized (to highest value of WT ZT7) and averaged MFI profile of CCL21 in specific distances 
around the lymphatic vessel (LV) using either WT or Prox1cre-Bmal1
-/- 
(KO) ears. N = 5 mice at ZT7 
and ZT19 measured each. * = Dunn’s correction for multiple comparisons, # = Kruskal-Wallis test. 
Dotted line represents SEM. 
(D) Exemplary whole mount stainings of split and non-permeabilized ears for CCL21 at ZT7 from 
either WT or Prox1cre-Bmal1
-/- 
(KO) animals. LVs are indicated with a dashed line (based on LYVE-1 
staining). Scale bar = 50µm. LEC = lymphatic endothelial cell; *p<0.05, **p<0.01, ***p<0.001, 




In a final approach, I sought to further scrutinize the consequence of genetic ablation of 
Bmal1 in LECs. I surveyed the DC cellularity of Cdh5cre-Bmal1-/- and WT ears across four 
different time points using flow-cytometry. Strikingly, the previously observed rhythm in DC 
cell numbers in KO animals was abolished compared to WT control animals, especially at ZT7 
(Figure 4-17A). Specifically, LC and cDC2 oscillations were ablated (Figure 4-17A). This could 
point towards a functional role of BVs and LVs and their respective clocks in the regulation of 
ear cellularity. 
I further assessed the emigration capacity of dermal DCs employing crawl-out assays since an 
altered CCL21 gradient and less lymphatic trafficking in KO animals might lead to increased 
lymphatic vessel-independent emigration of DCs, as shown by Förster and colleagues [191]. 
Whilst in WT animals, only a low number of DCs emigrated the ear and reproduced the results 
depicted in Figure 4-10, in Cdh5cre-Bmal1-/- animals, a greater absolute number of DCs 
emigrated the ear at ZT7 and ZT19 (Figure 4-17B). In detail, cDC2s showed significant 
differences between KO and WT animals and harvest times specifically in KO animals. On the 
contrary LCs and cDC1s gave a trend but no significant differences in emigration tested.  
Importantly, the increase in emigration was more pronounced at ZT7 compared to ZT19 
(Figure 4-17B). This might be partially explained by an altered or reduced CCL21 gradient, 
leading to loss of orientation and elevated emigration of DCs. However, this needs to be 
confirmed in Prox1cre-Bmal1-/- mice, as this model is tailored to solely LECs.  
Irrespectively, the loss of Bmal1 clearly alters the ability of DCs to migrate to LVs and modifies 
the ear cellularity.  
Together, these genetic KO data create a strong link between the observed rhythmic 
processes and the molecular clock. Both the LEC and DC clock seem to either be capable to 








Figure 4-17: Genetic ablation of Bmal1 leads to alteration in ear cellularity and increased 
dendritic cell emigration 




 dendritic cell (DC) cellularity normalized to ear 
weight from either WT or Cdh5cre-Bmal1
-/- 
(EC-KO) mice. LC = Langerhans cell, cDC1/2 = conventional 
DC 1/2. #= two-way ANOVA, *= Tukey’s multiple comparisons test. N = 9 mice across 4 Zeitgeber times 
(ZT) measured each.  
(B) Flow-cytometric analyses of emigrated DCs from cultured, split ears (crawl-out assay) from either 
WT or Cdh5cre-Bmal1
-/- 
(EC-KO) mice normalized to ear weight. Statistical testing equal to A. N = 4-5 
mice across ZT7 and ZT19 measured each; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. All data are 




 Discussion and future perspectives 5
 
In the past years, the circadian clock has been identified as an elemental modulator of the 
immune system. Various components of immunity are under the control of the molecular 
clock [338-340], but we only just commenced understanding the molecular circuits. Very little 
is known about how the lymphatic system, an important component of the immune system, is 
shaped by environmental factors throughout the day. This study provides first evidence for 
rhythmic lymphatic immune cell migration, temporal regulation of protein and RNA 
expression within LECs and sheds light on tissue-specific loss of the molecular clock and its 
consequences on dermal immune cell trafficking.   
In this final chapter of the work, rhythmic leukocyte trafficking of dermal DCs into lymphatics 
and its potential future investigation are discussed. 
5.1 Circadian rhythms in lymphatic dendritic cell migration  
 
Ex-vivo ear migration assays using dermal DCs or BMDCs revealed a circadian migration 
capacity, peaking during the behavioral resting phase of the mouse at ZT7 (Figure 4-3 and 
Figure 4-4). The endogenous and exogenous crawl-in assays address different questions. The 
exogenous assay gives a clear indication about the influence of the microenvironment, as 
cultured BMDCs do not display a synchronized clock during typical culture conditions [331]. 
Individual BMDCs express all clock components, but on average, the population as a whole 
does not show a rhythm in expression across 24h. On the contrary, the endogenous crawl-in 
assay only allows for the assumption of general rhythms in lymphatic DC migration. 
Additionally, examined CD11c+ cells in the endogenous assay comprise all dermal DC 
subtypes, which were previously described owning distinct differences in their migratory 
behavior (see 4.4 and [108]). Moreover, BMDCs are transcriptionally and evolutionary distinct 
from dermal (especially cDC1 and cDC2) DCs and thus, differing activation state, cytoskeletal 
components as well as expression of chemokine receptors and trafficking molecules might 
influence the outcome of the trafficking assay. A study by Helft and colleagues could reveal 
differences amongst BMDCs which adds another level of complexity to the reasons presented 
above [341]. Another culture method, e.g. Flt3L culture rather than GM-CSF or a pre-sort 
between culture and crawl-in assay could be employed here. Nonetheless, during both 




strength of immigration into lymphatics is likely being explained by the higher activation 
status of LPS-derived BMDCs compared to non-activated tissue-resident cells. 
Reported oscillations in dermal DC cell numbers (Figure 4-9) could not be observed in total 
CD11c+ DC numbers per field of view analyzed in the endogenous crawl-in assay (Figure 4-4). 
Due to physical reasons, spinning disk confocal microscopy of dermal explants is not able to 
visualize and quantify the whole ear cellularity (owing to limiting imaging depth). Additionally, 
DCs do not only arrange in close proximity to LVs, they also reside in dermal segments directly 
underneath the epidermis and thus are missed during image acquisition. This is why the 
cellularity shown in Figure 4-4 is only used as a control for even distribution of cell numbers 
amongst different groups to ascertain comparability.  
Collectively, both cell migration assays strongly support the hypothesis of rhythmic DC 
trafficking across lymphatics. Velocity, directionality towards LVs and other migration 
parameters were not assessed but are currently being investigated in real-time assays. In 
contrast to end point analyses, live imaging of migrating BMDCs allows further resolution of 
rhythmic migration [178], especially in the context of the rhythmic CCL21 gradient and the 
consequence of genetic Bmal1 ablation. Preliminary data show that the method per se is 
working and data can be readily generated in the future (see appendix Figure 7-1). 
What could be the functional importance of an increased migration capacity during the 
behavioral rest phase? Herein, migration capacities of dermal DCs were highest at ZT7, 
whereas in other studies, leukocytes show an elevated migratory state and enter organs at 
ZT13, and DCs peaked in migration in mesenteric LNs at around ZT9 [56, 291]. Migration 
regulation of different leukocytes and ECs by the circadian clock seems to be tissue-specific. 
This was also reported in a study by Druzd et al., in which the egress rate of lymphocytes via 
efferent LVs from the LN was assessed. This rate was highest between ZT7 and ZT9, revealing 
a pro-migratory state of efferent LVs during the behavioral rest phase of mice due to temporal 
upregulation of S1pr1, a receptor binding the factor S1P promoting lymphocyte egress [291]. 
Conversely, LN BVs adopt a pro-migratory protein signature and homing of lymphocytes to 
the LN via BVs was highest at ZT13 [56, 291]. Diversity in rhythmic leukocyte trafficking allows 
for flexibility and a balanced immunity. Complete concentration of immune effectivity at one 
time point during the day would increase the risk of immune overreaction during that time 
and susceptibility to pathogens at other times of the day. Thus, differing peaks in migration 
enhance the flexibility and secure adequate immune reactions. Another explanation could be 
found in increased LN lymphocyte numbers at the onset of the active phase [291]. During the 
active phase, organisms capture antigens of all kinds on the surface of the skin. Afterwards, 




requires multiple hours. Consequently, DCs are likely to arrive at the dLN after several hours, 
coinciding with a higher cellularity and an increasing chance of antigen cross-presentation to T 
cells. By maximizing the efficiency of immune responses, metabolic costs are reduced, which 
may be one of the main reasons why the immune system temporally changes its reactivity 
and activity [339].  
5.2 The role of oscillations in lymphatic protein and RNA expression 
 
Quantitative immuno-fluorescence profiling of organ sections and RNA sequencing of sorted 
dermal LECs at different times of the day unveiled a rhythmic expression map of proteins and 
genes (see 4.3). Rhythmic pro-migratory proteins investigated peak at ZT1 or ZT7, coinciding 
with an upregulation of adhesion genes at ZT1 (Figure 4-5, Figure 4-6, Figure 4-7, Figure 4-8).  
The protein screen employed a LYVE-1 based mask of the region of interesting, in which the 
target protein was then quantified. Interestingly, LYVE-1 exhibited a rhythm in expression, 
which could lead to varying mask sizes through the analysis. The algorithm generating the 
mask (see appendix 7.2) is based on relative fluorescence intensities. Consequently, absolute 
changes in LYVE-1 MFIs do not alter the mask size, unless LYVE-1 is changing its distribution 
pattern on the surface of the cell. Although this was not investigated, differing distribution 
patterns should only negligibly alter the mask size. Irrespectively, approaching distribution 
patterns of proteins of interest could be important for time-of-day dependent cargo-transport 
of proteins to the cell surface, especially for released chemokines such as CCL21.  
Similar to differences in leukocyte trafficking, regulation of trafficking factors seems to be 
differing between BVs and LVs. Under steady-state conditions, dermal LECs maintain unique 
expression patterns of migratory factors when compared to inflammation, during which they 
acquire a BEC-like phenotype by up-regulating integrin ligands such as ICAM-1 [206]. In BVs, 
organ- and site-specific BECs up-regulate pro-migratory factors at the onset of the active 
phase (e.g. ZT13; Table 2-3) [55, 243, 271]. Tissue-specific LECs contrarily display augmented 
expression of pro-migratory factors during the resting phase (ZT1/ZT7; Figure 4-5). The 
question remains, how heterogeneity between different ECs and within organ-specific LECs 
can be established by the circadian clock. In the following, multiple reasons are discussed. 
Temporal regulation of clock controlled genes relies on genetic regulatory elements, such as 
E-boxes and ROR elements, as well as post-transcriptional modifications [338]. An 
evolutionary reason for this might be the multiplication of diversity in gene regulation and a 




CCL2 in human and murine macrophages as proven by pharmacological activation (REV-ERB 
ligand GSK4112) of REV-ERBα and chromatin immunoprecipitation (ChIP) assays, in which 
REV-ERBα binds to a proximal ROR element in the promoter region [288, 342]. At the same 
time the cognate receptor of CCL2, CCR2, is regulated by PER1 together with the nuclear 
receptor peroxisome proliferator-activated receptor gamma (PPARγ) [343]. Additionally, 
RORα opposes REV-ERBα in its regulation and positively influences the Ccl2 expression via 
binding to ROR elements, whereas BMAL1 promotes methylation of Ccl2 together with 
reducing its expression using E-boxes at ZT7 in peritoneal macrophages [276, 342].  
Despite the complexity of E-box- and ROR-mediated gene regulation, differences between cell 
types also heavily depend on individual interactions with hormone signals. Hormones are an 
essential internal entrainment factor [243] and their receptors are expressed on cells in a 
tissue-specific manner. For example, adrenaline and noradrenaline are important 
neurotransmitters and hormones in the periphery and are able to entrain the circadian clock 
via numerous adrenoceptors including α1A, α1B, α1D, α2A/D, α2B, α2C, β1, β2, and β3 receptors 
[243, 344, 345]. Tissue-specific BECs or myocytes provide different signatures of these 
receptors to maximize the flexibility in physiological function. For instance, in humans 
adrenaline consistently reduces renal and skin blood flow because α-adrenoceptors are 
predominant, whereas in skeletal muscle and splanchnic vasculature adrenaline acts mainly 
via β-adrenoceptors and induces vasodilatation [345]. As another example, β2 adrenergic 
receptor agonists cause a dilatation of smooth muscles in the lung leading to opening of the 
airways, although in large arteries and heart tissue their binding enhances myocyte 
contraction [346, 347]. The functional role of the autonomic nervous system on LECs under 
physiological conditions was only recently described by Bachmann et al., demonstrating 
functional expression of α1 (contraction) and β2 (dilatation) adrenoceptors on flank collector 
LVs in-vivo, whereas lacteals express β2 adrenoceptors only [348]. Furthermore, RNA-
sequencing of sorted dermal LECs performed here could reveal and oscillation in the β2 
receptor subunit, pointing at a possible entrainment of LECs by the peripheral nervous system 
(Figure 4-8). Although more research is required to disentangle the role of the nervous system 
on regulating LECs, distinctive humoral signals might increase tissue-specificity and generate 
differences observed in this thesis.  
Epigenetic changes in chromatin accessibility of different cell types or methylation processes 
regulating transcription of clock-controlled genes might contribute to the observed 
heterogeneity. For example, CLOCK functions as histone acetyl transferase (HAT) regulating 
glucocorticoid receptors [349]. Furthermore, polycomb repressive complexes (PRC) such as 




a rhythmic manner [276]. Finally, recent in-vivo quantification of circadian phosphorylation in 
the liver suggests a crucial role for phosphorylation-dependent circadian tuning of molecular 
pathways as well [350]. 
Accordingly, circadian regulation of target genes is depending on numerous factors and could 
explain differences between cell types. This complex regulation might lead to differences in 
protein expression within organ-specific LEC subtypes, such as ICAM1 expression levels in 
lacteal and SMLV LECs (Figure 4-4). 
Results from the protein and RNA screen can only be interpreted to a certain extent as the 
direct molecular link, how clock genes regulate respective lymphatic genes is yet to be 
discovered. Localization of E-boxes and other regulatory elements in the promoter region of 
genes of interest together with promoter binding assays of BMAL1 or other transcription 
factors such as REV-ERBα could be a first step linking rhythmic expression with the binding of 
transcription factors of the circadian clock family. An overview of proposed binding regions for 
the clock genes Bmal1, Dbp, Nfil3 and ROR-binding clock genes Rora and Nr1d1/Nr1d2 in 
promoters of genes relevant for this thesis is provided in Table 5-1 and appendix 7.3. Based on 
the results from the promoter database, F11r and Jam3 (JAM-A and JAM-C, respectively), 
Ackr4 and Cd86 might be directly regulated via ROR-binding clock proteins, whereas Reln 
could be under the direct control of Bmal1. Other genes such as Ccl21-a, Ccl21-c or Lyve-1 
yield elements for a more complex regulation (Table 5-1 and appendix 7.3). Importantly, loss 
of Bmal1 in ECs led to a downregulation of target proteins LYVE-1, JAM-A, JAM-C, CD99 and 
CCL21, pointing towards a direct molecular link between the circadian clock and pro-
migratory molecules in lymphatics (Figure 4-16). BMAL1 or REV-ERBα could be possible 
candidates in LECs, as they have been involved in chemokine expression as mentioned above 








Bmal1 Dbp Nfil3 Rora 
p-value 0.01 0.001 0.0001 0.01 0.001 0.0001 0.01 0.001 0.0001 0.01 0.001 0.0001 
Ccl21-a 29|9 4|2 1 28 2 0 34 3 0 40 5 0 
Ccl21-c 26 3 1 28 2 0 31 2 0 40 3 1 
Lyve1 44 6 1 43 8 0 28 3 1 42 4 0 
Jam3 22 1 0 15 0 0 21 0 0 23 3 0 
F11r 19 0 0 9 0 0 18 1 0 47 6 0 
Cd99L2  45 1 0 25 1 0 18 2 0 40 3 1 
Reln 61 9 1 14 0 0 18 1 0 30 1 0 
Ackr4 32 2 0 26 1 0 24 2 0 41 3 0 
Ccr7 49 6 0 19 2 0 20 2 0 44 6 0 
Cd80 32 5 0 19 0 0 26 2 0 40 2 0 
Cd86 37 0 0 22 1 0 20 3 0 31 2 0 
Cd40 32 2 0 10 1 0 8 2 0 37 4 0 
Table 5-1: Number of promoter binding sites for clock genes Bmal1, Dbp, Nfil and Rora  
Genes were screened using the eukaryotic promoter database provided by the Swiss Institute of 
Bioinformatics. Motifs were searched within -2000bp to +100bp distance in the promoter region using 
the JASPAR CORE 2018 vertebrates library and with different p-values. Canonical binding sites (CAN 
NTG) for Bmal1 in the Ccl21a promoter region calculated in red as an example (see 7.3 for sequence) . 
Cd99 was not found in database; instead the closely related Cd99L2 was presented as an example. 
Jam3 = JAM-C, F11r = JAM-A, Transcr. = transcription. The exact sites and example of Ccl21a are shown 
in the appendix 7.3. 
RNA sequencing of sorted LECs revealed oscillations in clock gene expression. Internal control 
of sufficient RNA quality (not provided but ensured by the sequencing core facility), high 
amount of detected transcripts (>10,000) with more than 35 million reads and satisfactory 
gene body coverage to avoid the bias of RNA degradation at the 5’ / 3’ end ensured a 
successful and well-controlled RNA sequencing (controls not shown). Besides this, confidence 
in the sequencing results can be built on the observed clock gene expression (Figure 4-7). 
Other studies have shown similar expression patterns in different cell types, including 
neutrophils [299], NK cells [351], eosinophils and mast cells [352], T cells and LN tissue [280, 
291], large arteries and veins [271], macrophages and monocytes [277, 353], as well as B cells 
and DCs [278]. In LECs, Bmal1 peaks at the transition of active to resting phase (ZT19-ZT1), 
and Per2 and Per3 peak during the trough of Bmal1, at the transition of active to resting phase 
(ZT13). Dbp, Nr1d1 and Nr1d2 peak during the active phase (ZT7 and ZT7-13 for Nr1d2). 
Consequently these results are consistent with the published literature.  
Sorted LECs presented an upregulation of adhesion genes during the resting phase, as shown 
by DeSeq2 and one-way ANOVA statistical evaluation. Ackr4 was excluded from the adhesion 
gene clustering (Figure 4-8) as it represents a negative regulator of leukocyte trafficking [202]. 
Studies have shown, that Ackr4 expressed on keratinocytes sequesters chemokines such as 




physiological frames [202]. Expression and relevance of Ackr4 within the LEC has not been 
fully understood yet, but was found to be important in the development of the lymphatic 
system at the embryonic day 6 and might be of similar relevance compared to ACKR4 on 
keratinocytes in adult mice [214]. Down-regulation of Ackr4 at ZT1 might therefore positively 
influence leukocyte trafficking and is in support of this proposed role in LECs (Figure 4-5).  
Other genes encoding rhythmic proteins of interest could not be sequenced or proven 
rhythmic. A complete lack of signal during sequencing could be due to RNA degradation or 
complexity in gene and RNA structure, e.g. by splicing. Notably, there is no published study 
showing the mRNA expression profile of Ccl21b/c in the skin.  
For other genes, e.g. LYVE-1, high but non-rhythmic expression could be quantified. 
Nonetheless, studies by Hughes and colleagues as well as Geyfman et al. describe rhythmic 
expression of Lyve1 in liver and epidermal tissue with a peak occurring at CT14 and ZT14 and a 
trough at CT3 and ZT2, respectively [308, 354]. Besides regulatory elements in promoters, the 
temporal regulation of CCGs is heavily dependent on post-transcriptional modifications by 
clock genes. In particular, a study by Kojima and colleagues could identify circadian rhythms in 
mouse liver mRNA poly(A) tails uncoupled from rhythmic transcription. This means that the 
circadian clock can regulate the post-transcriptional regulation of mRNA resulting in 
oscillatory protein expression irrespective of steady-state mRNA levels [355]. Consequently, 
the RNA expression profile does not necessarily have to reflect the rhythmic pattern in order 
for its protein product to be rhythmically expressed. Nevertheless, a second proof of diurnal 
protein expression by quantitative flow-cytometric screening and quantitative real-time PCR 
of RNA could aid in clarification. Targets should include Ccl21 and Lyve1 to not only validate 
the previous results but also gain further insight into mRNA abundance. 
Collectively, these data support the hypothesis that up-regulation of pro-migratory factors 
heavily contributes to rhythmic trafficking of DCs within the skin and might be under the 
control of the molecular clock. 
 
5.3 Temporal chemokine patterning during steady state – pointing 
towards rhythmic tolerance induction? 
 
CCL21 was found to be rhythmically expressed in dermal LECs, with a peak at ZT7 (Figure 4-6). 
This timed-expression of CCL21 was already published by Druzd and colleagues in the LN, in 




[291]. This is in line with micro-array profiling of the gene Ccl21a in liver tissue [354]. Profiling 
of CCL21 in skin whole mounts indicated that not only the storage, but specifically the release 
of CCL21 might be rhythmic (Figure 4-6). Further experiments assaying the CCL21 release 
capacity and RNA sequencing for rhythmic factors involved in cargo-transport are required for 
a better understanding of temporal CCL21 release. Several chemical compounds interfering 
with secretion pathways, such as brefeldin A, Exo1 or secramine B could be used to further 
dissect molecular mechanisms [356, 357]. Moreover, generated RNA-sequencing data could 
be screened for genes associated with transport of proteins.  Nevertheless, an increased 
storage or release rate at ZT7 might be beneficial in immediate inflammatory responses and 
would be a novel phenomenon to be observed in rhythmic leukocyte trafficking.  
Furthermore, an oscillation in dermal CCL21 micro-patterning could be visualized, which 
influenced the localization and migration of dermal DCs under steady-state conditions (Figure 
4-12). Since CCL21 is rhythmically expressed and released in dermal and LN LECs under 
steady-state conditions [291], the question arises, whether other LEC activities important for 
tissue homeostasis might oscillate as well.  
One possible role of steady-state rhythms in migration and chemotaxis might be the induction 
of self- and peripheral tolerance, which partially relies on interactions with DCs [358]. Indeed, 
LECs from the thymus [359, 360], LN [361] and (to a lesser extent) from colon and diaphragm 
[362] were demonstrated to be heavily involved in T cell- and self-tolerance. In detail, LN LECs 
present peripheral tissue antigens (PTA) under the control of autoimmune regulatory 
elements [359] and members of the SAND family such as Deformed epidermal autoregulatory 
factor 1 homolog (Deaf1) [363, 364]. They display tyrosinase antigen by MHCI molecules to 
activate CD8+ T cell proliferation, which undergo apoptosis and deletion rather than 
accumulation (resembling a form of extra-thymic negative selection). LN LECs additionally 
express a particularly high level of PD-L1 instead of co-stimulatory molecules such as OX40L, 
CD86, CD80, or CD70 to regulate other cells [361, 365, 366]. Finally, LECs express 
intermediate levels of MHCII, proposing a role in CD 4+ T cell tolerance that requires DC 
interaction [358, 367] as well as IL-7 and its receptor IL-7Rα, important in T cell homeostasis 
and lymphatic drainage [368, 369]. Results from this thesis give compelling hints at rhythmic 
self-tolerance induction as described below.  
First, sorted and sequenced LECs from the skin in this study strongly expressed Deaf1, and at 
lower levels Cd274 (encoding the protein PD-L1) and H2-ab1 (encoding the protein MHCII) 
with slight oscillations, peaking at ZT13/19 for Deaf1 (not significant but indicative) and ZT7 




Figure 7-2 since they are not relevant for this thesis per se but could imply steady-state 
rhythms in self- and peripheral-tolerance induction.  
Secondly, more DCs localized inside the LVs during steady-state conditions at ZT7 compared 
to ZT19, which could be a direct consequence of augmented interstitial CCL21 micro-patterns 
and facilitate T cell: DC communication (Figure 4-12).  
Third, LECs displayed rhythms in a variety of genes and proteins that facilitate permeability as 
well as adhesion during the resting phase, possibly aiding in induction of self-tolerance, which 
is supported by two studies showing rhythmicity in AQUAPORIN 3 and 4 in skin and the 
glymphatic system in the CNS, respectively, leading to increased interstitial fluid clearance 
during the resting phase (Figure 4-5) [309, 370]. Moreover, LN LECs displayed rhythmicity in 
protein expression, with differences between anatomical sub-regions (Figure 4-5). This might 
be relevant as self- and peripheral-tolerance induction includes site-specificity within the LN. 
The fact that dermal DCs were more efficient in following an external source of CCL21 during 
crawl-out assays supports the hypothesis of rhythmic CCL21 chemotaxis to be essential during 
steady state (Figure 4-11). Since ears used for the crawl-out assay were not inflamed and 
splitting of the ears without an external CCL21 source only led to an emigration of around 
22% and 15% for ZT7 and ZT19, respectively, CCL21 seems to be very potent in activating and 
attracting DCs during the day. The up-regulation of the cognate receptor CCR7 and several 
activation markers of DCs corroborate the elevated chemotaxis ability of DCs during the day 
(Figure 4-11). Notably, results from the flow-cytometric profiling require repetition as all 
rhythmic markers provide the exact same peaks in expression.  
Although more experiments are necessary to fully clarify the role of steady-state rhythms in 
chemokine micro-patterning and DC migration in the skin, results in this thesis point towards 
rhythms in steady-state functions of LECs. 
 
5.4 Chrono-pharmacological targeting of lymphatic leukocyte trafficking 
 
In this study, circadian DC trafficking was abrogated by time-of-day-dependent administration 
of neutralization antibodies against LYVE-1, CD99, JAM-A, JAM-C and CCL21 (Figure 4-13 and 
Figure 4-14). These effects link the oscillation of target molecules in LECs with the peak in 
migration capacity at ZT7. Literature showing time-of-day neutralization of leukocyte 
trafficking is very limited. He and colleagues for example could reduce leukocyte trafficking by 




LYVE-1 is involved in early adhesion of DCs onto lymphatics by binding surface HA. Although 
literature is scarce concerning manipulation of LYVE-1-mediated migration, Johnson and 
colleagues could reduce trafficking of DCs by blocking or genetically ablating LYVE-1. 
Employing adoptive transfer assays as well as FITC painting and crawl-out assays, they 
highlighted the involvement of LYVE-1 in DC migration across lymphatics [209]. Here, and in 
line with the presented peak in expression at ZT7, LYVE-1-mediated trafficking could only be 
reduced during the day (Figure 4-5 and Figure 4-14). Another proof-of-concept might be found 
in CD44-mediated trafficking of leukocytes, since CD44 is the homologue of LYVE-1 and also 
binds HA [371]. CD44 supports the rolling and firm adhesion of various leukocytes [371-373] 
and has been implied as regulator of trans-endothelial migration and chemotaxis [142] by use 
of neutralization antibodies. Further studies on LYVE-1 might reveal a more defined role 
especially in the context of molecular clock regulation.   
CD99 and CD31 are mediators of leukocyte transmigration across lymphatic endothelial 
barriers. Blockade of CD99 or CD31 markedly reduced trafficking, with CD99 blockade 
showing highest reduction at ZT7, and CD31 blockade reducing DC trafficking at both ZT7 and 
ZT19 (Figure 4-14). CD99 has been implicated in lymphatic transmigration of human DCs. 
Torzicky et al. could quantify the expression of CD99 on cultured human LECs and skin LECs 
and could impair reverse transmigration of monocyte-derived DCs in vitro and in situ by 
manipulating CD99 [218]. It is currently discussed, whether CD31 acts ahead of CD99, with 
CD99 being higher expressed on the intra-luminal side of LECs, whereas CD31 is found rather 
on the extra-luminal side of the cellular junctions [374, 375], similar to what has been 
described for BECs [376]. Nevertheless, more research is required on CD99 and its role in 
lymphatic trafficking. This evokes the question, to what degree transmigration of DCs in 
dermal LVs might be influenced by time. Blocking data shown here indicate control of CD99 
but not CD31, as CD31 was neither rhythmically expressed, nor did its neutralization show 
time-of-day dependent effects. The study of Torzicky et al. revealed comparable results for 
CD31 blockade, consequently showing that both CD31 and CD99 are required for DC 
trafficking into LVs [218]. Notably, here the effect of CD31 blockage is unexpectedly strong, 
hence further experiments are required for validation. 
Two other molecules involved in the transmigration of leukocytes are the tight junctional 
adhesion molecules JAM-A and JAM-C. Block of each reduced DC trafficking across dermal LVs 
especially at ZT7, with JAM-A showing a stronger effect (Figure 4-14). JAM-A is expressed on 
multiple leukocytes, including DCs, whereas in mice, JAM-C – with respect to leukocyte 
migration – is restricted to endothelial and stromal cells [377-380]. So far, JAM-A has received 




JAM-A can either engage in homotypic cis interactions, regulating the tight junctional 
stabilization or simultaneously perform trans interactions, allowing the modulation of tight 
junctions to support leukocyte migration as shown in BVs [21]. In the only published study to 
date, endothelial specific deletion of JAM-A did not result in significant impairment in DC 
trafficking in vivo. On the contrary, cultured JAM-A-/- DCs displayed increased transmigration 
through JAM-A+/+ LEC monolayers in vitro and an elevated migration capacity in vivo when 
adoptively transferred into WT mice under inflammatory conditions [221]. The results 
obtained here seem contradictory. However, both studies used different models of leukocyte 
trafficking in addition to steady state and inflammation. Thus, comparability of both studies is 
compromised and requires further experiments. It is known that lymphatics alter their 
transcriptional landscape during inflammation and consequently, a bipartite system could be 
possible, since in BVs antibody-mediated neutralization of JAM-A led to a significant reduction 
in neutrophil transmigration in-vitro under inflammatory conditions [381]. Notably, it is 
possible that the culture of JAM-A-/- DCs caused compensatory mechanisms as they will lose 
their clock synchrony that could change their migration in an unexpected manner. 
JAM-C interacts with JAM-B and can simultaneously bind the integrin αMβ2 [382]. 
Neutralization of JAM-C leads to reduced JAM-B binding and subsequent redistribution of 
JAM-C on the endothelial surface [383]. Lamagna and colleagues neutralized JAM-C and 
subsequently observed an increase in adhesion of neutrophils and monocytes on BECs. In a 
more recent study by Ballet et al., neutralization of JAM-C increased trafficking of leukocytes 
including dermal DCs, monocyte-derived DCs as well as neutrophils in an infection model of 
Leishmania major. The effect of blockade here contradicts the results of the previously 
mentioned study. Although experiments in this thesis where performed under almost steady-
state conditions, a repetition of JAM-C and JAM-A blockage should lead to clarification if 
blockade of respective molecules is different under steady-state compared to inflammatory 
conditions. For this purpose a repetition with the same conditions together with a repetition 
under inflammatory condition is necessary since JAMs could be pro-migratory in steady-state 
but inhibitory in inflammation. 
In all neutralization experiments, including various modes of CCL21 blockade, trafficking could 
not be reduced below a certain baseline. Remarkably, no neutralization (except for the CCR7-/- 
BMDC and CD31 neutralization experiment) alone could completely abrogate DC trafficking 
(Figure 4-13 and Figure 4-14). This might be due to pro-migratory factors compensating for 
the loss of a single factor. Hence, a multi-blockade approach might be necessary, if other 
molecules compensate the “loss of functionality” of one molecule. One hint that supports this 




CD31 alone meets the requirements to facilitate successful transmigration. On the other 
hand, loss of CCR7 completely abolished BMDC trafficking, possibly owing to an inability of 
cells to detect the CCL21 gradient within the tissue.  
Many other interesting targets were not screened in this study, but might be a subject in the 
future, such as ACKR4 (important in embryonic development of lymphatics and expressed on 
LECs [214]) or REELIN, which was recently shown to be of importance in CNS leukocyte 
trafficking during autoimmune encephalomyelitis [49] and was strongly and rhythmically 
expressed in dermal LECs in this study (Figure 4-7).  One of the pitfalls of pharmacological 
intervention via antibodies is the missing guarantee for complete neutralization of 
antigenicity, which might explain the different results obtained between loss of CCR7 and 
CCL21 blockade. Of note, although endotoxin levels of commercially available antibodies are 
advertised as being low, small traces of sodium azide or endotoxins are sufficient to damage 
the sensitive dermis. Moreover, a FC-block during a crawl-in assay should be performed, as 
FC-receptors on both LECs and DCs could also oscillate throughout the day and might thus 
additionally influence the neutralization experiments.  
Nonetheless, neutralization of oscillatory proteins validates the concept of time-of-day 
dependent administration of antibodies for chrono-therapeutic targeting of diseases. As of 
the end of 2019, 79 therapeutic monoclonal antibodies have been approved by the United 
States Food and Drug Administration (US FDA) for treating various human diseases [384]. By 
targeting proteins such as α4β7 integrin, P-selectin, CCR4, IL-5 or IL-17α essential arms of the 
immune system are blocked to treat diseases [384]. Financially (estimated market value of 
monoclonal antibodies is about to be 300 billion in 2025 [384]) and from the perspective of 
therapy, this market is very important for research and development, which is why its 
optimization is of greatest interest. One relatively easy and cost-saving method is to 
investigate the timed administration of antibodies and other drugs. Chronotherapy has long 
been acknowledged in treatment of diseases, yet it remains relatively scarce in clinical trials. 
Theophylline was one of the first drugs for which circadian variation in pharmacokinetic 
parameters was proven and since then, many studies have supported the chronotherapy of 
medicines such as statins, antihypertensive agents and proton pump inhibitors [385]. Despite 
evidence received in vaccination studies (see 2.5.4) timed administration of antibodies or 
antigens is not commonly pursued and this study should add valuable insight into avenues for 
the timed dosing of anti-migration interventions with respect to vaccinations and 





5.5 Do cell type-specific intrinsic clocks govern rhythmic dermal leukocyte 
trafficking? 
 
Tissue-specific genetic ablation of Bmal1 in either LECs or DCs was sufficient to ablate 
oscillations in DC migration and cellularity (Figure 4-15 and Figure 4-17). Moreover, loss of 
Bmal1 perturbed oscillations of pro-migratory trafficking molecules (Figure 4-16). The protein 
screen indicated that the daily rhythms in migration were driven (at least in part) by the LEC 
clock. Molecules such as dermal CCL21 were starkly decreased in their expression at ZT7 in 
LEC specific Bmal1-/- mice, which points at a possible direct regulation. This effect was also 
reported for BECs using the model of Cdh5cre-Bmal1fl/fl, in which ICAM-1 levels were 
significantly reduced in liver BECs [56]. Knocking out other components of the clock such as 
Per2 or Nr1d1/Nr1d2, could further shine light on which pro-migratory factor is regulated by 
which clock protein in LECs. For this purpose, a mouse harboring floxed Nr1d1 and Nr1d2 loci 
would be beneficial, which was recently generated for metabolic research by Dierickx and 
colleagues [386]. Another faster method would be ChIP-sequencing to survey regulatory sides 
for molecular clock components. The list of binding motifs provided in Table 5-1 and appendix 
7.3 also offers possible sites for the introduction of targeted mutations, which could lead to a 
down-regulation of respective proteins and thus create a strong mechanistic link between 
immune cell clocks and rhythms in protein expression. Collectively, these experiments could 
give compelling evidence of molecular clock regulation. 
Skin circadian clocks have already been implicated as regulators of immune cellularity, as 
described in human epidermal stem cells [387]. Here, flow-cytometric analysis of ears 
revealed a diurnal rhythm in ear cellularity (Figure 4-9). In addition, time-of-day dependent 
proliferation of CD11c+ cells using KI67 as marker could be shown. Although this is an 
interesting first indication of rhythmic dermal cellularity, further experiments are required to 
validate time-of-day dependent proliferation. Intra-cellular flow-cytometric analysis of KI67 
together with another model such as 5-ethynyl-2’-deoxyuridine (EdU) or bromodeoxyuridine 
(BrdU) staining could give further insights into the proliferative state of immune cells. Of note, 
EdU would be favored as its incorporation is not influenced by steric hindrance of double-
stranded DNA [388]. This association of dermal clock genes and cell cycle was already shown 
early on in 2001 [389]. Other cells such as keratinocytes in the epidermis were also indicated 
to be rhythmic (circadian rhythms in the G2-M phase of the cell cycle) [311], and thus, a 
complete 24h overview of immune cell demographics in the skin would be of high interest. 
For the DC intrinsic clock, data presented using Clec9acre-Bmal1-/- mice can only give limited 




study do not allow assumptions to what degree the DC clock influences the observed 
phenotypes. The screening of activation markers and receptors involved in trafficking as well 
as the DC-specific KO indicates that the DC clock might be involved. However, for a more 
profound understanding, further experiments are required. BMDC synchronization might be a 
possible experiment to regard the influence of the DC intrinsic clock on the phenotype 
observed during crawl-in assays [331]. Secondly, further in-vitro chemotaxis assays using 
sorted DCs from phase-shifted mice could identify chemotaxis abilities of different DCs. Use of 
other cell type-specific Bmal1 KOs would also be important, such as Langerin-Cre or CD11c-
Cre mice. Although Cd11c-Cre mice will also affect macrophages and monocytes, it will cover 
all DCs. In the literature, a molecular link between leukocyte specific clocks and migratory 
behavior and immune function could be shown in BMDCs,  (Cd11c-Cre [296]) T cells (Cd4-Cre 
[279, 291] and Lck-Cre [291]), B cells (Cd19-Cre [56, 291] and Mb1-Cre [279]), 
macrophages/monocytes and neutrophils (Lyz2-Cre / LysM-Cre [56, 276, 288, 390] and 
hMRP8-Cre [299]) and site-specific immune cells, such as microglia in the CNS (Cd11b-Cre 
[391]) or club cells in the lung (Ccsp-iCre [292]). Yet, the study by Hopwood and colleagues 
does not address the migration of DCs, and thus, the molecular link between the circadian 
clock and DCs, especially dermal DCs, remains elusive [296]. Nevertheless, given the long list 
of cell-specific effects of Bmal1 in leukocytes, a direct link between immune function and 





WIn this study, it was shown that LECs governed rhythmic DC trafficking into lymphatic 
capillaries. Future experiments (Figure 5-1) should dissect how the molecular clock of LECs 
regulates respective pro-migratory components, since a direct molecular link was not 
established in this study. For this purpose, ChIP sequencing might be a perfect candidate to 
understand which pro-migratory genes harbor regulatory elements of clock genes (Table 5-1 
and appendix 7.3). Moreover, other KO models of various clock genes can further specify 
which transcription factor is modulating the expression of pro-migratory factors. A special 





Further studies are required to understand the link between the circadian clock and DCs on a 
cell type-specific level. Using synchronized BMDCs (for example by horse serum shock) in 
exogenous crawl-in assays will give an estimate to what degree the DC clock influences the 
observed phenotype. To further differentiate the differences between dermal DCs, other cell 
type-specific Bmal1 KOs are necessary. A combination of Cd11c (targeting all DCs), Langerin 
(to target LCs only) and possibly Cd103 (only cDC1) mediated CRE expression will allow 
complete differentiation between LCs, cDC1s and cDC2s. Additionally this could be used to 
investigate if dermal DCs influence each other in their rhythm in migration, for example by 
releasing chemokines such as CCL17 [392]. Furthermore, RNA-sequencing of genetically 
modified LECs and DCs is required to understand the impact of loss of the clock on a more 
global level. 
As already alluded in the introduction, microbiota and the nervous system heavily influence 
circadian rhythms, as they are entrainment factors [340]. Consequently, the observed 
phenotype might be altered during loss of microbial or neuronal influence.  
To analyze the involvement of the autonomic nervous system, various methodologies can be 
employed. SCGx (see 3.2.2.3) or adrenoceptor KO mice could be used to gather a first glimpse 
into the impact of loss of neuronal influence onto the clock of LECs. 
Recently rhythms in the microbiota and the closely related topic of intestinal microbiota 
tolerance were receiving more attention. For example, restricted feeding influences the 
intestinal microbiome-epithelial-immune homeostasis in the intestine [393]. To investigate 
the role of the microbiota in the skin on circadian leukocyte trafficking, Myd88-/- or germ-free 
mice together with mice treated with antibiotics (erasing the microbiota of the skin) could be 
utilized. Early experiments performed by me and my colleague Chien-Sin Chen (LMU, Munich) 
of ear cellularity and crawl-out assays showed ablated or inverse rhythmic immune cell 
cellularity in Myd88-/- mice (see appendix Figure 7-3). Likewise, local sympathetic tone in SCGx 
mice perturbed time-of-day dependent differences in ear cellularity (see appendix Figure 7-3). 
Other cells like T cells and neutrophils might be an interesting target, as they also migrate 
through LVs. For this purpose, single-cell RNA-sequencing of the whole leukocyte populations 
could be employed to gain a complete overview of the immune cell landscape in the skin. 
Additionally, quantitative immunofluorescence of respective cell types and crawl-in assays can 
be performed to possibly reveal other rhythms in leukocyte trafficking.  
This study opens up potential future projects regarding dermal leukocyte trafficking, dermal 






Figure 5-1: Future directions and arising projects 
Many possible experiments and projects can arise from this thesis. By investigating the molecular 
clock connection, neuronal and microbial influence on the dermis, dendritic cell (DC) clock 
involvement on trafficking as well as a general cellularity screen and self-tolerance induction, a 
more profound understanding of how circadian clocks influence the immune system of the skin and 
its draining lymph nodes (LN) can be gained. LEC = lymphatic endothelial cell, ChIP = chromatin 






Migration of DCs through LVs is an integral part of immune responses, induction of self-
tolerance, as well as inflammatory processes. By employing ex-vivo trafficking assays using 
split ear halves and spinning disk confocal microscopy, I showed that migration of dermal DCs 
into LVs is time-of-day dependent, experiencing a peak during the day and a trough at night. 
This oscillation was facilitated by temporal up-regulation of trafficking factors in dermal LECs, 
such as LYVE-1, CCL21 and CD99. In addition, rhythmic micro-patterning of CCL21 heavily 
contributed to time-of-day differences in DC migration, with a more pronounced CCL21 
gradient found in close proximity to lymphatic capillaries during the day. Dermal DCs could 
follow this gradient better during the day as they transiently up-regulated the cognate 
receptor (CCR7), along with a subset of activation markers. 
Pharmacological neutralization of the rhythmic CCL21 gradient or the oscillatory proteins such 
as LYVE-1 and CD99 abrogated time-of-day dependent trafficking only during the day. The 
circadian migration of DCs as well as the up-regulation of trafficking factors might be under 
the control of the circadian clock, since tissue-specific genetic ablation of the core clock 
component Bmal1 led to a reduction in trafficking and loss of rhythms in pro-migratory 
factors. The results are summarized in a graphical abstract shown in Figure 5-2. 
This study reveals a novel understanding of lymphatic trafficking, as the molecular clock 
comes into play as a new regulator. This study underlines the importance of circadian rhythm 
in regulating immunity. Moreover, results point to the importance of maintaining healthy 
biological rhythms to regulate immune tolerance. This regulation could be used for future 
experiments dissecting the timing of self- and peripheral-tolerance induction, vaccination, 













Figure 5-2: Time-of-day dependent trafficking of leukocytes across lymphatics 
During the day, more dermal DCs migrate into the lymphatic vessels (LVs) due to a stronger 
extracellular CCL21 gradient and up-regulation of trafficking factors such as LYVE-1, CCR7, CD99 and 
intracellular / surface CCL21 in both lymphatic endothelial cells (LECs) and dendritic cells (DCs). 
Collectively, this allows for higher motility, interstitial migration, adhesion and transmigration of DCs 
into LVs.  
At night, these factors are downregulated and a lower migratory state is induced. Consequently, less 
DCs are found within the lymphatic capillaries since interstitial migration, adhesion and transmigration 
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Figure 7-1: Live imaging of exogenous crawl-in assays 
(A) 50,000 Activated and stained bone-marrow-derived dendritic cells (BMDCs) were added on 
explanted, split ear halves previously stained for LAMININ. After 35 min incubation in an imaging 
CO2 chamber with 37°C, the majority of BMDCs has migrated to the lymphatic vessels (LV), as 
indicated by the arrows. Scale bar = 50µm. 
(B) 3D views of BMDCS migrating into LAMININ
+
 LVs after 0 and 35 min. Arrows indicate 
transmigrating BMDCs. Scale bar = 40µm. 
Figure 7-2: Expression of genes associated with tolerance induction 
Measured expression of genes associated with self-tolerance induction in sorted dermal LECs. N = 5 
mice measured for 4 time points each. # = one-way ANOVA; * = Tukey’s multiple comparisons test, 






7.2 Codes and algorithms 
 
LYVE-1 mask / protein screen (FIJI) 
 
makeRectangle(3, 2, 506, 509); 
setBackgroundColor(0, 0, 0); 








GOLPH4 mask (FIJI) 
 
run("Next Slice [>]"); 
makeRectangle(0, 1, 512, 504); 
setAutoThreshold("Triangle dark"); 
Figure 7-3: Ear cellularity and crawl-out assay using SCGx and Myd88-/- mice 
(A) Flow-cytometric analyses of cellularity normalized to tissue weight from harvested WT or Myd88
-/-
 
ears. LC = Langerhans cell, cDC1/2 = conventional dendritic cell, T = T cell.  
(B) Flow-cytometric analyses of emigrated immune cells from cultured, split ears (crawl-out assay) into 
medium. Cell counts normalized to tissue weight from harvested WT or Myd88
-/-
 ears.  
(C) Flow-cytometric analyses of cellularity normalized to tissue weight from ears harvested from sham 
or SCGx mice. Briefly, the anterior tip of the sternum to the chin was opened and the cervical ganglion 
of anaesthetized mice was gently removed during a surgery, after which animals were given a 2 weeks 
recovery period. #= two-way ANOVA, *= Šidák’s multiple comparisons test, n = 2 mice across 2 time 
points measured each, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. All data are represented as 





setBackgroundColor(0, 0, 0); 
run("Clear Outside", "stack"); 
resetThreshold(); 




run("Next Slice [>]"); 
makeLine(260, 190, 260, 190); 
setAutoThreshold("IJ_IsoData dark"); 
run("Create Selection"); 
run("Next Slice [>]"); 
run("Measure"); 
run("Clear", "stack"); 








LYVE-1 dependent binary mask for further analysis (Matlab) 
#1 
 
function [ROI_Mask] = Stephan_LymphaticROIs(RawData_Directory,ImageName,Nr_ROIs) 
  
  
% change directory 
cd(RawData_Directory) 
  
% load Lymphatic AB tiff 
AB_Lymph = imread(ImageName); 
  
% preallocate ROI structure 
ROIs = cell(1,Nr_ROIs); 
  
% draw ROIs for binary mask on lymphatic antibody picture 
for i = 1:Nr_ROIs 
    imshow(AB_Lymph) 
    ROI = drawfreehand(); 
    ROIs{i} = ROI.createMask(); 
end 
  




for j = 1:Nr_ROIs 
    if j == 1 
        ROI_Mask = ROIs{j}; 
    else 
        ROI_Mask = ROI_Mask + ROIs{j}; 
    end 
end 
  
% binarize in case of overlap 
ROI_Mask(ROI_Mask > 1) = 1; 












% select all tifs to be ROI-ed 
[FileNames,~] = uigetfile('.tif','Select all images to be ROI-ed','MultiSelect','on');     
  
% enter number of picture to be ROI-ed 




% draw and extract ROIs for each picture 
for i = 1:Nr_Reps 
  
    % select & load Lymphatic AB tiff 
    [FileName,FilePath] = uigetfile({'.tif'},'Select an image'); 
    AB_Lymph = imread(strcat(FilePath,FileName)); 
  
    % define number of necessary ROIs to be drawn based on picture 
    imshow(AB_Lymph) 
    answer = inputdlg('Define number of necessary ROIs','Lymphatic Sample'); 
    Nr_ROIs = str2num(answer{1}); 
    clear answer 
    close gcf 
  
    % preallocate ROI structure 





    % draw ROIs for binary mask on lymphatic antibody picture 
    for i = 1:Nr_ROIs 
        imshow(AB_Lymph) 
        ROI = drawfreehand(); 
        ROIs{i} = ROI.createMask(); 
    end 
  
    % combine all ROIs 
    for j = 1:Nr_ROIs 
        if j == 1 
            ROI_Mask = ROIs{j}; 
        else 
            ROI_Mask = ROI_Mask + ROIs{j}; 
        end 
    end 
  
    % binarize in case of overlap 
    ROI_Mask(ROI_Mask > 1) = 1; 
    ROI_Mask = logical(ROI_Mask); 
  
    % Save ROI Mask for later processing 
    cd(FilePath) 
    save(['ROI_Mask_' FileName(1:end-4) '.mat'],'ROI_Mask'); 
    close gcf 
end 
 




% define number of staining protocols 
answer = inputdlg('Define number of staining protocols','Lymphvessel experiments'); 




DistanceStatistics = []; 
for m = 1:Nr_StainingProtocols             
    DistanceStatistics(m).RawDistancePixelFs = []; 
    DistanceStatistics(m).NormDistancePixelFs = []; 
    DistanceStatistics(m).AllNormDistancePixelFs = []; 
    DistanceStatistics(m).AllRawDistancePixelFs = []; 
    DistanceStatistics(m).DistanceMeans = []; 
    DistanceStatistics(m).DistanceSTDs = []; 
    DistanceStatistics(m).DistanceSEMs = []; 
    DistanceStatistics(m).GlobalDistanceMeans = []; 
    DistanceStatistics(m).GlobalDistanceSTDs = []; 
    DistanceStatistics(m).GlobalDistanceSEMs = []; 
    DistanceStatistics(m).normGlobalDistanceMeans = []; 
    DistanceStatistics(m).normGlobalDistanceSTDs = []; 









    %% parameter switchboard 
  
    % select all Interstitium images 
    if Nr_StainingProtocols == 2 
        if k == 1 
            [FileNames,FilePath] = uigetfile('.tif','Select non-control Interstitium images','MultiSelect','on'); 
        else 
            [FileNames,FilePath] = uigetfile('.tif','Select control Interstitium images','MultiSelect','on');                 
        end 
    elseif Nr_StainingProtocols == 4 
        if k == 1 
            [FileNames,FilePath] = uigetfile('.tif','Select non-control ZT7 Interstitium images','MultiSelect','on'); 
        elseif k == 2 
            [FileNames,FilePath] = uigetfile('.tif','Select non-control ZT19 Interstitium images','MultiSelect','on'); 
        elseif k == 3 
            [FileNames,FilePath] = uigetfile('.tif','Select iso-control ZT7 Interstitium images','MultiSelect','on'); 
        elseif k == 4 
            [FileNames,FilePath] = uigetfile('.tif','Select iso-control ZT19 Interstitium images','MultiSelect','on'); 
        end 
    elseif Nr_StainingProtocols == 6 
        if k == 1 
            [FileNames,FilePath] = uigetfile('.tif','Select WT non-control ZT7 Interstitium images','MultiSelect','on'); 
        elseif k == 2 
            [FileNames,FilePath] = uigetfile('.tif','Select WT non-control ZT19 Interstitium images','MultiSelect','on'); 
        elseif k == 3 
            [FileNames,FilePath] = uigetfile('.tif','Select WT iso-control ZT7 Interstitium images','MultiSelect','on'); 
        elseif k == 4 
            [FileNames,FilePath] = uigetfile('.tif','Select WT iso-control ZT19 Interstitium images','MultiSelect','on'); 
        elseif k == 5 
            [FileNames,FilePath] = uigetfile('.tif','Select KO non-control ZT7 Interstitium images','MultiSelect','on'); 
        elseif k == 6 
            [FileNames,FilePath] = uigetfile('.tif','Select KO non-control ZT19 Interstitium images','MultiSelect','on'); 
        end 
    end 
    Nr_files = length(FileNames); 
  
    % change directory to filepath 
    cd(FilePath) 
  
    % preallocate 
    AB_Interstitium = cell(Nr_files,1); 
    LymphMasks = cell(Nr_files,1); 
%     AB_Lymph = cell(Nr_files,1); 
    Pixel2Microns = NaN(Nr_files,1); 
  
    % load Interstitium images and Lymph ROIs with Pixel Conversion Factors 
    for i = 1:Nr_files 
        FileName_temp = FileNames{i}; 
        AB_Interstitium{i} = double(imread(FileName_temp)); 
%         ImInfo_temp = imfinfo(FileName_temp); 
%         Pixel2Microns(i) = 1/ImInfo_temp.XResolution; 
        Pixel2Microns(i) = 1/1.5; 
        if Nr_StainingProtocols == 2 
            LymphMasks{i} = load(['ROI_Mask_' FileName_temp(1:end-10) '_LV.mat']); 
%             AB_Lymph{i} = double(imread([FileName_temp(1:end-10) '_LV.tif'])); 
        elseif Nr_StainingProtocols == 4 
            LymphMasks{i} = load(['ROI_Mask_' FileName_temp(1:end-5) '0.mat']); 
%             AB_Lymph{i} = double(imread([FileName_temp(1:end-5) '0.tif'])); 
        elseif Nr_StainingProtocols == 6 
            LymphMasks{i} = load(['ROI_Mask_' FileName_temp(1:end-5) '0.mat']); 
%             AB_Lymph{i} = double(imread([FileName_temp(1:end-5) '0.tif'])); 
        end 
        clear FileName_temp 
        clear ImInfo_temp 
    end 
  
  
    %% calculate and plot Distance Mask from Lymphatic ROI 
     
    % determine longest distance from Lymph vessel from all pictures for preallocation 




        DistanceLength = length(unique(round(bwdist(LymphMasks{h,1}.ROI_Mask,'euclidean')*Pixel2Microns(h)))); 
        if h == 1 
            MaxDistance = DistanceLength; 
        elseif DistanceLength > MaxDistance 
            MaxDistance = DistanceLength; 
        end 
    end 
     
    % determine longest distance from Lymph vessel from all pictures for preallocation 
    PixelFrequency = zeros(MaxDistance,1); 
    for h = 1:Nr_files 
        [~,~,PixelFrequency_ic] = unique(round(bwdist(LymphMasks{h,1}.ROI_Mask,'euclidean')*Pixel2Microns(h))); 
        PixelFrequency_temp = accumarray(PixelFrequency_ic,1); 
        PixelFrequency(1:length(PixelFrequency_temp)) = PixelFrequency(1:length(PixelFrequency_temp)) + PixelFrequency_temp; 
    end 
    MaxPixelFrequency = max(max(PixelFrequency)); 
     
    % preallocate 
    DistanceStatistics(k).AllNormDistancePixelFs = NaN(MaxPixelFrequency,MaxDistance); 
    DistanceStatistics(k).AllRawDistancePixelFs = NaN(MaxPixelFrequency,MaxDistance); 
    if k == 1 
        Excel_ZT7 = NaN(MaxDistance,Nr_files); 
    elseif k == 2 
        Excel_ZT19 = NaN(MaxDistance,Nr_files); 
    elseif k == 3 
        Excel_isoZT7 = NaN(MaxDistance,Nr_files); 
    elseif k == 4 
        Excel_isoZT19 = NaN(MaxDistance,Nr_files); 
    elseif k == 5 
        Excel_KO_ZT7 = NaN(MaxDistance,Nr_files); 
    elseif k == 6 
        Excel_KO_ZT19 = NaN(MaxDistance,Nr_files); 
    end 
     
    for j = 1:Nr_files 
  
        % create distance mask around Lymph Vessel mask (round to nearest decimal) 
        DistanceMask = round(bwdist(LymphMasks{j,1}.ROI_Mask,'euclidean')*Pixel2Microns(h)); 
  
        % find pixels of Lymph Vessel Mask and Perimeter 
%         [ROI_IDs_Y,ROI_IDs_X] = find(LymphMasks{j,1}.ROI_Mask == 1); 
%         Lymph_mask_perim = bwperim(LymphMasks{j,1}.ROI_Mask); 
%         [ROIperim_IDs_Y,ROIperim_IDs_X] = find(Lymph_mask_perim); 
%  
%         % plot original picture and Distance Mask with ROI 
%         f1 = figure('Name','Lymphatic ROI & Distance Mask','color','w','Visible','off'); 
%         p = uipanel('Parent',f1,'BorderType','none');  
%         p.Title = 'Lymphatic ROI & Distance Mask';  
%         p.TitlePosition = 'centertop'; 
%         p.FontSize = 12; 
%         p.FontWeight = 'bold'; 
%  
%         subplot(1,2,1,'Parent',p); 
%         imshow(AB_Lymph{j}); 
%         hold on 
%         plot(ROIperim_IDs_X,ROIperim_IDs_Y,'.r','MarkerSize',1.5) 
%         title('Lymphatic ROI') 
%         colormap(gca,'gray') 
%         axis off 
%         hold off 
%  
%         subplot(1,2,2,'Parent',p); 
%         imagesc(DistanceMask) 
%         hold on 
%         colormap(gca,'cool'); 
%         colorbar 
%         plot(ROI_IDs_X,ROI_IDs_Y,'.k') 
%         plot(ROIperim_IDs_X,ROIperim_IDs_Y,'.w','MarkerSize',1.5) 
%         title('Distance Mask') 
%         axis square 




%         hold off 
%  
%         % save figure 
%         saveas(f1,[char(FileNames(j)) '_ROI_DistanceMask.fig']); 
%         saveas(f1,[char(FileNames(j)) '_ROI_DistanceMask.svg']); 
%         saveas(f1,[char(FileNames(j)) '_ROI_DistanceMask.pdf']); 
  
  
        %% extract distance dependent fluorescence values (normalized to F(max)) of Interstitium (relative from Lymph Vessel) 
  
        % preallocate 
        Fluorescence_Dist = cell(1,length(unique(DistanceMask))-1); 
        MEAN_FDist = NaN(1,length(unique(DistanceMask))-1); 
        STD_FDist = NaN(1,length(unique(DistanceMask))-1); 
        SEM_FDist = NaN(1,length(unique(DistanceMask))-1); 
  
        % find F(max) for normalization 
        Fmax = max(max(AB_Interstitium{j}(~LymphMasks{j,1}.ROI_Mask))); 
        
        % extract distance dependent fluorescence values & stats 
        Mask_Distances = unique(DistanceMask); 
        for i = 1:length(Mask_Distances) 
            ID = Mask_Distances(i); 
            if ID > 0 
                DistanceIDs = (DistanceMask == ID); 
                Fluorescence_Dist{ID} = AB_Interstitium{j}(DistanceIDs); 
                MEAN_FDist(ID) = nanmean(Fluorescence_Dist{ID}); 
                STD_FDist(ID) = nanstd(Fluorescence_Dist{ID}); 
                SEM_FDist(ID) = nanstd(Fluorescence_Dist{ID})/sqrt(length(Fluorescence_Dist{ID})); 
                clear DistanceIDs 
  
                % save variables 
                DistanceStatistics(k).RawDistancePixelFs{j,ID} = Fluorescence_Dist{ID}; 
                DistanceStatistics(k).NormDistancePixelFs{j,ID} = Fluorescence_Dist{ID}/Fmax; 
                if j == 1 
                    DistanceStatistics(k).AllNormDistancePixelFs(1:length(Fluorescence_Dist{ID}),ID) = Fluorescence_Dist{ID}/Fmax; 
                    DistanceStatistics(k).AllRawDistancePixelFs(1:length(Fluorescence_Dist{ID}),ID) = Fluorescence_Dist{ID}; 
                else 
                    First_NaN_position = find(isnan(DistanceStatistics(k).AllNormDistancePixelFs(:,ID)) == 1, 1,'first'); 
                    DistanceStatistics(k).AllNormDistancePixelFs(First_NaN_position:First_NaN_position+length(Fluorescence_Dist{ID})-
1,ID) = Fluorescence_Dist{ID}/Fmax; 
                    DistanceStatistics(k).AllRawDistancePixelFs(First_NaN_position:First_NaN_position+length(Fluorescence_Dist{ID})-
1,ID) = Fluorescence_Dist{ID}; 
                    clear First_NaN_position 
                end 
                DistanceStatistics(k).DistanceMeans(j,ID) = MEAN_FDist(ID); 
                DistanceStatistics(k).DistanceSTDs(j,ID) = STD_FDist(ID); 
                DistanceStatistics(k).DistanceSEMs(j,ID) = SEM_FDist(ID); 
                if k == 1 
                    Excel_ZT7(ID,j) = MEAN_FDist(ID); 
                elseif k == 2 
                    Excel_ZT19(ID,j) = MEAN_FDist(ID); 
                elseif k == 3 
                    Excel_isoZT7(ID,j) = MEAN_FDist(ID); 
                elseif k == 4 
                    Excel_isoZT19(ID,j) = MEAN_FDist(ID); 
                elseif k == 5 
                    Excel_KO_ZT7(ID,j) = MEAN_FDist(ID); 
                elseif k == 6 
                    Excel_KO_ZT19(ID,j) = MEAN_FDist(ID); 
                end 
            end 
            clear ID 
        end    
    end 
  
    % calculate Means, STDs and SEMs for each distance over all pictures (repetitions) 
    for i = 1:length(DistanceStatistics(k).AllNormDistancePixelFs(1,:)) 
        DistanceStatistics(k).GlobalDistanceMeans(i) = nanmean(DistanceStatistics(k).AllRawDistancePixelFs(:,i)); 




        DistanceStatistics(k).GlobalDistanceSEMs(i) = 
nanstd(DistanceStatistics(k).AllRawDistancePixelFs(:,i))/sqrt(sum(~isnan(DistanceStatistics(k).AllRawDistancePixelFs(:,i)))); 




%% Normalize Means, STDs and SEMs to Means (non-control) for plotting 
  
if Nr_StainingProtocols == 2 
    for m = 1:Nr_StainingProtocols 
        if m == 1 
            DistanceStatistics(m).normGlobalDistanceMeans = 
DistanceStatistics(m).GlobalDistanceMeans/max(DistanceStatistics(m).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSTDs = 
DistanceStatistics(m).GlobalDistanceSTDs/max(DistanceStatistics(m).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSEMs = 
DistanceStatistics(m).GlobalDistanceSEMs/max(DistanceStatistics(m).GlobalDistanceMeans); 
        else 
            DistanceStatistics(m).normGlobalDistanceMeans = DistanceStatistics(m).GlobalDistanceMeans/max(DistanceStatistics(m-
1).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSTDs = DistanceStatistics(m).GlobalDistanceSTDs/max(DistanceStatistics(m-
1).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSEMs = DistanceStatistics(m).GlobalDistanceSEMs/max(DistanceStatistics(m-
1).GlobalDistanceMeans);         
        end 
    end 
elseif Nr_StainingProtocols == 4 
    for m = 1:Nr_StainingProtocols 
        if m == 1 || 2 
            DistanceStatistics(m).normGlobalDistanceMeans = 
DistanceStatistics(m).GlobalDistanceMeans/max(DistanceStatistics(m).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSTDs = 
DistanceStatistics(m).GlobalDistanceSTDs/max(DistanceStatistics(m).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSEMs = 
DistanceStatistics(m).GlobalDistanceSEMs/max(DistanceStatistics(m).GlobalDistanceMeans); 
        elseif m == 3 || 4 
            DistanceStatistics(m).normGlobalDistanceMeans = DistanceStatistics(m).GlobalDistanceMeans/max(DistanceStatistics(m-
2).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSTDs = DistanceStatistics(m).GlobalDistanceSTDs/max(DistanceStatistics(m-
2).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSEMs = DistanceStatistics(m).GlobalDistanceSEMs/max(DistanceStatistics(m-
2).GlobalDistanceMeans);     
        end 
    end 
elseif Nr_StainingProtocols == 6 
    for m = 1:Nr_StainingProtocols 
        if m == 1 || 2 
            DistanceStatistics(m).normGlobalDistanceMeans = 
DistanceStatistics(m).GlobalDistanceMeans/max(DistanceStatistics(m).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSTDs = 
DistanceStatistics(m).GlobalDistanceSTDs/max(DistanceStatistics(m).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSEMs = 
DistanceStatistics(m).GlobalDistanceSEMs/max(DistanceStatistics(m).GlobalDistanceMeans); 
        elseif m == 3 || 4 
            DistanceStatistics(m).normGlobalDistanceMeans = DistanceStatistics(m).GlobalDistanceMeans/max(DistanceStatistics(m-
2).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSTDs = DistanceStatistics(m).GlobalDistanceSTDs/max(DistanceStatistics(m-
2).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSEMs = DistanceStatistics(m).GlobalDistanceSEMs/max(DistanceStatistics(m-
2).GlobalDistanceMeans);  
        elseif m == 5 || 6 
            DistanceStatistics(m).normGlobalDistanceMeans = 
DistanceStatistics(m).GlobalDistanceMeans/max(DistanceStatistics(m).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSTDs = 
DistanceStatistics(m).GlobalDistanceSTDs/max(DistanceStatistics(m).GlobalDistanceMeans); 
            DistanceStatistics(m).normGlobalDistanceSEMs = 
DistanceStatistics(m).GlobalDistanceSEMs/max(DistanceStatistics(m).GlobalDistanceMeans); 
        end 






     
%% plot distance dependent fluorescence values (normalized to F(max)) of Interstitium (relative from Lymph Vessel) 
  
% plot mean F with SEM  
if Nr_StainingProtocols == 2 
    f2 = figure('Name','Distance Dependent F','color','w'); 
    hold on 
    
errorbar((1:length(DistanceStatistics(1).normGlobalDistanceMeans)),DistanceStatistics(1).normGlobalDistanceMeans,DistanceSta
tistics(1).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    
errorbar((1:length(DistanceStatistics(2).normGlobalDistanceMeans)),DistanceStatistics(2).normGlobalDistanceMeans,DistanceSta
tistics(2).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    title('Distance Dependent Fluorescence'); 
    xlabel('Distance from LV [um]'); 
    ylabel('Normalized Fluorescence Intensity'); 
    legend('ZT7','iso control') 
    xlim([0 100]); 
    ylim_curr = get(gca,'ylim');  
    ylim_curr(2) = 1; 
    set(gca,'ylim',ylim_curr) 
    hold off 
elseif Nr_StainingProtocols == 4 
    f2 = figure('Name','Distance Dependent F','color','w'); 
    hold on 
    
errorbar((1:length(DistanceStatistics(1).normGlobalDistanceMeans)),DistanceStatistics(1).normGlobalDistanceMeans,DistanceSta
tistics(1).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    
errorbar((1:length(DistanceStatistics(2).normGlobalDistanceMeans)),DistanceStatistics(2).normGlobalDistanceMeans,DistanceSta
tistics(2).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    
errorbar((1:length(DistanceStatistics(3).normGlobalDistanceMeans)),DistanceStatistics(3).normGlobalDistanceMeans,DistanceSta
tistics(3).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    
errorbar((1:length(DistanceStatistics(4).normGlobalDistanceMeans)),DistanceStatistics(4).normGlobalDistanceMeans,DistanceSta
tistics(4).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    title('Distance Dependent Fluorescence'); 
    xlabel('Distance from LV [um]'); 
    ylabel('Normalized Fluorescence Intensity'); 
    legend('ZT7','ZT19','ZT7 iso control','ZT19 iso control') 
    xlim([0 100]); 
    ylim_curr = get(gca,'ylim');  
    ylim_curr(2) = 1; 
    set(gca,'ylim',ylim_curr) 
    hold off 
elseif Nr_StainingProtocols == 6 
    f2 = figure('Name','Distance Dependent F','color','w'); 
    hold on 
    
errorbar((1:length(DistanceStatistics(1).normGlobalDistanceMeans)),DistanceStatistics(1).normGlobalDistanceMeans,DistanceSta
tistics(1).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    
errorbar((1:length(DistanceStatistics(2).normGlobalDistanceMeans)),DistanceStatistics(2).normGlobalDistanceMeans,DistanceSta
tistics(2).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    
errorbar((1:length(DistanceStatistics(3).normGlobalDistanceMeans)),DistanceStatistics(3).normGlobalDistanceMeans,DistanceSta
tistics(3).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    
errorbar((1:length(DistanceStatistics(4).normGlobalDistanceMeans)),DistanceStatistics(4).normGlobalDistanceMeans,DistanceSta
tistics(4).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    
errorbar((1:length(DistanceStatistics(5).normGlobalDistanceMeans)),DistanceStatistics(5).normGlobalDistanceMeans,DistanceSta
tistics(5).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    
errorbar((1:length(DistanceStatistics(6).normGlobalDistanceMeans)),DistanceStatistics(6).normGlobalDistanceMeans,DistanceSta
tistics(6).normGlobalDistanceSEMs,'.','MarkerSize',15) 
    title('Distance Dependent Fluorescence'); 
    xlabel('Distance from LV [um]'); 
    ylabel('Normalized Fluorescence Intensity'); 




    xlim([0 100]); 
    ylim_curr = get(gca,'ylim');  
    ylim_curr(2) = 1; 
    set(gca,'ylim',ylim_curr) 







%% save plot and data matrix 
  



















         
%% select and load all relevant data 
  
% select all Cell/Interstitium images 
[FileNames,FilePath] = uigetfile('.tif','Select Cell images','MultiSelect','on'); 
Nr_files = length(FileNames); 
  




LymphMasks = cell(Nr_files,1); 
Cell_image = cell(Nr_files,1); 
Lymph_image = cell(Nr_files,1); 
Pixel2Microns = NaN(Nr_files,1); 
  
% load Cell/Interstitium images and Lymph ROIs with Pixel Conversion Factors 
for i = 1:Nr_files 
    FileName_temp = FileNames{i}; 
%         ImInfo_temp = imfinfo(FileName_temp); 
%         Pixel2Microns(i) = 1/ImInfo_temp.XResolution; 
    Pixel2Microns(i) = 1/1.5; 
    if exist(['ROI_Mask_' FileName_temp(1:end-10) '_LV.mat'],'file') > 0 




        Cell_image{i} = imread([FileName_temp(1:end-10) '_LV.tif']); 
    elseif exist(['ROI_Mask_' FileName_temp(1:end-5) '0.mat'],'file') > 0 
        LymphMasks{i} = load(['ROI_Mask_' FileName_temp(1:end-5) '0.mat']); 
        Cell_image{i} = imread([FileName_temp(1:end-5) '0.tif']); 
    else 
        LymphMasks{i} = load(['ROI_Mask_' FileName_temp(1:end-5) '1.mat']); 
        Cell_image{i} = imread(FileName_temp); 
        Lymph_image{i} = imread([FileName_temp(1:end-5) '1.tif']); 
    end 
    clear FileName_temp 




%% calculate and plot 20 microns contour lines from Lymphatic ROI for each selected image 
  
for j = 1:Nr_files 
  
    % create distance mask around Lymph Vessel mask (round to nearest decimal) 
    DistanceMask = round(bwdist(LymphMasks{j,1}.ROI_Mask,'euclidean')*Pixel2Microns(j)); 
  
    % extract contour lines in 20 micron steps up to 100 microns 
    [CL20_Y,CL20_X] = find(DistanceMask == 20); 
    [CL40_Y,CL40_X] = find(DistanceMask == 40); 
    [CL60_Y,CL60_X] = find(DistanceMask == 60); 
    [CL80_Y,CL80_X] = find(DistanceMask == 80); 
    [CL100_Y,CL100_X] = find(DistanceMask == 100); 
  
    % find pixels of ROI and Perimeter 
    Lymph_mask_perim = bwperim(LymphMasks{j,1}.ROI_Mask); 
    [ROIperim_IDs_Y,ROIperim_IDs_X] = find(Lymph_mask_perim); 
     
    % define colormap for colormap indexing 
    Colormap = cool(5); 
  
    % plot cell picture and overlay contour lines 
    f1 = figure; 
    imshow(Cell_image{j}); 
    hold on 
    plot(ROIperim_IDs_X,ROIperim_IDs_Y,'.w','MarkerSize',1.5) 
    plot(CL20_X,CL20_Y,'.','Color',[Colormap(1,:)],'MarkerSize',1.5) 
    plot(CL40_X,CL40_Y,'.','Color',[Colormap(2,:)],'MarkerSize',1.5) 
    plot(CL60_X,CL60_Y,'.','Color',[Colormap(3,:)],'MarkerSize',1.5) 
    plot(CL80_X,CL80_Y,'.','Color',[Colormap(4,:)],'MarkerSize',1.5) 
    plot(CL100_X,CL100_Y,'.','Color',[Colormap(5,:)],'MarkerSize',1.5) 
%     title('20 micron contour lines') 
    axis off 





    % save figure 
    saveas(f1,[char(FileNames(j)) '_Cell_ROI_20umContour.fig']); 
    export_fig(f1,[char(FileNames(j)) '_Cell_ROI_20umContour.png']); 
%     saveas(f1,[char(FileNames(j)) '_Cell_ROI_20umContour.pdf']); 
     
     
    % plot lymph picture and overlay contour lines 
    f2 = figure; 
    imshow(Lymph_image{j}); 
    hold on 
    plot(ROIperim_IDs_X,ROIperim_IDs_Y,'.w','MarkerSize',1.5) 
    plot(CL20_X,CL20_Y,'.','Color',[Colormap(1,:)],'MarkerSize',1.5) 
    plot(CL40_X,CL40_Y,'.','Color',[Colormap(2,:)],'MarkerSize',1.5) 
    plot(CL60_X,CL60_Y,'.','Color',[Colormap(3,:)],'MarkerSize',1.5) 
    plot(CL80_X,CL80_Y,'.','Color',[Colormap(4,:)],'MarkerSize',1.5) 
    plot(CL100_X,CL100_Y,'.','Color',[Colormap(5,:)],'MarkerSize',1.5) 
%     title('20 micron contour lines') 
    axis off 
    hold off 
  
    % save figure 
    saveas(f2,[char(FileNames(j)) '_Lymph_ROI_20umContour.fig']); 
    export_fig(f2,[char(FileNames(j)) '_Lymph_ROI_20umContour.png']); 






7.3 Promoter binding sites of clock genes  
 
Ccl21a 
Arntl [p-value = 0.01]: 83, 82, -72, -73, -86, -98, -172, -292, -293, -409, -418, -448, -449, -966, -967, -1221, -1228, -1235, -1244, -
1261, -1342, -1384, -1405, -1586, -1587, -1833, -1968, -1982, -1983  
Arntl [p-value = 0.001]: -966, -1586, -1587, -1982  
Arntl [p-value = 0.0001]: -1586  
Dbp [p-value = 0.01]: 49, -29, -81, -82, -299, -300, -362, -363, -399, -400, -413, -414, -565, -650, -651, -720, -721, -740, -956, -957, 
-1273, -1274, -1405, -1406, -1434, -1900, -1901, -1977 
Dbp [p-value = 0.001]: -650, -651 
Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]: -31, -298, -301, -401, -412, -472, -564, -567, -599, -616, -644, -649, -719, -722, -811, -814, -884, -891, -916, 
-942, -958, -960, -970, -1240, -1272, -1275, -1311, -1483, -1493, -1541, -1644, -1692, -1899, -1962 
Nfil3 [p-value = 0.001]: -301, -884, -1692 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: 91, 77, 37, 12, -78, -164, -192, -238, -425, -513, -535, -539, -660, -721, -736, -789, -901, -946, 
-961, -1008, -1176, -1195, -1216, -1233, -1244, -1298, -1400, -1417, -1497, -1529, -1663, -1669, -1683, -1779, -1814, -1888, -
1900, -1938, -1952, -1967 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -1008, -1417, -1888, -1900, -1952 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]: none 
 
Promoter sequence of Ccl21a and Bmal1 canonical binding sites (as an example of methodology): 
Red shows canonical (CAN NTG) Bmal1 binding site. 
(-2000) gaaagaacat  ccacacacat   gaaataaaat   cactttttta   atttaaaaga   tcaagtcatt (-1941) 
gaagtcaaaa gtgaaagtag ggacatcagt ataatttgac ataaataaaa aaggtccaat (-1881) 
aaaccgggtg tggtggtgct tgcttttaat cccagactgg ggaggcaggg ggaggtggat (-1821) 
ctctgagttc aaagccagcc tgctctacag agcaagttct aggatagcca gggctacaca (-1761) 
gagaaaccct gtctcaaaac aaaaaacaaa caacaaagca aaaaacaaac aaacaaaaag (-1701) 
agtgtgctat gtatgactct gttccaacct aggtgaaatg gataaattcc aaactcacaa (-1641) 
aatctaccaa aatcagctgg agaggaaacg cacctccgag tgcattcaca ccacgtgaga (-1581) 
acacggaata aggagtaaca attgccaaat acccaaacta agaaaatacc aggtccaatg (-1521) 
gcttcagtgt gaattctctt caacatcaca acagttttaa catccattgt tctcaaagtt (-1461) 
tccaaaagtc tgaagagctg gcattcccta acacagtgtc tgaggtcagc gttacctgat (-1401) 
cctgaggctg gaaaacgagc ctacaggaaa acagcagacc aacccccatc cctcatacat (-1341) 
gaaaacacaa aagtcctcca caaaatatta aaaaaaaaac aaactcagca gcacagtgaa (-1281) 
gtattatata ctacgaccaa gtggggtctg ctctcaggtt aaaacaagac cacattaaca (-1221) 
tgaaggggaa acccatactt cttcggatca ggaacataca agatgctcac ttcaacccaa (-1161) 
cagtgcaagc tatagtggag agagggaggg agggagagag agagagagag agagagagag (-1101) 
agagagagag agagagagag agagagagaa ctattagcaa ttaataattc cagcactcag (-1041) 
aggcagaggc aggtagatct ctgtgagttc aaggccaacc tggtctatga atcccagaac (-981) 
agccaaggct acatgtgaca ttgtgtctca aaaaagtaac aacaataaca acaacaacaa (-921) 
aattccaaaa ggaaataaag aacacaatta tatttataac agcaccaaac agaatactta (-861) 




ttaaaggagg cctaaatgaa taaaaagcta tcccttattc ttggattgaa ttctaatttt (-741) 
acaaagacag tgataacgac gtaagtggtc ctcagattca gtacaatatc tattagaatc (-610) 
cctagggagg gatggaaagg ggacagttgt gtaattatat tataatccca aaagctaaaa (-621) 
gaaataataa taaataaaac ataagggagg ggcagaaaga tggctcagca cttatggaag (-561) 
ggtgttgctc ttgcagagga cctgagttca gttccctgca ccctcaccta ccacttccac (-501) 
ttacagccac acaaaaatac acattgtttt aaaaagcaga ggaaagtttc atgggcttgg (-441) 
atctgttaat gatcggttca gtgtgatgtc gcggtagtaa catcacagct agtaggggaa (-381) 
gagggggagt tgggtttcac aaaactttaa aattttgtgc gctactatca ggaagtctat (-321) 
agactgagag gatgcagtta tatatcatat gtctaaaata aggcctattg tcagggatct (-261) 
ataaagaact cctagtcatt agctagatta ttacttgccg aaaggagagg agatgtgtgg (-201) 
ggcctgaagg gcagggagga agcaatcatg ctttggggac agtggctgga aggaccaggg (-141) 
agagatgagg agctgaacag ctaggagctg actgtatgct cacactaatg ccatctgatc (-81) 
caactcacag gaaaaggagg gggagcgagg gaagcgaaag tctcagactg cataaatagg (-21) 
cagcaagcca gtcgcagccc (0) ACACACACAG ACCCCAACTT GCGGCTGTCC ATCTCACCTA (+40) 
CAGCTCTGGT CTCATCCTCA ACTCAACCAC AATCATGGCT CAGATGATGA CTCTGAGCCTC (+100) 
 
Ccl21b/c 
Arntl [p-value = 0.01]: -1761, -1760, -1579, -1558, -1516, -1435, -1418, -1402, -1395, -1341, -1330, -967, -966, -449, -448, -418, -
293, -292, -172, -105, -98, -86, -73, -72, 82, 83 
Arntl [p-value = 0.001]: -1761, -1760, -966 
Arntl [p-value = 0.0001]: -1760 
Dbp [p-value = 0.01]: -1608, -1580, -1579, -1519, -1518, -1448, -1447, -1361, -1360, -957, -956, -740, -721, -720, -651, -650, -565, 
-414, -413, -400, -399, -363, -362, -300, -82, -81, -29, 49 
Dbp [p-value = 0.001]: -651, -650 
Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]:  -1866, -1715, -1667, -1657, -1520, -1449, -1446, -1414, -1362, -1281, -970, -960, -958, -942, -916, -891, -
884, -814, -811, -722, -719, -649, -644, -616, -599, -567, -564, -472, -412, -401, -31 
Nfil3 [p-value = 0.001]: -1866, -884 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: -1988, -1953, -1857, -1843, -1837, -1703, -1671, -1591, -1574, -1472, -1418, -1407, -1390, -
1336, -1271, -1243, -1222, -1213, -1194, -1008, -961, -946, -901, -789, -736, -721, -660, -539, -535, -513, -425, -238, -192, -164, -
108, -78, 12, 37, 77, 91 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -1591, -1407, -1008 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]:  -1008 
Lyve1 
Arntl [p-value = 0.01]: 31, -54, -147, -148, -177, -239, -275, -276, -355, -372, -454, -455, -553, -554, -617, -618, -673, -696, -796, -
836, -853, -916, -917, -1139, -1153, -1171, -1339, -1340, -1381, -1382, -1402, -1457, -1478, -1489, -1490, -1515, -1516, -1558, -
1592, -1671, -1694, -1818, -1846, -1872 
Arntl [p-value = 0.001]: -276, -455, -916, -917, -1339, -1516 
Arntl [p-value = 0.0001]: -276 
Dbp [p-value = 0.01]: -123, -172, -173, -330, -331, -374, -375, -448, -449, -536, -537, -644, -645, -742, -743, -800, -801, -819, -820, 
-848, -849, -887, -950, -951, -1024, -1025, -1212, -1213, -1314, -1351, -1352, -1471, -1472, -1597, -1711, -1712, -1740, -1741, -
1763, -1764, -1888, -1889, -1956 
Dbp [p-value = 0.001]: -819, -820, -848, -849, -1471, -1472, -1888, -1889 




Nfil3 [p-value = 0.01]: -376, -414, -447, -505, -729, -741, -744, -799, -802, -821, -847, -949, -1140, -1211, -1317, -1350, -1353, -
1470, -1473, -1509, -1679, -1710, -1713, -1739, -1842, -1887, -1890, -1919 
Nfil3 [p-value = 0.001]: -741, -799, -1890 
Nfil3 [p-value = 0.0001]: -1890 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: 67, -68, -72, -123, -135, -149, -172, -365, -441, -456, -510, -543, -562, -644, -731, -848, -922, -
1073, -1194, -1207, -1235, -1254, -1258, -1278, -1297, -1315, -1322, -1340, -1372, -1392, -1437, -1472, -1521, -1562, -1569, -
1699, -1722, -1749, -1815, -1910, -1944, -1968 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -1073, -1562, -1749, -1910 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]: none 
Jam3 
Arntl [p-value = 0.01]: 86, 51, 0, -35, -36, -96, -97, -180, -181, -226, -351, -352, -412, -413, -449, -471, -496, -518, -519, -550, -574, 
-895 
Arntl [p-value = 0.001]: -519 
Arntl [p-value = 0.0001]: none 
Dbp [p-value = 0.01]: -255, -256, -294, -295, -461, -524, -562, -684, -685, -769, -770, -836, -837, -895, -896 
Dbp [p-value = 0.001]: none 
Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]: -87, -186, -254, -257, -275, -282, -541, -562, -587, -621, -683, -705, -768, -835, -838, -894, -897, -973, -974, 
-987, -990 
Nfil3 [p-value = 0.001]: none 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: 88, 64, -7, -128, -135, -166, -201, -309, -367, -371, -401, -441, -454, -532, -579, -611, -704, -
780, -793, -825, -858, -873, -935 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -128, -454, -611 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]: none 
F11r 
Arntl [p-value = 0.01]: -1975, -1880, -1879, -1698, -1536, -1533, -1107, -1106, -1026, -841, -840, -371, -356, -337, -211, -137, -
136, 9, 10 
Arntl [p-value = 0.001]: none 
Arntl [p-value = 0.0001]: none 
Dbp [p-value = 0.01]: -1980, -1979, -1594, -1359, -1358, -810, -805, -773, -772 
Dbp [p-value = 0.001]: none 
Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]: -1981, -1978, -1769, -1532, -1384, -1307, -1207, -1067, -1037, -1022, -804, -774, -771, -747, -670, -577, -
547, -468 
Nfil3 [p-value = 0.001]: -747 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: -1940, -1910, -1893, -1874, -1828, -1801, -1795, -1760, -1724, -1716, -1707, -1693, -1664, -
1644, -1602, -1557, -1541, -1497, -1437, -1418, -1364, -1350, -1329, -1324, -1277, -1218, -1192, -1175, -1163, -1066, -1031, -
956, -846, -727, -696, -644, -620, -589, -573, -545, -345, -312, -207, -196, -186, -26, -4 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -1801, -1602, -1175, -644, -589, -345 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]: none 
CD99L2 
Arntl [p-value = 0.01]: 42, 41, -13, -58, -59, -79, -96, -97, -135, -167, -220, -223, -324, -325, -379, -408, -486, -487, -545, -558, -
575, -576, -748, -769, -770, -844, -849, -1030, -1187, -1188, -1234, -1331, -1463, -1464, -1690, -1691, -1715, -1716, -1880, -1881, 
-1917, -1960, -1961, -1979, -1980 




Arntl [p-value = 0.0001]: none 
Dbp [p-value = 0.01]: -162, -163, -227, -228, -390, -433, -434, -495, -496, -758, -1118, -1119, -1195, -1196, -1357, -1451, -1452, -
1468, -1469, -1544, -1545, -1664, -1958, -1959, -1976 
Dbp [p-value = 0.001]: -1118 
Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]: -139, -350, -392, -517, -980, -1107, -1117, -1120, -1194, -1228, -1283, -1358, -1453, -1457, -1522, -1536, -
1543, -1960 
Nfil3 [p-value = 0.001]: -1117, -1453 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: 60, -35, -53, -64, -162, -215, -257, -261, -281, -306, -380, -428, -451, -507, -550, -711, -779, -
783, -827, -946, -978, -1138, -1171, -1207, -1246, -1276, -1325, -1364, -1387, -1406, -1458, -1487, -1642, -1703, -1813, -1850, -
1875, -1886, -1952, -1984 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -64, -257, -1952 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]: -1952 
Reln 
Arntl [p-value = 0.01]: 93, 75, 74, 22, 21, -7, -39, -71, -72, -97, -117, -133, -134, -153, -154, -218, -247, -263, -264, -294, -363, -
433, -445, -454, -475, -499, -500, -555, -556, -623, -742, -818, -821, -834, -835, -854, -855, -880, -888, -921, -1107, -1202, -1203, -
1245, -1246, -1317, -1404, -1411, -1463, -1464, -1570, -1605, -1672, -1757, -1758, -1769, -1770, -1892, -1904, -1987, -1988 
Arntl [p-value = 0.001]:  21, -71, -72, -854, -1203, -1570, -1757, -1758, -1987 
Arntl [p-value = 0.0001]: -72 
Dbp [p-value = 0.01]: -537, -996, -997, -1083, -1084, -1216, -1217, -1269, -1270, -1639, -1849, -1850, -1908, -1909 
Dbp [p-value = 0.001]: none 
Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]: -712, -812, -861, -995, -1072, -1082, -1268, -1271, -1515, -1521, -1583, -1586, -1601, -1637, -1655, -1693, -
1872, -1910 
Nfil3 [p-value = 0.001]: -1601 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: -26, -246, -266, -403, -426, -444, -501, -536, -698, -721, -734, -810, -942, -996, -1036, -1064, -
1136, -1177, -1255, -1343, -1364, -1552, -1593, -1665, -1745, -1799, -1838, -1881, -1897, -1969 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -1838 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]: none 
Ackr4 
Arntl [p-value = 0.01]: 78, -44, -71, -72, -96, -97, -172, -173, -229, -230, -402, -456, -472, -512, -766, -767, -1149, -1150, -1168, -
1237, -1288, -1456, -1484, -1485, -1587, -1601, -1615, -1616, -1738, -1739, -1835, -1873 
Arntl [p-value = 0.001]:  -1149, -1150 
Arntl [p-value = 0.0001]: none 
Dbp [p-value = 0.01]: -60, -73, -74, -148, -288, -289, -304, -410, -953, -976, -1048, -1049, -1157, -1158, -1460, -1461, -1473, -
1474, -1582, -1583, -1599, -1632, -1633, -1757, -1839, -1840 
Dbp [p-value = 0.001]: -1757 
Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]: -201, -331, -646, -694, -954, -975, -1000, -1047, -1050, -1159, -1211, -1385, -1388, -1553, -1581, -1584, -
1707, -1720, -1751, -1756, -1770, -1861, -1959, -1980 
Nfil3 [p-value = 0.001]: -1707, -1751 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: 3, -34, -62, -85, -122, -161, -183, -210, -228, -344, -517, -543, -597, -621, -632, -647, -696, -
746, -777, -789, -805, -945, -998, -1035, -1061, -1130, -1146, -1197, -1273, -1325, -1338, -1444, -1512, -1557, -1600, -1744, -




Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -85, -1061, -1557 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]: none 
Ccr7 
Arntl [p-value = 0.01]: 51, 50, -54, -85, -93, -103, -116, -257, -258, -324, -373, -374, -484, -485, -740, -748, -769, -770, -887, -914, -
915, -937, -965, -966, -990, -991, -1025, -1057, -1085, -1135, -1136, -1187, -1188, -1269, -1270, -1337, -1338, -1507, -1529, -
1530, -1555, -1669, -1670, -1751, -1935, -1936, -1952, -1953, -1963 
Arntl [p-value = 0.001]: -914, -915, -965, -966, -990, -1269 
Arntl [p-value = 0.0001]: none 
Dbp [p-value = 0.01]: -199, -200, -341, -428, -429, -568, -569, -771, -772, -955, -956, -1198, -1199, -1430, -1610, -1611, -1646, -
1647, -1755 
Dbp [p-value = 0.001]: -428, -429 
Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]: -97, -116, -198, -245, -430, -499, -667, -857, -873, -1024, -1126, -1418, -1429, -1551, -1612, -1630, -1648, -
1704, -1818, -1821 
Nfil3 [p-value = 0.001]: -198, -1612 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: 88, 85, -80, -261, -303, -323, -326, -386, -490, -560, -665, -684, -704, -764, -787, -802, -856, -
868, -973, -985, -1042, -1056, -1067, -1197, -1220, -1264, -1300, -1405, -1423, -1438, -1441, -1475, -1502, -1568, -1596, -1627, -
1655, -1754, -1823, -1847, -1865, -1886, -1958, -1971 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -323, -490, -684, -787, -1264, -1958 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]: none 
Cd80 
Arntl [p-value = 0.01]: -1904, -1883, -1858, -1769, -1745, -1644, -1643, -1525, -1524, -1464, -1426, -1414, -1413, -1334, -1309, -
1289, -1288, -1132, -1131, -1069, -1068, -992, -796, -795, -586, -432, -431, -226, -192, -87, -19, 78 
Arntl [p-value = 0.001]: -1769, -1643, -1525, -1413, -431 
Arntl [p-value = 0.0001]: none 
Dbp [p-value = 0.01]: -1623, -1622, -1545, -1544, -828, -771, -665, -540, -539, -503, -469, -468, -330, -315, -314, 15, 16, 83, 84 
Dbp [p-value = 0.001]: none 
Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]: -1899, -1868, -1685, -1652, -1546, -1452, -1423, -1393, -1276, -1233, -959, -948, -897, -875, -780, -663, -
502, -467, -435, -336, -313, -195, -154, 17, 43, 82 
Nfil3 [p-value = 0.001]: -897, 17 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: -1934, -1863, -1845, -1829, -1787, -1774, -1633, -1590, -1532, -1507, -1467, -1431, -1396, -
1327, -1239, -1228, -1216, -1197, -1147, -1115, -1099, -1005, -987, -916, -882, -841, -794, -649, -620, -589, -567, -412, -378, -
236, -113, -100, -86, -34, -22, -9 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -620, -412 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]: none 
Cd86 
Arntl [p-value = 0.01]: 87, 58, -150, -161, -251, -380, -405, -423, -496, -564, -752, -818, -900, -961, -962, -1001, -1002, -1026, -
1027, -1135, -1152, -1251, -1259, -1401, -1476, -1477, -1535, -1536, -1564, -1681, -1765, -1792, -1793, -1843, -1844, -1905, -
1906 
Arntl [p-value = 0.001]: none 
Arntl [p-value = 0.0001]: none 
Dbp [p-value = 0.01]: -141, -396, -397, -450, -459, -495, -496, -520, -521, -592, -680, -681, -801, -802, -1254, -1255, -1509, -1510, 
-1664, -1686, -1977, -1978 




Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]: -31, -265, -347, -395, -451, -519, -615, -682, -756, -803, -894, -1052, -1088, -1215, -1362, -1394, -1662, -
1665, -1685, -1979 
Nfil3 [p-value = 0.001]: -451, -519, -682 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: -4, -24, -77, -104, -152, -287, -357, -376, -410, -495, -520, -555, -569, -670, -1015, -1074, -
1090, -1107, -1157, -1187, -1380, -1527, -1569, -1619, -1631, -1717, -1723, -1782, -1794, -1915, -1946 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -410, -1717 
Rora/Nr1d1/Nr1d2 [p-value = 0.0001]: none 
Cd40 
Arntl [p-value = 0.01]: -1911, -1870, -1869, -1832, -1791, -1722, -1486, -1415, -1414, -1344, -1234, -1199, -1143, -1142, -1092, -
1089, -1002, -1001, -812, -811, -610, -609, -599, -596, -476, -359, -304, -22, -10, -2, 89, 90 
Arntl [p-value = 0.001]: -610, -609 
Arntl [p-value = 0.0001]: none 
Dbp [p-value = 0.01]: -1130, -1129, -1044, -1043, -1014, -1013, -377, -376, -226, -225 
Dbp [p-value = 0.001]: -1013 
Dbp [p-value = 0.0001]: none 
Nfil3 [p-value = 0.01]: -1896, -1625, -1365, -1286, -1012, -690, -227, -224 
Nfil3 [p-value = 0.001]: -1012, -690 
Nfil3 [p-value = 0.0001]: none 
Rora/Nr1d1/Nr1d2 [p-value = 0.01]: -1974, -1944, -1895, -1882, -1860, -1827, -1794, -1741, -1606, -1586, -1519, -1420, -1406, -
1349, -1313, -1294, -1229, -1186, -1137, -1084, -1079, -841, -835, -824, -806, -693, -624, -571, -514, -454, -435, -362, -269, -265, 
-200, -155, -24 
Rora/Nr1d1/Nr1d2 [p-value = 0.001]: -1586, -1313, -1137, -693 
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